0001213900-23-039823.txt : 20230515 0001213900-23-039823.hdr.sgml : 20230515 20230515162525 ACCESSION NUMBER: 0001213900-23-039823 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMAGING DIAGNOSTIC SYSTEMS INC /FL/ CENTRAL INDEX KEY: 0000790652 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 222671269 STATE OF INCORPORATION: FL FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26028 FILM NUMBER: 23922963 BUSINESS ADDRESS: STREET 1: 1291-B NW 65TH PLACE CITY: FORT LAUDERDALE STATE: FL ZIP: 33309 BUSINESS PHONE: 954 581-9800 MAIL ADDRESS: STREET 1: 1291-B NW 65TH PLACE CITY: FORT LAUDERDALE STATE: FL ZIP: 33309 FORMER COMPANY: FORMER CONFORMED NAME: ALKAN CORP DATE OF NAME CHANGE: 19940623 10-Q 1 f10q0323_imagingdia.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[Mark One]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____to______

 

Commission file number: 000-26028

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

 

Florida   22-2671269
(State of
Incorporation)
  (IRS Employer
Ident. No.)
     
618 E South St, Suite 500, Orlando, FL   32801
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number: (954) 581-9800

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         

  

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer        ☐ Accelerated filer        ☐ Smaller reporting company        
Non-accelerated filer          ☐   Emerging growth company        

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) 

Yes ☐ No

 

The number of shares outstanding of the issuer’s common stock as of May 15, 2023: 123,156,941 shares of common stock, no par value.

 

 

 

 

 

 

  IMAGING DIAGNOSTIC SYSTEMS, INC.  
     
    Page
  Part I - Financial Information  1
     
Item 1. Financial Statements
     
  Balance Sheets – March 31, 2023 (Unaudited) and June 30, 2022 1
     
  Statements of Operations – (Unaudited) Three and nine months ended March 31, 2023 and 2022 2
     
  Statements of Changes in Stockholders’ Deficit – (Unaudited) Three and nine months ended March 31, 2023 and 2022 3
     
  Statements of Cash Flows - (Unaudited) Nine months ended March 31, 2023 and 2022 4
     
  Notes to Unaudited Financial Statements 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
     
  Financial Condition and Results 20
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 27
     
Item 4. Controls and Procedures 27
     
  Part II - Other Information  
     
Item 1. Legal Proceedings 28
   
Item 1A. Risk Factors 28
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28
     
Item 3. Defaults Upon Senior Securities 28
     
Item 4. Mine Safety Disclosures 28
     
Item 5. Other Information 28
     
Item 6. Exhibits 28
     
Signatures 29

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

 

Balance Sheets

 

   (unaudited)     
   March 31,
2023
   June 30,
2022
 
Assets        
Current assets:        
Cash  $123   $613 
Prepaid expenses and deposits   11,783    11,989 
           
Total current assets   11,906    12,602 
           
Property and equipment, net   -    
-
 
           
Total assets  $11,906   $12,602 
           
Liabilities and Stockholders’ Deficit          
Current liabilities:          
Accounts payable and accrued expenses  $910,920   $767,317 
Accrued payroll taxes and penalties   314,019    314,019 
Promissory notes, related party   753,954    671,276 
PPP loan payable   72,930    72,930 
           
Total current liabilities   2,051,823    1,825,542 
           
Total liabilities   2,051,823    1,825,542 
           
Commitment and Contingencies (Note 17)   
 
    
 
 
           
Temporary equity          
Convertible Preferred Stock -Series L   447,451    433,939 
           
Total temporary equity   447,451    433,939 
           
Stockholders’ Deficit:          
           
Preferred stock, no par , 2,000,000 authorized Convertible preferred stock, Series M, 600 designated 0 shares issued and outstanding at March 31, 2023 and June 30, 2022   
-
    
-
 
Common stock, no par value, 500,000,000 authorized , 123,156,941 shares issued and outstanding March 31, 2023 and June 30, 2022   133,296,816    133,236,117 
Accumulated Deficit   (135,784,184)   (135,482,996)
           
Total stockholders’ deficit   (2,487,368)   (2,246,879)
           
Total liabilities and stockholders’ deficit  $11,906   $12,602 

 

See accompanying notes to the unaudited financial statements

 

1

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

 

Statements of Operations

(unaudited)

 

   Three Months
Ended
   Three Months
Ended
   Nine Months
Ended
   Nine Months
Ended
 
   March 31,
2023
   March 31,
2022
   March 31,
2023
   March 31,
2022
 
                 
Total Revenue  $
-
   $
-
   $
-
   $
-
 
                     
Cost of Sales   
-
    
-
    
-
    
-
 
                     
Gross Profit   
-
    
-
    
-
    
-
 
                     
Operating Expenses:                    
General and administrative   15,223    13,873    76,983    73,547 
Sales and marketing   124    314    630    551 
Consulting expenses (including share-based compensation)   5,888    171,479    148,704    334,178 
Total Operating Expenses   21,235    185,666    226,317    408,276 
                     
Operating Loss   (21,235)   (185,666)   (226,317)   (408,276)
                     
Other Income (expense)                    
                     
Interest expense   (20,155)   (20,215)   (61,359)   (61,391)
Total Other Expense   (20,155)   (20,215)   (61,359)   (61,391)
Net Loss   (41,390)   (205,881)   (287,676)   (469,667)
                     
Preferred Stock Dividends   (4,438)   (4,438)   (13,512)   (13,512)
Net Loss Available to Common Stockholders  $(45,828)  $(210,319)  $(301,188)  $(483,179)
                     
Net Loss per common share:                    
Basic and diluted  $
-
   $
-
   $
-
   $
-
 
Weighted average number of common shares outstanding:                    
Basic and diluted
   123,156,941    123,156,941    123,156,941    123,156,941 

 

See accompanying notes to the unaudited financial statements

 

2

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

 

Statements of Changes in Stockholders’ Deficit

For the three and nine months ended March 31, 2023 and 2022

(unaudited)

 

   Common Stock       Total 
   Number of       Accumulated   Stockholders’ 
   Shares   Amount   Deficit   Deficit 
                 
Balance at June 30, 2022   123,156,941   $133,236,117   $(135,482,996)  $(2,246,879)
                     
Cummulative Dividend on Series L CV Preferred   -    
-
    (4,537)   (4,537)
                     
Net loss   -    
-
    (117,325)   (117,325)
                     
Balance at September 30, 2022   123,156,941   $133,236,117   $(135,604,858)  $(2,368,741)
                     
Cummulative Dividend on Series L CV Preferred   -    
-
    (4,537)   (4,537)
                     
Stock options expense   -    60,699    
-
    60,699 
                     
Net loss   -    
-
    (128,961)   (128,961)
                     
Balance at December 31, 2022   123,156,941   $133,296,816   $(135,738,356)  $(2,441,540)
                     
Cummulative Dividend on Series L CV Preferred   -    
-
    (4,438)   (4,438)
                     
Net loss   -    
-
    (41,390)   (41,390)
                     
Balance at March 31, 2023   123,156,941   $133,296,816   $(135,784,184)  $(2,487,368)
                     
Balance at June 30, 2021   123,156,941   $132,974,686   $(134,817,667)  $(1,842,981)
                     
Cummulative Dividend on Series L CV Preferred   -    
-
    (4,537)   (4,537)
                     
Net loss   -    
-
    (111,984)   (111,984)
                     
Balance at September 30, 2021   123,156,941   $132,974,686   $(134,934,188)  $(1,959,502)
                     
Cummulative Dividend on Series L CV Preferred   -    
-
    (4,537)   (4,537)
                     
Stock options expense   -    60,699    
-
    60,699 
                     
Net loss   -    
-
    (151,802)   (151,802)
                     
Balance at December 31, 2021   123,156,941   $133,035,385   $(135,090,527)  $(2,055,142)
                     
Cummulative Dividend on Series L CV Preferred   -    
-
    (4,438)   (4,438)
                     
Stock options expense   -    120,479    
-
    120,479 
                     
Net loss   -    
-
    (205,881)   (205,881)
                     
Balance at March 31, 2022   123,156,941   $133,155,864   $(135,300,846)  $(2,144,982)

 

See accommpanying notes to the unaudited financial statements

 

3

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC.

 

Statements of Cash Flows

(unaudited)

 

   Nine Months
Ended
   Nine Months
Ended
 
   March 31,
2023
   March 31,
2022
 
         
Cash flows from operating activities:        
Net loss  $(287,676)  $(469,667)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock option expense   60,699    181,178 
           
Changes in assets and liabilities:          
Decrease in prepaid expenses and deposits   206    528 
Increase in accounts payable and accrued expenses   147,272    212,718 
Total adjustments   208,177    394,424 
           
Net cash used in operating activities   (79,499)   (75,243)
           
Cash flows from financing activities:          
Proceeds from promissory notes, related party   79,009    80,000 
(Repayment) of Paycheck Protection Program Loan   
-
    (6,670)
Net cash provided by financing activities   79,009    73,330 
           
Net (decrease) in cash   (490)   (1,913)
           
Cash at the beginning of year   613    2,473 
           
Cash at end of the period  $123   $560 
           
Supplemental Disclosure of cash flow information:          
Cash paid for interest  $
-
   $1,497 
Cash paid for taxes  $
-
   $
-
 
           
Non-cash investing and financing activities:          
Promissory notes issued in exchange for settlement of accounts payable  $3,669   $
-
 

 

See accompanying notes to the unaudited financial statements

 

4

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(1) ORGANIZATION AND NATURE OF BUSINESS

 

Imaging Diagnostic Systems, Inc. (the “Company” or “IDSI”) is a medical technology company that has developed a new, non-invasive CT scanner called CTLM® that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM® will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound.

 

Since inception in December 1993 as a Florida corporation and subsequently its reverse merger with Alkan Corp., a New Jersey Corporation on April 14, 1994, we continued operations and changed our state of incorporation from New Jersey to Florida, effective July 1, 1995.

 

(2) GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying financial statements are prepared assuming the Company will continue as a going concern. As of March 31, 2023, the Company had an accumulated deficit of $135,784,184, a stockholders’ deficit of $2,487,368 and a working capital deficiency of $2,039,917. For the nine months ended March 31, 2023, net loss totaled $287,676. The net cash used in operating activities for the nine months ended March 31, 2023 totaled $79,499. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. The ability of the Company to continue as a going concern is dependent upon generating sales and obtaining additional capital and financing. While the Company believes in the viability of its strategy to generate material sales volume and in its ability to raise additional funds, there can be no assurances to that effect. The Company received from the Chinese FDA (“CFDA”) marketing clearance for the CTLM® effective November 16, 2018 to November 15, 2023. However, there can be no assurance that we will obtain U.S. Food and Drug Administration (“FDA”) marketing or other new international marketing clearances, that the CTLM® will achieve market acceptance or that sufficient revenues will be generated from sales of the CTLM® in China or elsewhere to allow us to operate profitably. Since 2016, we have financed our operations through loans by Viable International Investments, LLC (“Viable”), our majority shareholder, and its affiliates and the private placement of common stock to Viable affiliates and independent Chinese investors. We do not have any formal financing arrangements with Viable and its affiliates; however, Viable has stated its intention to continue to provide financing of our operations consistent with past practice. While we believe that Viable and its affiliates will provide on commercially reasonable terms the funding we need until we achieve a positive cash flow from operations, there can be no assurance that we will receive such funding or that we will ever achieve profitability. If Viable fails to continue funding, the Company would be materially adversely affected and may have to cease operations due to a lack of funding. These matters affect the Company’s liquidity profile, and management’s plans in those regards are discussed in the paragraphs that follow.

 

During fiscal year 2023, we anticipate that losses from operations will continue until we begin to generate revenues through the sales of CTLM® systems in China. These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM®, expenses associated with FDA approval processes, and the costs associated with advanced product development activities.

 

The Company’s next focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM® Breast Imaging System through the FDA. The premarket approval (“PMA”) process for U.S. marketing clearance is expected to take longer than the Chinese process, and we intend to resume this effort after achieving successful marketing and sales of CTLM® systems in China. Our sales and marketing efforts in China have been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue from China in the foreseeable future. No sales in other countries are expected in the foreseeable future, as we do not intend to pursue sales in other countries until after obtaining FDA marketing clearance, as to which there can be no assurance.

 

5

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(2) GOING CONCERN AND MANAGEMENT’S PLANS (Continued)

 

In analyzing the regulatory path forward, timeline, and costs associated with the level of effort required to upgrade the Company’s Quality Management System (QMS), we have decided not to renew our CE mark (required for sales in the European Union) for this year and to consider reapplying in 2 to 3 years to avoid these regulatory fees. Similarly, we will maintain our Quality Management System to be compliant to ISO 13485:2016 but not certify to ISO 13485:2016 by Underwriters Laboratories (UL) which will allow us to avoid fees associated with certification, travel, and hosting audits. Maintaining our QMS to be ISO 13485:2016 compliant will allow us to quickly schedule an audit with UL and become ISO 13485 certified when necessary.

 

On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s Computed Tomography Laser Mammography (CTLM®) breast imaging device. Dr. Jiang has completed the first phase of image quality improvement and is currently collecting image data for evaluation and further technical improvement.

 

Xi’an IDI has been working with Yiling Hospital Management Group based in Beijing, China (“Yiling”) to evaluate CTLM®’s potential use and application. As of the date of this report, Xi’an IDI has loaned three CTLM® systems to Yiling and Yiling is at the stage of testing and data validation.

 

It is important that the effectiveness of the image quality improvements be established before Xi’an IDI can resume their sales and marketing efforts in China. Once the Company has substantial revenues and cash flow, it believes it will be able to raise the necessary funding to allow the Company to move forward with its various R&D and regulatory initiatives that have been put on hold due to the COVID-19 pandemic.

 

The Company’s ability to continue as a going concern and its future success are dependent upon its ability to raise additional capital in the near term to: (1) satisfy its current obligations, (2) continue its research and development efforts, and (3) successfully develop, market, and sell its products. Due to the difficulty of raising additional capital during the current COVID-19 crisis, the Company has been taking aggressive measures to reduce its operating costs in order to preserve cash. The Company’s ability to meet its cash flow requirements through fiscal 2023 and continue its development and commercialization efforts will be dependent on the length and severity of the COVID-19 crisis and the Company’s ability to secure additional funding. There can be no assurance that IDSI will generate sufficient revenue to provide positive cash flows from operations or that sufficient capital will be available, when required, to permit the Company to execute its plan of operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

(a) Basis of presentation and use of estimates

 

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The unaudited interim financial information furnished herein reflects all adjustments, consisting only of normal recurring items, which in the opinion of management are necessary to fairly state the Company’s financial position, results of operations and cash flows for the dates and periods presented and to make such information not misleading. The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

 

6

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal year ended June 30, 2022, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “Commission”) on October 4, 2022. The results of operations for the nine months ended March 31, 2023, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2023.

 

(b) Revenue recognition

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue.

 

The Company also receives royalties pursuant to a licensing relationship with Trifoil Imaging. Revenue is recognized in the reporting periods in which royalties are due to the Company. During the nine months ended March 31, 2023 and 2022, there was no income from royalties.

 

(c) Allowance for doubtful accounts

 

In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.

 

Our allowance for doubtful accounts was $850 as of March 31, 2023 and June 30, 2022. These amounts consist of other receivables that have been fully reserved.

 

(d) Cash and cash equivalents

 

Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2023 and June 30, 2022.

 

(e) Concentration of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

 

The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. March 31, 2023 and June 30, 2022, the Company did not have cash balances in excess of the federally insured limit.

 

7

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

The Company did not have any revenue for the nine months ended March 31, 2023 and 2022.

 

(f) Inventory

 

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of obsolete inventory. The Company maintains an allowance for obsolete inventory and generally makes inventory value adjustments against the allowance.

 

(g) Property and equipment

 

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.

 

(h) Research and development

 

Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company’s CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.

 

(i) Net loss per share

 

The Company relies on the guidance provided by ASC 260, (“Earnings per Share”), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.

 

The Company had 5,110,000 and 9,610,012 options vested as of March 31, 2023 and June 30, 2022, respectively and 1,095,290 and 1,595,290 options not yet vested as of March 31, 2023 and June 30, 2022, respectively.

 

(j) Stock-based compensation

 

In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard.

 

The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

8

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. No stock options were granted during nine months ended March 31, 2023 and 2022. Stock options are being expensed pursuant to ASC 718.

 

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (16) Stock Options.

 

(k) Long-lived assets

 

The Company relies on the guidance provided by ASC 360 (“Property, Plant & Equipment”). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.

 

The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2023 and 2022.

 

(l) Income taxes

 

The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.

 

9

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. 

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2020 to 2022 are still potentially subject to audit by the taxing authorities.

 

(m) Warranty reserve

 

The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company’s experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company’s estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2023 or June 30, 2022.

 

(n) Impact of recently issued accounting pronouncements

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

 

(o) Fair Value of Financial Instruments

 

The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company’s debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2023 and June 30, 2022, the aggregate fair value of the Company’s debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 (“Fair Value Measurements and Disclosures”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities

 

10

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

 

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

 

(4) REVENUE

 

The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Sales taxes and other similar taxes are excluded from revenue. 

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on its financial statements. The Company expects that the impact to net income of the new standard will be immaterial on an ongoing quarterly and annual basis. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.

 

The Company had no revenues during the nine months ended March 31, 2023 and 2022.

 

(5) RELATED PARTY TRANSACTIONS

 

Related party revenues

 

On March 22, 2018, the Board of Directors approved the execution of two agreements with Xi’an of China, an affiliated Company of IDSI. The agreements are a Know How Transfer Contract and a CTLM® Know How Confidentiality Agreement. The contract, having a term of 20 years, stipulates that Xi’an will pay IDSI a know how transfer fee of 25% of revenue for CTLM® product sales in their territory. There were no such sales during the nine months ended March 31, 2023 and 2022.

 

Related party fees

 

Erhfort, LLC earned a consulting fee of $51,000 for the nine-month period ended March 31, 2023 and $76,500 for the nine-month period ending March 31, 2022. Erhfort, LLC regularly reviews the Company’s operations and reports to IDSI’s CEO who lives in China. Erhfort, LLC is a related party because it owns Company common stock directly and indirectly.

 

David Fong, who served as the Company’s CFO through August 10, 2022 and as a consultant on an as needed basis thereafter, earned consulting fees of $32,545 for the nine-month period ended March 31, 2023 and $76,500 for the nine-month period ended March 31, 2022. These fees were assigned to his affiliated business, Fong & Associates, LLC.

 

11

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(5) RELATED PARTY TRANSACTIONS (Continued)

 

Related party payables and accrued expenses

 

As of March 31, 2023 and June 30, 2022, the amount of interest on related party notes due to Erhfort, LLC, which is included in accounts payable, is $219,814 and $161,260, respectively.

 

As of March 31, 2023 and June 30, 2022, the amount of consulting fees due to Ehrfort, LLC, which is included in accounts payable, is $204,000 and $153,000, respectively.

 

As March 31, 2023 and June 30, 2022, the amount of consulting fees due to Fong & Associates, LLC, which is included in accounts payable and accrued expenses, is $318,545 and $286,000, respectively.

 

As of March 31, 2023 and June 30, 2022, the amount of reimbursable expenses due to Fong & Associates, LLC, which is included in accounts payable, is $2,808 and $839, respectively.

 

As of March 31, 2023 and June 30, 2022, the amount of interest on related party notes due to JM One Holdings, LLC, which is included in accrued expenses, is $11,112 and $8,860, respectively. JM One Holdings, LLC is an entity affiliated with David Fong.

 

Related party debt

 

As of March 31, 2023 and June 30, 2022, the amount in promissory notes due to related parties are $753,954 and $671,276, respectively (See Note 12).

 

(6) ROYALTY RECEIVABLE

 

On June 16, 2006, the Company entered into a Royalty Agreement with Bioscan Inc. whereby the Company established a licensing relationship with Bioscan which granted Bioscan an exclusive sublicensable, royalty-bearing license to make, use, offer for sale, import and otherwise develop and commercialize products in its territory. Bioscan Inc. was subsequently purchased by TriFoil Imaging. During the nine months ended March 31, 2023 and 2022, there was no royalty income. As of March 31, 2023 and June 30, 2022, the Company had royalty receivable balances of $0.

 

(7) INVENTORIES

 

Inventories consisted of the following:

 

   March 31,
2023
   June 30,
2022
 
         
Raw materials consisting of purchased parts, components and supplies  $92,587   $92,587 
Finished goods   7,500    7,500 
Total Inventory  $100,087   $100,087 
Allowance for Obsolete Inventory   (100,087)   (100,087)
Net Inventory  $
-
   $
-
 

 

Due to the age of the inventory, lack of demand for parts and lack of sales the Company reserved for all inventory during the year ended June 30, 2017. The Company is not carrying any inventory purchased after June 30, 2017 and has booked an allowance for the entire value of its inventory.

 

12

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(8) PREPAID EXPENSES AND DEPOSITS

 

The following is a summary of prepaid expenses:

 

   March 31,
2023
   June 30,
2022
 
         
Prepaid Software  $
-
   $206 
Rent Security Deposits   1,783    1,783 
Consulting Retainers   10,000    10,000 
Total Prepaid expenses and Deposits  $11,783   $11,989 

 

(9) PROPERTY AND EQUIPMENT

 

The following is a summary of property and equipment, less accumulated depreciation:

 

   March 31,
2023
   June 30,
2022
   Useful life
            
Computers and Equipment  $12,612   $12,612   5 years
Third Party Software   10,291    10,291   5 years
Clinical Equipment   15,000    15,000   5 years
Total Property & Equipment  $37,903   $37,903    
Less: accumulated depreciation   (37,903)   (37,903)   
Total Property & Equipment - Net  $
-
   $
-
    

 

Depreciation expense for the nine months ended March 31, 2023 and 2022 was $0.

 

(10) ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

As of March 31, 2023 and June 30, 2022, accounts payable and accrued expenses totaled $910,920 and $767,317 respectively, which consists of accounts payable of $898,468 and $758,171 and other accrued expenses of $12,452 and $9,146, respectively.

 

(11) ACCRUED PAYROLL TAXES AND PENALTIES

 

As of March 31, 2023 and June 30, 2022, the Company owed the IRS $314,019. Accrued payroll taxes represent outstanding interest and penalties based on prior management’s failure to pay payroll taxes commencing with the quarter ending March 31, 2010. As part of new management’s restructuring plan, the Company received funds from an accredited investor to be able to make a payment to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting penalty and interest abatement. The amount due at March 31, 2023 of $314,019 represents the interest and penalties. The Company has formally asked the IRS to abate all remaining interest and penalties of $314,019. The Company had a telephone conference on April 18, 2019 with the office of appeals and is waiting for further communications from the appeals officer. As of March 31, 2023, the Company’s tax counsel is in the process of reviewing recent IRS correspondence to determine appeals status and will work towards final resolutions with the IRS on all outstanding liabilities. The Company has decided to wait until all resolutions are final before making any adjustments to the balance of $314,019 owed to the IRS.

 

13

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(12) PROMISSORY NOTES – RELATED PARTY

 

The following table is a summary of the outstanding note balances as of March 31, 2023 and June 30, 2022.

 

Noteholder  Interest
Rate
   Maturity
Date
  March 31,
2023
   June 30,
2022
 
Related Party Notes:               
Erhfort, LLC   15%  6/30/23  $100,000   $100,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
JM One Holdings, LLC   15%  6/30/23   20,000    20,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
Erhfort, LLC   15%  6/30/23   10,000    10,000 
Erhfort, LLC   15%  6/30/23   10,000    10,000 
Erhfort, LLC   0%  On Demand   2,260    
-
 
Erhfort, LLC   0%  On Demand   3,669    
-
 
Viable International Investments, LLC   0%  On Demand   7,865    7,865 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   3,000    3,000 
Viable International Investments, LLC   0%  On Demand   15,000    15,000 
Viable International Investments, LLC   0%  On Demand   30,000    30,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   8,847    
-
 
Viable International Investments, LLC   0%  On Demand   12,768    
-
 
Viable International Investments, LLC   0%  On Demand   9,988    
-
 
Viable International Investments, LLC   0%  On Demand   7,968    
-
 
Viable International Investments, LLC   0%  On Demand   6,968    
-
 
Viable International Investments, LLC   0%  On Demand   7,786    
-
 
Viable International Investments, LLC   0%  On Demand   5,368    
-
 
Viable International Investments, LLC   0%  On Demand   5,488    
-
 
Viable International Investments, LLC   0%  On Demand   11,568    
-
 
Xi’an IDI   0%  On Demand   10,411    10,411 
Total Related Party Notes          $753,954   $671,276 

 

Erhfort, LLC and Viable International Investments, LLC own Company common stock directly and indirectly. JM One Holdings, LLC is an entity affiliated with the Company’s former CFO. Hence, these debts are considered related party debt. Xi’an IDI is affiliated with IDSI due to a licensing agreement.

 

During the nine months ended March 31, 2023, the Company received loan proceeds of $76,749 from Viable International Investments, LLC and $2,260 from Erhfort, LLC with an annual interest rate of 0%. The Company also converted $3,669 of accounts payables into a loan from Erhfort, LLC with an annual interest rate of 0%. During the nine months ended March 31, 2022, the Company received loan proceeds of $80,000 from Viable International Investments, LLC with an annual interest rate of 0%.

 

On March 31, 2023, the maturity dates of the loans that were due to mature on March 31, 2023 were extended to June 30, 2023. The extension of the maturity dates is a modification of the loans, and not accounted for as gain or loss extinguishments.

 

14

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(13) LONG-TERM DEBT

 

The following table is a summary of the outstanding loan balances as of March 31, 2023 and June 30, 2022.

 

Noteholder  Interest
Rate
   Maturity
Date
  March 31,
2023
   June 30,
2022
 
Truist Bank   1%  In Default  $72,930   $72,930 
Total Debt           72,930    72,930 
Current Portion of Debt           (72,930)   (72,930)
Total Long-term Debt          $
-
   $
-
 

 

On May 9, 2020, the Company entered into a loan with Truist Bank, a lender pursuant to the Paycheck Protection Program of the CARES Act as administered by the SBA in the amount of $79,600. The loan, in the form of a promissory note, had an original maturity date of May 1, 2025. No additional collateral or guarantees were provided by the Company for the loan. The PPP loan provides for customary events of default. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, rent payments, mortgage interest and covered utilities during the 24-week period beginning on the date of loan disbursement.  The Company is required to repay the entire amount of outstanding principal, along with accrued interest, as the Company is not eligible for forgiveness. The Company began to make payments, beginning October 2021, including interest accruing at an annual interest rate of 1.0% beginning on the date of disbursement. On May 17, 2022, the Company received a default and demand letter from Truist Bank in regards to the PPP loan due to non-payment. As such the remaining balance of the PPP loan became due immediately. As of March 31, 2023 and June 30, 2022, the Company reported an accrued interest balance related to the PPP Loan of $740 and $186, respectively. The accrued interest is included in accounts payable and accrued expenses on our balance sheets.

 

(14) CONVERTIBLE PREFERRED STOCK

 

The following schedule reflects the number of shares of preferred stock that have been issued, converted and are outstanding as of March 31, 2023:

 

Security  Date Issued  No. of
Shares
   Amount   Date of
Conversion
  No. of
Shares
Converted
   Amount
Converted
   Balance
3/31/2023
 
Series L Cv Pfd  3/31/2010   35   $350,000   1/6/2011   15   $150,000   $200,000 
Dividends                             247,451 
Total redemption value                        $447,451 
                                
Total Series M Cv Pfd  Various   600   $6,000,000   1/6/2011   600   $6,000,000   $-0- 
Dividends                             -0- 
Total redemption value                        $-0- 

 

15

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(14) CONVERTIBLE PREFERRED STOCK (Continued)

 

Series L Convertible Preferred Stock

 

On March 31, 2010, a private investor converted a $350,000 short-term promissory note into 35 shares of Series L Convertible Preferred Stock. The original purchase price/stated value is $10,000 per share and dividends accrue at an annual rate of 9%. The preferred stock is convertible into 474 shares of common stock for each share of preferred stock. On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time. At March 31, 2023 and June 30, 2022, the balance of cumulative dividends owed to the investor which is included in redemption value was $247,450 and $233,939, respectively. The total presented on the balance sheet as temporary equity is $447,451 as of March 31, 2023 and $433,939 as of June 30, 2022.

 

Series M Convertible Preferred Stock

 

The Company had previously sold 600 Series M Convertible Preferred Stock to Viable International Investments, LLC, a Florida limited liability company, (“Viable”). Each share of the Series M Preferred Stock was convertible into 147,283 shares of Common Stock. In the event of a liquidation, the holders of the Series M Preferred Stock would have been entitled to receive, prior to any distribution of assets to holders of Common Stock or other class of capital stock or other equity securities of the Corporation, $10,000 per share of Series M Preferred Stock held plus accrued but unpaid dividends. The holders of the Series M Preferred Stock would have had identical voting rights as any holder of Common Stock and would have voted together, not as separate classes. The original purchase price/stated value of each share of Series M Preferred Stock was $10,000 and Viable was be entitled to receive cumulative dividends at the fixed rate of 9% of the stated value per share per annum. On November 21, 2017, Viable converted 3 shares of its Series M Preferred Stock to 441,878 shares of restricted common stock. On April 18, 2017, Viable converted 6 shares of its Series M Preferred Stock to 883,696 shares of restricted common stock, and on August 7, 2018, Viable converted its remaining 591 shares of Series M Preferred Stock into 87,044,089 shares of restricted common stock. As of March 31, 2023 and June 30, 2022, the balance of Series M Preferred Stock was $0.

 

(15) COMMON STOCK

 

The Company has 500,000,000 of common shares no par value authorized and 2,000,000 of no par preferred shares authorized.

 

The Company did not issue any shares of common or preferred stock during the nine months ended March 31, 2023 and 2022.

 

(16) STOCK OPTIONS

 

On December 4, 2016, the Board of Directors adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”) which was subsequently approved and adopted by majority written consent in lieu of an annual meeting. The purpose of the 2016 Plan is to encourage and enable the officers, employees, directors and other key persons (including consultants) of the Company, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

 

16

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(16) STOCK OPTIONS (Continued)

 

In computing the impact of stock option grants, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility of a comparable company; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future.

 

In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company cannot assess its forfeiture rate at this time due to the lack of historical data.

 

   As of
March 31,
2023
   As of
June 30,
2022
 
Expected volatility   20% to 44%    20% to 44% 
Expected term   0.08 to 3.08 Years    0.5 to 4.83 Years 
Risk-Free interest rate   0.05% to 2.49%    0.05% to 2.49% 
Forfeiture rate   0.00%    0.00% 
Expected dividend rate   0.00%   0.00%

 

At March 31, 2023, the Company has unvested and vested options under the 2016 Plan with exercise prices that range from a low of $.20 per share to a high of $.51 per share. The following table summarizes information about all of the stock options granted, exercised, expired and cancelled under the 2016 Plan at March 31, 2023 and June 30, 2022:

 

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
   Wtd. Avg.
Remaining
Term
  Aggregate
Intrinsic
Value
 
Outstanding at June 30, 2021   16,752,935   $0.25   1.76 Years  $
         -
 
Granted   
-
   $
-
         
Expired   (5,547,645)  $0.20         
Exercised   
-
   $
-
       
 
 
Cancelled   
-
   $
-
       
 
 
Outstanding at June 30, 2022   11,205,290   $0.30   1.39 Years  $
-
 
Granted   
-
   $
-
         
Expired   (5,000,000)  $0.20         
Exercised   
-
   $
-
         
Cancelled   
-
   $
-
       
 
 
Outstanding at March 31, 2023   6,205,290   $0.39   1.34 Years  $
-
 

 

17

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(16) STOCK OPTIONS (Continued)

 

The following table summarizes information about vested and unvested options under the 2016 Plan at March 31, 2023 and June 30, 2022. The Company recognized an expense of $60,699 for options vested during the nine months ended March 31, 2023.

 

 

Employees/Consultants

  Unvested   Vested and Exercisable   Total 
Outstanding at June 30, 2021   2,830,290    13,922,645    16,752,935 
Granted   
-
    
-
    
-
 
Vested and Exercisable   (1,235,000)   1,235,000    
-
 
Cancelled   
-
    
-
    
-
 
Expired   
-
    (5,547,645)   
-
 
Outstanding at June 30, 2022   1,595,290    9,610,000    11,205,290 
Granted   
-
    
-
    
-
 
Vested and Exercisable   (500,000)   500,000    
-
 
Cancelled   
-
    
-
    
-
 
Expired   
-
    (5,000,000)   
-
 
Adjustment   
-
    
-
    
-
 
Outstanding at March 31, 2023   1,095,290    5,110,000    6,205,290 

 

Unvested options will be expensed under the Black-Scholes options-pricing model when they vest. As of March 31, 2023 remaining options to be expensed when vested over the next year are estimated to be $118,328.

 

At March 31, 2023, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan. All the options for the previous five plans through and including the 2012 Non-Statutory Plan have expired.

 

The tables below summarize information about these five plans:

 

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
   Wtd. Avg.
Remaining
Term
   Aggregate Intrinsic Value 
Outstanding at June 30, 2021   12   $350     1.11 Years   $
         -
 
Granted   
-
   $
-
           
Exercised   
-
   $
-
           
Cancelled   
-
   $
-
      
 
   
Outstanding at June 30, 2022   12   $350     0.11 Years   $
-
 
Granted   
-
   $
-
           
Exercised   
-
   $
-
           
Cancelled   (12)  $350           
Outstanding at March 31, 2023   
-
   $
-
    
-
   $
-
 

 

Vested & Exercisable Stock Options  March 31,
2023
   June 30,
2022
 
Employee 2016 Equity Plan   
-
    
-
 
Director 2016 Equity Plan   
-
    
-
 
Employee Other Plans   
-
    12 
Directors and Consultants Other Plans   
-
    
-
 
Total   
-
    12 

 

18

 

 

IMAGING DIAGNOSTIC SYSTEMS, INC

 

Notes to Unaudited Financial Statements

 

March 31, 2023

 

(16) STOCK OPTIONS (Continued)

 

The table below summarizes information about all stock options outstanding as of March 31, 2023:

 

   Outstanding Options   Vested Options 
Range of Exercise price  Number
Outstanding at
March 31,
2023
   Weighted
Averaged
Exercise
Price
   Weighted
Averaged
Remaining
Life (Years)
   Number
Exercisable at
March 31,
2023
   Weighted
Averaged
Exercise
Price
   Weighted
Averaged
Remaining
Life (Years)
 
$0.20 - $0.51   6,205,290   $0.39    1.34    5,110,000   $0.36    1.05 
Total Outstanding options   6,205,290   $0.39    1.34    5,110,000   $0.36    1.05 

 

The Company’s common stock, symbol IMDS, was quoted on OTCmarkets.com Pink until September 25, 2014 at which time IDSI’s registration was revoked by the Securities and Exchange Commission (SEC) for failure to timely file its Quarterly and Annual Reports. The last quoted price was $0.1. Because the Company was de-registered and OTC markets did not provide a quote for IMDS, there is no public market for the Company’s shares. Given the exercise prices adjusted for the reverse split, it is highly unlikely that any employee holding pre-2016 Plan options will exercise them. The Company has sufficient authorized shares available for all outstanding option; however, if exercised, the shares will be issued with a restrictive legend because the Company was not an SEC reporting company until October 2018. Further, given its recent return to SEC reporting status, the Company is unable to file an S-8 Registration Statement to register shares issued because of option exercise pursuant to various stock option agreements.

 

(17) COMMITMENTS AND CONTINGENCIES

 

The Company previously carried $3,000,000 in product liability insurance to cover both clinical sites and sales. As part of its cost savings initiatives, the Company cancelled the policy as it had not had any adverse experiences after conducting more than 25,000 patient scans worldwide. The Company is now self-insuring the risk of product liability.

 

From May 2010 to June 2012, claims were made by the IRS for payment of the Company’s accrued payroll taxes, interest and penalties, which as of June 30, 2012 was $1,489,640. The Company engaged tax counsel to handle this matter and intends to fully satisfy its payroll tax obligations. On August 4, 2014, Viable purchased 250 shares of convertible preferred stock for $2,500,000, which gave them a 78.9% voting and economic interest in the Company’s capital stock representing a change in control of the Company. New management’s tax counsel negotiated a new Installment Agreement which stipulated a lump sum payment of $250,000, which was paid on September 4, 2014 and monthly installment payments of $20,000 beginning in September 2014 due on the 18th of each month until the balance of payroll taxes, interest and penalties are paid in full (Note 11).

 

During fiscal 2018, as part of new management’s restructuring plan, the Company received funds from an accredited investor to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting abatement of penalties and interest totaling $314,019. As of March 31, 2023, the Company’s tax counsel is in the process of reviewing recent IRS correspondence to determine appeals status and will work towards final resolutions with the IRS on all outstanding liabilities. The Company has decided to wait until all resolutions are final before making any adjustments to the balance of $314,019 owed to the IRS.

 

On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s CTLM® breast imaging device. Per the Agreement, the goal of the initial project was to complete image quality improvement by November 1, 2020. A payment of $500,000 will be due upon satisfactory completion of the project. As of March 31, 2023, Dr. Jiang has completed the first phase of image quality improvement and is currently collecting image data for evaluation and further technical improvement. We have yet to establish the effectiveness of the improvements, as completion of the project has been delayed due to the COVID-19 crisis.

 

(18) SUBSEQUENT EVENTS

 

On April 5, 2023, the Company received loan proceeds of $1,620 from Erhfort, LLC. Interest is 0% and the principal is payable upon demand.

 

19

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

 

This quarterly report on Form 10-Q for the period ended March 31, 2023, contains “forward-looking statements” within the meaning of the federal securities laws and use terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “projects”, “potential,” or “continue,” or the negative or other comparable terminology regarding beliefs, plans, expectations, or intentions regarding the future. These forward-looking statements involve substantial risks and uncertainties, and actual results could differ materially from those discussed and anticipated in such statements. These forward-looking statements include, among others, statements relating to our business strategy, which is based upon our interpretation and analysis of trends in the healthcare treatment industry, especially those related to the diagnosis and treatment of breast cancer, and upon management’s ability to successfully develop and commercialize its principal product, the CTLM®. This strategy assumes that the CTLM® will provide benefits, from both a medical and an economic perspective, to current alternative techniques for diagnosing and managing breast cancer. Factors that could cause actual results to materially differ include, without limitation, the ongoing global COVID-19 pandemic/economic crisis, the timely and successful completion of our clinical trials required by the U.S. Food and Drug Administration (“FDA”) and compliance with the regulations of the FDA and the China Food and Drug Administration (“CFDA”); the timely and successful submission of our FDA application for pre-market approval and our ability to obtain U.S. marketing clearance; manufacturing risks relating to the CTLM®, including our reliance on a single or limited source or sources of supply for some key components of our products as well as the need to comply with especially high standards for those components and in the manufacture of optical imaging products in general; uncertainties inherent in the development of new products and the enhancement of our existing CTLM® product, including technical and regulatory risks, cost overruns and delays; our ability to accurately predict the demand for our CTLM® product as well as future products and to develop strategies to address our markets successfully; the early stage of market development for medical optical imaging products and our ability to gain market acceptance of our CTLM® product by the medical community; our ability to expand our international distributor network for both the near and longer-term to effectively implement our globalization strategy; our dependence on senior management and key personnel and our ability to attract and retain additional qualified personnel; risks relating to financing through private placements or other working capital financing arrangements; technical innovations that could render the CTLM® or other products marketed or under development by us obsolete; competition; risks and uncertainties relating to intellectual property, including claims of infringement and patent litigation; risks relating to future acquisitions and strategic investments and alliances; and reimbursement policies for the use of our CTLM® product and any products we may introduce in the future. There are also many known and unknown risks, uncertainties and other factors, including, but not limited to, technological changes and competition from new diagnostic equipment and techniques, changes in general economic conditions, healthcare reform initiatives, legal claims, regulatory changes and risk factors detailed from time to time in our Securities and Exchange Commission filings that may cause these assumptions to prove incorrect and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, those described above and in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022, filed on October 4, 2022. All forward-looking statements and risk factors included in this Form 10-Q report and in the Form 10-K report are made as of the date of the relevant disclosure document based on information available to us as of the date thereof, and we assume no obligation to update any forward-looking statements or risk factors. The occurrence of any of the events described as risk factors or other future events could have a material adverse effect on our business, results of operations and financial position. Since our common stock is considered a “penny stock,” we are ineligible to rely on the safe harbor for forward-looking statements provided in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). You are cautioned not to place undue reliance on these forward-looking statements.

 

20

 

 

OVERVIEW

 

Our business address is 618 E South St, Suite 500, Orlando, FL 32801. Our Internet website address is www.imds.comThe information contained in, or that can be accessed through, our website is not part of this Form 10-Q quarterly report.

 

Imaging Diagnostic Systems, Inc. (“IDSI” or the “Company”) is a late development stage medical technology company that has developed a new, non-invasive CT scanner (“CTLM®”) that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM® will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound.

 

Since inception in December 1993 as a Florida corporation and subsequently its reverse merger with Alkan Corp., a New Jersey Corporation on April 14, 1994, we continued operations and changed our state of incorporation from New Jersey to Florida, effective July 1, 1995. On July 14, 1995, we filed with the United States Securities and Exchange Commission (“SEC”) a Form 10 SB for registration of our securities as a small business issuer. The Form 10 SB was declared effective in September 1995 and our stock began trading on the OTC Bulletin Board (OTC:BB) on September 20, 1995 under the symbol IMDS. We became a fully reporting company under Commission File Number 0-26028 and traded on the OTC:BB and then on the OTC:QB and ultimately on the OTC PINK until September 25, 2014, at which time our registration was revoked by the SEC for failure to timely file our required periodic reports. Our latest quarterly report on Form 10-Q that was filed prior to our filing of our Form 10 registration statement on August 28, 2018, was filed on May 15, 2013, for the quarter ended March 31, 2013. Our latest annual report on Form 10-K that was filed prior to the filing of our Form 10 registration statement on August 28, 2018, was filed on October 15, 2012, for the year ended June 30, 2012. Copies of our SEC reports through the date of revocation (the “Prior Reports”) are available at www.sec.gov.

 

On August 28, 2018, we filed a Form 10 registration statement to register issued and outstanding shares held by our shareholders and to become a fully reporting company under the Securities Exchange Act of 1934 (the “Exchange Act”). The Form 10 was amended in response to SEC comments on October 5, 2018 and November 14, 2018. On February 7, 2019, the SEC confirmed that it had no further comments on the Form 10. Under the Exchange Act, our registration became effective on October 29, 2018, i.e. 60 days after filing the Form 10. The Form 10 was further amended on September 26, 2019 to correct the classification of the Series L Convertible Preferred Stock from a current liability to temporary equity.

 

As of the date of this quarterly report on Form 10-Q for the nine months ended March 31, 2023, we have had no revenues from our operations and have incurred net losses applicable to common shareholders since inception through March 31, 2023 of $135,784,184 after discounts and dividends on preferred stock. We incurred net losses applicable to common shareholders of $301,188 for the nine months ended March 31, 2023 and $483,179 for the nine months ended March 31, 2022.

 

The Company received marking clearance for the CTLM® from the Chinese FDA (“CFDA”) effective November 16, 2018 to November 15, 2023 as disclosed in the Company’s 8-K report filed December 11, 2018; however, we anticipate that substantial losses from operations will continue until we begin to generate revenues through the sales of CTLM® systems in China. We believe that we face substantial delays before receiving marketing clearance through the U.S. Food and Drug Administration (“FDA”). These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM®, expenses associated with international commercialization of the CTLM®, expenses associated with FDA approval processes, and the costs associated with advanced product development activities. We have implemented a new business strategy which includes a licensing agreement on June 20, 2017 with Xi’an IDI Laser Imaging Co. Ltd (Xi’an IDI), a related party, to shift manufacturing of the CTLM® for the China and Asian markets to China.

 

21

 

 

The Company’s next regulatory focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM® Breast Imaging System through the FDA. The premarket approval (“PMA”) process for U.S. marketing clearance is expected to take longer than the Chinese process, and we intend to resume this effort after successful marketing and sales of CTLM® systems in China. Our sales and marketing efforts in China have been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue from China in the foreseeable future. No sales in other countries are expected in the near future, as we do not intend to pursue sales in other countries until after obtaining FDA marketing clearance.

 

In analyzing the regulatory path forward, timeline, and costs associated with the level of effort required to upgrade the Company’s Quality Management System (QMS), we have decided not to renew our CE mark (required for sales in the European Union) for this year and to consider reapplying in 2 to 3 years to avoid these regulatory fees. Similarly, we will maintain our Quality Management System to be compliant to ISO 13485:2016 but not certify to ISO 13485:2016 by Underwriters Laboratories (UL) which will allow us to avoid fees associated with certification, travel, and hosting audits. Maintaining our QMS to be ISO 13485:2016 compliant will allow us to quickly schedule an audit with UL and become ISO 13485 certified when necessary.

 

On October 23, 2019, we entered into a consulting agreement effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant (the “Consulting Agreement”). Pursuant to the Consulting Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s Computed Tomography Laser Mammography (CTLM®) breast imaging device. The details of this Agreement were disclosed on our Form 8-K report filed with the SEC on October 29, 2019. As of the date of this report, Dr. Jiang has completed the first phase of image quality improvement and is currently collecting image data for evaluation and further technical improvement.

 

Xi’an IDI has been working with Yiling Hospital Management Group based in Beijing, China (“Yiling”) to evaluate CTLM’s potential use and application. As of the date of this report, Xi’an IDI has loaned three CTLM® systems to Yiling and Yiling is at the stage of testing and data validation.

 

It is important that the effectiveness of the image quality improvements be established before Xi’an IDI can resume their sales and marketing efforts in China. Once IDSI has substantial revenues and cash flow, we believe we will be able to raise from operations and/or private investors the necessary funding to allow us to move forward with our CTLM® 3.0 project, as discussed in detail in the “CTLM®” section below. The CTLM® 3.0 project and some regulatory initiatives have been put on hold due to the COVID-19 pandemic and its consequences.

 

CRITICAL ACCOUNTING POLICIES

 

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

 

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements:

 

22

 

 

Stock-Based Compensation

 

We rely on the guidance provided by ASC 718, (“Share Based Payments”). ASC 718 requires companies to expense the value of employee stock options and similar awards and applies to all outstanding and vested stock-based awards.

 

In computing the impact, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, we analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If our actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. During the nine months ended March 31, 2023 and 2022, no stock options were granted to employees or consultants. Those options are being expensed pursuant to ASC 718.

 

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite service period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model.

 

RESULTS OF OPERATIONS

 

Sales and Cost of Sales

 

Revenues during the three months ended March 31, 2023 and 2022 were $0.

 

The Cost of Sales during the three months ended March 31, 2023 and 2022 was $0.

 

Revenues during the nine months ended March 31, 2023 and 2022 were $0.

 

The Cost of Sales during the nine months ended March 31, 2023 and 2022 was $0.

 

Our sales and marketing efforts been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue in the foreseeable future. We also did not receive any royalties for the three and nine months ended March 31, 2023.

 

GENERAL AND ADMINISTRATIVE

 

Our general and administrative expenses include travel/subsistence related to general and administrative activities, property and casualty insurance, professional fees associated with our corporate and securities attorneys and independent auditors, corporate governance expenses, stockholder expenses, utilities, maintenance, telephones, office supplies and sales and property taxes.

 

23

 

 

General and administrative expenses during the three months ended March 31, 2023, were $15,223 representing an increase of $1,350 or 10% from $13,873 during the three months ended March 31, 2022.

 

The general and administrative increase of $1,350 is due primarily to higher filing fees during the three months ended March 31, 2023.

 

General and administrative expenses during the nine months ended March 31, 2023, were $76,983 representing an increase of $3,436 or 5% from $73,547 during the nine months ended March 31, 2022.

 

The general and administrative increase of $3,436 is minor and is related to differences in the timing and payment of expenses.

 

SALARIES AND WAGES

 

Our salaries and wages expenses include compensation, related benefits, payroll taxes and other payroll fees for all employees.

 

Salaries and wages expense during the three months ended March 31, 2023 and 2022 was $0.

 

Salaries and wages expense during the nine months ended March 31, 2023 and 2022 was $0.

 

The lack of salaries and wages is due to the Company’s decision to furlough all employees on May 1, 2020 in response to the COVID-19 crisis. Some of these individuals have worked as independent contractors on an as-needed basis. Payments made to contractors are included in consulting expenses.

 

RESEARCH AND DEVELOPMENT

 

We incur research and development expenses to develop significant enhancements to our sole product, the CTLM®. These expenses consist primarily of clinical costs, costs of materials and components to make product enhancements, new product research costs, and costs associated with servicing clinical collaboration sites.

 

Research and development were $0 for the three months ended March 31, 2023 and 2022.

 

Research and development were $0 for the nine months ended March 31, 2023 and 2022.

 

Research and development costs of $0 was due to the lack of business activity during the three and nine months ended March 31, 2023 and 2022.

 

SALES AND MARKETING

 

Our sales and marketing expenses consist primarily of expenses associated with advertising and promotion, representative office expense, trade shows, conferences, promotional and training costs related to marketing the CTLM®, commissions, travel/subsistence, patent maintenance fees, consulting, certification expenses, and product liability insurance.

 

Sales and marketing expenses during the three months ended March 31, 2023, were $124 representing a decrease of $190 or 61% from $314 during the three months ended March 31, 2023.

 

All sales and marketing expenses during both the three months ended March 31, 2023 and 2022 were related to fees for maintaining our website. The difference relates to variations in website related fees between the two periods.

 

Sales and marketing expenses during the nine months ended March 31, 2023, were $630 representing an increase of $79 or 14% from $551 during the nine months ended March 31, 2022.

 

All sales and marketing expenses during both the nine months ended March 31, 2023 and 2022 were related to fees for maintaining our website. The difference relates to variations in website related fees between the two periods.

 

24

 

 

CONSULTING EXPENSES

 

Our consulting expenses consists of all consulting fees paid as well as share-based compensation issued to our consultants. Our share-based compensation expense consists of vested stock options expensed under the Black-Scholes options pricing model.

 

Consulting expenses for the three months ended March 31, 2023, were $5,888, representing a decrease of $165,591 or 97% from $171,479 during the three months ended March 31, 2022.

 

Consulting expenses for the nine months ended March 31, 2023, were $148,704, representing a decrease of $185,474 or 56% from $334,178 during the nine months ended March 31, 2022.

 

The consulting expense decreases are primarily due to the lack of stock option expenses during the three months ended March 31, 2023 as options had become fully vested in prior periods. Another reason for the decrease is due to changes in the compensation structure for David Fong, who served as the Company’s CFO until August 10, 2022, and as a consultant on an as-needed basis thereafter. Furthermore, Erhfort, LLC who had previously been receiving $8,500 per month in consulting fees no longer receives consulting fees as of January 1, 2023.

 

AGGREGATE OPERATING EXPENSES

 

Total operating expenses (general and administrative, salaries and wages, research and development, sales and marketing, depreciation and amortization, and stock options) and cost of sales during the three months ended March 31, 2023, were $21,235, representing a decrease of $164,431 or 89% from $185,666 when compared to the operating expenses and cost of sales during the three months ended March 31, 2023.  The decrease in operating expenses is primarily due to a decrease in consulting fees during the three months ended March 31, 2023.

  

Depreciation and amortization during the three months ended March 31, 2023 and 2022, was $0. All fixed assets are fully depreciated.

 

Interest expense during the three months ended March 31, 2023, was $20,155 representing a decrease of $60 or less than 1% from $20,215 during the three months ended March 31, 2022. Although the amount of outstanding debt at March 31, 2023 was higher, the more recent debt were 0% interest loans, which is why the amount of interest expense did not change significantly.

 

Total operating expenses (general and administrative, salaries and wages, research and development, sales and marketing, depreciation and amortization, and stock options) and cost of sales during the nine months ended March 31, 2023, were $226,317, representing a decrease of $181,959 or 45% from $408,276 when compared to the operating expenses and cost of sales during the nine months ended March 31, 2022.  The decrease in operating expenses is primarily due to decreases in consulting fees during the nine months ended March 31, 2023.

  

Depreciation and amortization during the nine months ended March 31, 2023 and 2022, was $0. All fixed assets are fully depreciated.

 

Interest expense during the nine months ended March 31, 2023, was $61,359 representing a decrease of $32 or less than 1% from $61,391 during the nine months ended March 31, 2022. Although the amount of outstanding debt at March 31, 2023 was higher, the more recent debt were 0% interest loans, which is why the amount of interest expense did not change significantly.

 

BALANCE SHEET DATA 

 

Our combined cash and cash equivalents totaled $123 at March 31, 2023 and $613 at June 30, 2022.  We do not expect to generate a positive internal cash flow for at least the next 12 months due to our efforts to generate sales in China and obtain FDA marketing clearance, the expected costs of commercializing our initial product, the CTLM®, and the time required for homologations from certain countries.

 

25

 

 

Our inventory, which consists of raw materials, work in process (including completed units under testing), and finished goods totaled $100,087 at March 31, 2023 and $100,087 at June 30, 2022.  Raw materials used for research and development or other purposes are expensed and not included in inventory. The net inventory is $0 at March 31, 2023 and June 30, 2022 because the Company has recorded an allowance for obsolete inventory for the entire value of the inventory due to lack of demand for parts and lack of sales.

 

Our property and equipment, net, totaled $0 at March 31, 2023 and June 30, 2022.

 

Our current liabilities, which consist of accounts payable, accrued payroll taxes and penalties, short term debt, and current portion of long-term debt, totaled $2,051,823 at March 31, 2023 and $1,825,542 at June 30, 2022. Accounts payable and accrued expenses totaled $910,920 at March 31, 2023 and $767,317 at June 30, 2022. Accrued payroll taxes and penalties totaled $314,019 at March 31, 2023 and June 30, 2022. Promissory notes totaled $753,954 at March 31, 2023 and $671,276 at June 30, 2022. The current portion of long-term debt was $72,930 at March 31, 2023 and $72,930 at June 30, 2022. Current liabilities increased primarily due to accounts payable and accrued expenses increasing by $143,603 and related party promissory notes increasing by $82,678.

 

Our temporary equity, which consists of Convertible Preferred Series L (including accrued dividends), totaled $447,451 at March 31, 2023 and $433,939 at June 30, 2022. The increase of $9,074 is due to dividends for the nine months ended March 31, 2023 that are being included in the total redemption value.

 

LIQUIDITY AND CAPITAL RESOURCES 

 

We are currently a development stage company and our continued existence is dependent upon our ability to resolve our liquidity problems, principally by obtaining additional debt and/or equity financing.  We have yet to generate a positive internal cash flow, and until significant sales of our product occur, we are mostly dependent upon debt and equity funding from Viable and its affiliates and/or outside investors. While Viable has stated its intention to provide, directly or through private investors it procures, the working capital that we need for the next 12 months, there can be no assurance that this funding will be provided. In the event that we are unable to obtain adequate debt or equity financing or are unable to obtain such financing on terms and conditions acceptable to us, we may have to cease or severely curtail our operations.  This would materially impact our ability to continue as a going concern.

 

We have financed our operating and research and development activities through multiple private placements of common stock as well as short term loans from related parties.  During the nine months ended March 31, 2023, we received $79,009 through short-term related party loans. We also converted $3,669 of accounts payables to a short-term related party loan during the nine months ended March 31, 2023. During the nine months ended March 31, 2022, we received $80,000 through short-term related party loans.

 

Net cash used in operating and product development expenses, which may include our purchase of additional materials to continue the manufacture of CTLM® Systems in anticipation of receiving orders from our distributors in certain countries where permitted by law was $79,499 for the nine months ended March 31, 2023, compared to net cash used in operating activities and product development of the CTLM® and related software development of $75,243 during the nine months ended March 31, 2022.  At March 31, 2023, we had negative working capital of $2,039,917 compared to negative working capital of $1,812,940 at June 30, 2022. We do not expect to generate a positive internal cash flow for at least the next 12 months due to the time needed to ramp up our sales and marketing plan in China. Implementation of our plan has been severely impeded by the ongoing COVID-19 crisis, and abatement of the crisis is needed in order for our plan to succeed.

 

26

 

 

If and when we receive marketing clearance from the FDA, which cannot be assured, we believe that we will need funding in excess of $5 million above and beyond normal operating expenses over the following year to fully complete all necessary stages in order for us to market the CTLM® in the United States and foreign countries other than China. In China Xi’an IDI will be responsible for all expenses relating to the manufacture, marketing and sale of the CTLM®.  The $5 million will be used to purchase inventory, sub-contracted components, tooling and manufacturing templates and pay non-recurring engineering costs associated with preparation for full capacity manufacturing and assembly and marketing, advertising and promotion, training, ongoing regulatory expenses, and other costs associated with product launch.  We expect to use the proceeds of the sale of restricted common stock through private placements as our preferred choice to raise the additional funds required to continue operations. In the event that we are unable to raise funds through private placements, of common or preferred stock, or debt securities, or combinations thereof; we will be materially adversely affected and may have to cease operations. If additional funds are raised by issuing equity securities, dilution to existing stockholders will result, and future investors may be granted rights superior to those of existing stockholders.

 

Through the date of this report, IDSI has been taking drastic measures as a response to the global COVID-19 crisis to preserve working capital. These measures include the conversion of our full-time employees to contractors working on an as-needed basis, deferral of payments to vendors, and transition of our facilities to a smaller, more cost-efficient space.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that the information required to be disclosed in the reports that we file under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.  

 

Under the supervision and participation of our Chief Executive Officer and Chief Financial Officer, our management has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer, or the persons performing similar functions, concluded that our disclosure controls and procedures were effective as of March 31, 2023.

  

There have been no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recent fiscal year that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

 

27

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

At this time, there are no material pending legal proceedings to which the Company is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

 

Item 1A. Risk Factors.

 

Our Annual Report on Form 10-K for the fiscal year ended June 30, 2022, filed on October 4, 2022, includes a detailed discussion of our risk factors. The risks described in our Form 10-K Report are not the only risks facing IDSI. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. For the nine months ended March 31, 2023, there were no material changes in risk factors as previously disclosed in our Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None

 

Item 3. Defaults Upon Senior Securities.

 

None

 

Item 4. (Mine Safety Disclosures)

 

Not Applicable

 

Item 5. Other Information

 

None

 

Item 6. Exhibits

 

31.1   Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2   Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1   Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2   Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

28

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: May 15, 2023   Imaging Diagnostic Systems, Inc.
     
  By: /s/ Rongbin Wang
    Rongbin Wang
    Chief Financial Officer
   

(PRINCIPAL ACCOUNTING OFFICER)

 

    /s/ Lun Li
    Lun Li
   

Chief Executive Officer

(PRINCIPAL EXECUTIVE OFFICER)

 

 

29

 

 

IMAGING DIAGNOSTIC SYSTEMS INC /FL/ 123156941 123156941 123156941 123156941 false --06-30 Q3 0000790652 0000790652 2022-07-01 2023-03-31 0000790652 2023-05-15 0000790652 2023-03-31 0000790652 2022-06-30 0000790652 imds:SeriesMPreferredStockMember 2023-03-31 0000790652 imds:SeriesMPreferredStockMember 2022-06-30 0000790652 2023-01-01 2023-03-31 0000790652 2022-01-01 2022-03-31 0000790652 2021-07-01 2022-03-31 0000790652 us-gaap:CommonStockMember 2022-06-30 0000790652 us-gaap:RetainedEarningsMember 2022-06-30 0000790652 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000790652 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000790652 2022-07-01 2022-09-30 0000790652 us-gaap:CommonStockMember 2022-09-30 0000790652 us-gaap:RetainedEarningsMember 2022-09-30 0000790652 2022-09-30 0000790652 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0000790652 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0000790652 2022-10-01 2022-12-31 0000790652 us-gaap:CommonStockMember 2022-12-31 0000790652 us-gaap:RetainedEarningsMember 2022-12-31 0000790652 2022-12-31 0000790652 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000790652 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000790652 us-gaap:CommonStockMember 2023-03-31 0000790652 us-gaap:RetainedEarningsMember 2023-03-31 0000790652 us-gaap:CommonStockMember 2021-06-30 0000790652 us-gaap:RetainedEarningsMember 2021-06-30 0000790652 2021-06-30 0000790652 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000790652 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000790652 2021-07-01 2021-09-30 0000790652 us-gaap:CommonStockMember 2021-09-30 0000790652 us-gaap:RetainedEarningsMember 2021-09-30 0000790652 2021-09-30 0000790652 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0000790652 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0000790652 2021-10-01 2021-12-31 0000790652 us-gaap:CommonStockMember 2021-12-31 0000790652 us-gaap:RetainedEarningsMember 2021-12-31 0000790652 2021-12-31 0000790652 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000790652 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000790652 us-gaap:CommonStockMember 2022-03-31 0000790652 us-gaap:RetainedEarningsMember 2022-03-31 0000790652 2022-03-31 0000790652 2021-07-01 2022-06-30 0000790652 2018-03-01 2018-03-22 0000790652 imds:EhrfortLLCMember 2022-07-01 2023-03-31 0000790652 imds:EhrfortLLCMember 2021-07-01 2022-03-31 0000790652 imds:DavidFongMember 2022-07-01 2023-03-31 0000790652 imds:DavidFongMember 2021-07-01 2022-03-31 0000790652 imds:EhrfortLLCMember 2023-03-31 0000790652 imds:EhrfortLLCMember 2022-06-30 0000790652 imds:ErhfortLLCOneMember 2023-03-31 0000790652 imds:ErhfortLLCOneMember 2022-06-30 0000790652 imds:FongAssociatesLLCMember 2023-03-31 0000790652 imds:FongAssociatesLLCMember 2022-06-30 0000790652 imds:JMOneHoldingsLLCMember 2023-03-31 0000790652 imds:JMOneHoldingsLLCMember 2022-06-30 0000790652 us-gaap:ComputerEquipmentMember 2023-03-31 0000790652 us-gaap:ComputerEquipmentMember 2022-06-30 0000790652 imds:ThirdPartySoftwareMember 2023-03-31 0000790652 imds:ThirdPartySoftwareMember 2022-06-30 0000790652 imds:ClinicalEquipmentMember 2023-03-31 0000790652 imds:ClinicalEquipmentMember 2022-06-30 0000790652 2018-06-27 0000790652 imds:ViableInternationalInvestmentsMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsMember 2021-07-01 2022-03-31 0000790652 2023-03-31 2023-03-31 0000790652 imds:ErhfortLLCsMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsMember 2023-03-31 0000790652 imds:ErhfortLLCsMember 2022-06-30 0000790652 imds:ErhfortLLCOneMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCOneMember 2023-03-31 0000790652 imds:ErhfortLLCOneMember 2022-06-30 0000790652 imds:JMOneHoldingsLLCMember 2022-07-01 2023-03-31 0000790652 imds:JMOneHoldingsLLCMember 2023-03-31 0000790652 imds:JMOneHoldingsLLCMember 2022-06-30 0000790652 imds:ErhfortLLCTwoMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCTwoMember 2023-03-31 0000790652 imds:ErhfortLLCTwoMember 2022-06-30 0000790652 imds:ErhfortLLCsThreeMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsThreeMember 2023-03-31 0000790652 imds:ErhfortLLCsThreeMember 2022-06-30 0000790652 imds:ErhfortLLCsFourMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsFourMember 2023-03-31 0000790652 imds:ErhfortLLCsFourMember 2022-06-30 0000790652 imds:ErhfortLLCsFiveMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsFiveMember 2023-03-31 0000790652 imds:ErhfortLLCsFiveMember 2022-06-30 0000790652 imds:ErhfortLLCsSixMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsSixMember 2023-03-31 0000790652 imds:ErhfortLLCsSixMember 2022-06-30 0000790652 imds:ErhfortLLCSevenMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCSevenMember 2023-03-31 0000790652 imds:ErhfortLLCSevenMember 2022-06-30 0000790652 imds:ErhfortLLCEightMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCEightMember 2023-03-31 0000790652 imds:ErhfortLLCEightMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCOneMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCOneMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCOneMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTwoMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwoMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwoMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCThreeMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCThreeMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCThreeMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCFourMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFourMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFourMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCFiveMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFiveMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFiveMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCSixMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSixMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSixMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCSevenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSevenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSevenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCEightMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCEightMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCEightMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCNineMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCNineMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCNineMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCElevenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCElevenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCElevenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTwelveMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwelveMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwelveMember 2022-06-30 0000790652 imds:ViablesInternationalInvestmentsLLCThirteenMember 2022-07-01 2023-03-31 0000790652 imds:ViablesInternationalInvestmentsLLCThirteenMember 2023-03-31 0000790652 imds:ViablesInternationalInvestmentsLLCThirteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCFourteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFourteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFourteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCFifteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFifteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFifteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCSixteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSixteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSixteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCSeventeenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSeventeenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSeventeenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCEighteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCEighteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCEighteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCNineteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCNineteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCNineteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTwentyMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwentyMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwentyMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTwentyOneMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwentyOneMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwentyOneMember 2022-06-30 0000790652 imds:XianIDIMember 2022-07-01 2023-03-31 0000790652 imds:XianIDIMember 2023-03-31 0000790652 imds:XianIDIMember 2022-06-30 0000790652 2020-05-01 2020-05-09 0000790652 2020-05-09 0000790652 2021-10-01 2021-10-31 0000790652 imds:PPPLoanMember 2022-07-01 2023-03-31 0000790652 imds:PPPLoanMember 2021-07-01 2022-06-30 0000790652 imds:TruistBankMember 2023-03-31 0000790652 imds:TruistBankMember 2022-07-01 2023-03-31 0000790652 imds:TruistBankMember 2022-06-30 0000790652 imds:SeriesLPreferredStockMember 2010-03-31 0000790652 imds:SeriesLPreferredStockMember 2010-03-01 2010-03-31 0000790652 imds:SeriesLPreferredStockMember 2011-01-01 2011-01-06 0000790652 imds:SeriesMPreferredStockMember 2022-07-01 2023-03-31 0000790652 imds:SeriesMPreferredStockMember 2017-11-21 0000790652 imds:SeriesMPreferredStockMember 2017-11-01 2017-11-21 0000790652 imds:SeriesMPreferredStockMember 2017-04-18 0000790652 imds:SeriesMPreferredStockMember 2017-04-01 2017-04-18 0000790652 imds:SeriesMPreferredStockMember 2018-08-07 0000790652 imds:SeriesMPreferredStockMember 2018-08-01 2018-08-07 0000790652 imds:IssuanceDate6Member imds:SeriesLPreferredStockMember 2022-07-01 2023-03-31 0000790652 imds:IssuanceDate6Member imds:SeriesLPreferredStockMember 2023-03-31 0000790652 imds:SeriesLPreferredStockMember 2022-07-01 2023-03-31 0000790652 srt:MinimumMember 2022-07-01 2023-03-31 0000790652 srt:MaximumMember 2022-07-01 2023-03-31 0000790652 srt:MinimumMember 2021-07-01 2022-06-30 0000790652 srt:MaximumMember 2021-07-01 2022-06-30 0000790652 imds:VestedAndUnvestedOptionsMember 2021-06-30 0000790652 imds:VestedAndUnvestedOptionsMember 2021-07-01 2022-06-30 0000790652 imds:VestedAndUnvestedOptionsMember 2022-06-30 0000790652 imds:VestedAndUnvestedOptionsMember 2022-07-01 2023-03-31 0000790652 imds:VestedAndUnvestedOptionsMember 2023-03-31 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2021-06-30 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2021-07-01 2022-06-30 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2022-06-30 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2022-07-01 2023-03-31 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2023-03-31 0000790652 imds:UnvestedMember 2021-06-30 0000790652 imds:VestedAndExercisableMember 2021-06-30 0000790652 imds:UnvestedMember 2021-07-01 2022-06-30 0000790652 imds:VestedAndExercisableMember 2021-07-01 2022-06-30 0000790652 imds:UnvestedMember 2022-06-30 0000790652 imds:VestedAndExercisableMember 2022-06-30 0000790652 imds:UnvestedMember 2022-07-01 2023-03-31 0000790652 imds:VestedAndExercisableMember 2022-07-01 2023-03-31 0000790652 imds:UnvestedMember 2023-03-31 0000790652 imds:VestedAndExercisableMember 2023-03-31 0000790652 imds:EmployeeTwoThousandSixteenPlanMember 2023-03-31 0000790652 imds:EmployeeTwoThousandSixteenPlanMember 2022-06-30 0000790652 imds:DirectorTwoThousandSixteenEquityPlanMember 2023-03-31 0000790652 imds:DirectorTwoThousandSixteenEquityPlanMember 2022-06-30 0000790652 imds:EmployeeOtherPlansMember 2023-03-31 0000790652 imds:EmployeeOtherPlansMember 2022-06-30 0000790652 imds:DirectorsAndConsultantsOtherPlansMember 2023-03-31 0000790652 imds:DirectorsAndConsultantsOtherPlansMember 2022-06-30 0000790652 imds:OutstandingOptionsMember imds:ExercisePriceRangeMember 2023-03-31 0000790652 imds:OutstandingOptionsMember imds:ExercisePriceRangeMember 2022-07-01 2023-03-31 0000790652 imds:VestedOptionsMember imds:ExercisePriceRangeMember 2023-03-31 0000790652 imds:VestedOptionsMember imds:ExercisePriceRangeMember 2022-07-01 2023-03-31 0000790652 imds:OutstandingOptionsMember 2023-03-31 0000790652 imds:OutstandingOptionsMember 2022-07-01 2023-03-31 0000790652 imds:VestedOptionsMember 2023-03-31 0000790652 imds:VestedOptionsMember 2022-07-01 2023-03-31 0000790652 2012-06-30 0000790652 2014-08-01 2014-08-04 0000790652 2014-09-04 0000790652 2014-04-04 0000790652 2018-06-29 0000790652 imds:ErhfortLLCMember us-gaap:SubsequentEventMember 2023-04-01 2023-04-05 0000790652 us-gaap:SubsequentEventMember 2023-04-05 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 f10q0323ex31-1_imagingdiag.htm CERTIFCATION

EXHIBIT 31.1

 

CERTIFCATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO EXCHANGE ACT SECTIONS 13(a) & 15(d)

AS REQUIRED BY

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Lun Li, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Imaging Diagnostic Systems, Inc.;
   
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  
     
  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and
     
  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  May 15, 2023 /s/ Lun Li
  Lun Li
  Chief Executive Officer

 

 

EX-31.2 3 f10q0323ex31-2_imagingdiag.htm CERTIFCATION

EXHIBIT 31.2

 

CERTIFCATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO EXCHANGE ACT SECTIONS 13(a) & 15(d)

AS REQUIRED BY

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Rongbin Wang, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Imaging Diagnostic Systems, Inc.;
   
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  
     
  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and
     
  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  May 15, 2023 /s/ Rongbin Wang
  Rongbin Wang
  Chief Financial Officer

 

EX-32.1 4 f10q0323ex32-1_imagingdiag.htm CERTIFCATION

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Imaging Diagnostic Systems, Inc. (the “Company”) on Form 10-Q for the quarter ending March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lun Li, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date:  May 15, 2023 /s/ Lun Li
  Lun Li
  Chief Executive Officer

 

EX-32.1 5 f10q0323ex32-2_imagingdiag.htm CERTIFCATION

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Imaging Diagnostic Systems, Inc. (the “Company”) on Form 10-Q for the quarter ending March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rongbin Wang, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date:  May 15, 2023 /s/ Rongbin Wang
  Rongbin Wang
  Chief Financial Officer

 

GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 7 imds-20230331.xsd XBRL SCHEMA FILE 001 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statements of Operations (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements of Changes in Stockholders’ Deficit (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Nature of Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern and Management's Plans link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Royalty Receivable link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Prepaid Expenses and Deposits link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Accrued Payroll Taxes and Penalties link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Promissory Notes – Related Party link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Long-Term Debt link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Common Stock link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Stock Options link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Prepaid Expenses and Deposits (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Promissory Notes – Related Party (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Convertible Preferred Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Stock Options (Tables) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Going Concern and Management's Plans (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Royalty Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Inventories (Details) - Schedule of inventories link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Prepaid Expenses and Deposits (Details) - Schedule of prepaid expenses link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment, less accumulated depreciation link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Accrued Payroll Taxes and Penalties (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Promissory Notes – Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Promissory Notes – Related Party (Details) - Schedule of outstanding note balances link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Long-Term Debt (Details) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Long-Term Debt (Details) - Schedule of a summary of the outstanding loan balances link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Convertible Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Convertible Preferred Stock (Details) - Schedule of number of shares of preferred stock that have been issued, converted and are outstanding link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Common Stock (Details) link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Stock Options (Details) link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Stock Options (Details) - Schedule of vested and unvested options link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Stock Options (Details) - Schedule of information about vested & exercisable stock options link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - Stock Options (Details) - Schedule of stock options outstanding link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 imds-20230331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 imds-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 imds-20230331_lab.xml XBRL LABEL FILE EX-101.PRE 11 imds-20230331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information - shares
9 Months Ended
Mar. 31, 2023
May 15, 2023
Document Information Line Items    
Entity Registrant Name IMAGING DIAGNOSTIC SYSTEMS INC /FL/  
Document Type 10-Q  
Current Fiscal Year End Date --06-30  
Entity Common Stock, Shares Outstanding   123,156,941
Amendment Flag false  
Entity Central Index Key 0000790652  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Mar. 31, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-26028  
Entity Incorporation, State or Country Code FL  
Entity Tax Identification Number 22-2671269  
Entity Address, Address Line One 618 E South St  
Entity Address, Address Line Two Suite 500  
Entity Address, City or Town Orlando  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 32801  
City Area Code (954)  
Local Phone Number 581-9800  
Entity Interactive Data Current Yes  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheets - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Current assets:    
Cash $ 123 $ 613
Prepaid expenses and deposits 11,783 11,989
Total current assets 11,906 12,602
Property and equipment, net
Total assets 11,906 12,602
Current liabilities:    
Accounts payable and accrued expenses 910,920 767,317
Accrued payroll taxes and penalties 314,019 314,019
Promissory notes, related party 753,954 671,276
PPP loan payable 72,930 72,930
Total current liabilities 2,051,823 1,825,542
Total liabilities 2,051,823 1,825,542
Commitment and Contingencies (Note 17)
Temporary equity    
Convertible Preferred Stock -Series L 447,451 433,939
Total temporary equity 447,451 433,939
Stockholders’ Deficit:    
Preferred stock, no par , 2,000,000 authorized Convertible preferred stock, Series M, 600 designated 0 shares issued and outstanding at March 31, 2023 and June 30, 2022
Common stock, no par value, 500,000,000 authorized , 123,156,941 shares issued and outstanding March 31, 2023 and June 30, 2022 133,296,816 133,236,117
Accumulated Deficit (135,784,184) (135,482,996)
Total stockholders’ deficit (2,487,368) (2,246,879)
Total liabilities and stockholders’ deficit $ 11,906 $ 12,602
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheets (Parentheticals) - $ / shares
Mar. 31, 2023
Jun. 30, 2022
Preferred stock, shares par value (in Dollars per share)
Preferred stock, shares authorized 2,000,000 2,000,000
Common stock, shares par value (in Dollars per share)
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 123,156,941 123,156,941
Common stock, shares outstanding 123,156,941 123,156,941
Series M    
Preferred stock, designated 600 600
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]        
Total Revenue
Cost of Sales
Gross Profit
Operating Expenses:        
General and administrative 15,223 13,873 76,983 73,547
Sales and marketing 124 314 630 551
Consulting expenses (including share-based compensation) 5,888 171,479 148,704 334,178
Total Operating Expenses 21,235 185,666 226,317 408,276
Operating Loss (21,235) (185,666) (226,317) (408,276)
Other Income (expense)        
Interest expense (20,155) (20,215) (61,359) (61,391)
Total Other Expense (20,155) (20,215) (61,359) (61,391)
Net Loss (41,390) (205,881) (287,676) (469,667)
Preferred Stock Dividends (4,438) (4,438) (13,512) (13,512)
Net Loss Available to Common Stockholders $ (45,828) $ (210,319) $ (301,188) $ (483,179)
Net Loss per common share:        
Basic and diluted (in Dollars per share)
Weighted average number of common shares outstanding:        
Basic and diluted (in Shares) 123,156,941 123,156,941 123,156,941 123,156,941
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Operations (Unaudited) (Parentheticals) - $ / shares
3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]        
Net Loss per common share diluted
Weighted average number of common shares outstanding diluted 123,156,941 123,156,941 123,156,941 123,156,941
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Changes in Stockholders’ Deficit (Unaudited) - USD ($)
Common Stock
Accumulated Deficit
Total
Balance at Jun. 30, 2021 $ 132,974,686 $ (134,817,667) $ (1,842,981)
Balance (in Shares) at Jun. 30, 2021 123,156,941    
Cummulative Dividend on Series L CV Preferred (4,537) (4,537)
Net loss (111,984) (111,984)
Balance at Sep. 30, 2021 $ 132,974,686 (134,934,188) (1,959,502)
Balance (in Shares) at Sep. 30, 2021 123,156,941    
Balance at Jun. 30, 2021 $ 132,974,686 (134,817,667) (1,842,981)
Balance (in Shares) at Jun. 30, 2021 123,156,941    
Net loss     (469,667)
Balance at Mar. 31, 2022 $ 133,155,864 (135,300,846) (2,144,982)
Balance (in Shares) at Mar. 31, 2022 123,156,941    
Balance at Sep. 30, 2021 $ 132,974,686 (134,934,188) (1,959,502)
Balance (in Shares) at Sep. 30, 2021 123,156,941    
Cummulative Dividend on Series L CV Preferred (4,537) (4,537)
Stock options expense 60,699 60,699
Net loss (151,802) (151,802)
Balance at Dec. 31, 2021 $ 133,035,385 (135,090,527) (2,055,142)
Balance (in Shares) at Dec. 31, 2021 123,156,941    
Cummulative Dividend on Series L CV Preferred (4,438) (4,438)
Stock options expense 120,479 120,479
Net loss (205,881) (205,881)
Balance at Mar. 31, 2022 $ 133,155,864 (135,300,846) (2,144,982)
Balance (in Shares) at Mar. 31, 2022 123,156,941    
Balance at Jun. 30, 2022 $ 133,236,117 (135,482,996) (2,246,879)
Balance (in Shares) at Jun. 30, 2022 123,156,941    
Cummulative Dividend on Series L CV Preferred (4,537) (4,537)
Net loss (117,325) (117,325)
Balance at Sep. 30, 2022 $ 133,236,117 (135,604,858) (2,368,741)
Balance (in Shares) at Sep. 30, 2022 123,156,941    
Balance at Jun. 30, 2022 $ 133,236,117 (135,482,996) (2,246,879)
Balance (in Shares) at Jun. 30, 2022 123,156,941    
Net loss     (287,676)
Balance at Mar. 31, 2023 $ 133,296,816 (135,784,184) (2,487,368)
Balance (in Shares) at Mar. 31, 2023 123,156,941    
Balance at Sep. 30, 2022 $ 133,236,117 (135,604,858) (2,368,741)
Balance (in Shares) at Sep. 30, 2022 123,156,941    
Cummulative Dividend on Series L CV Preferred (4,537) (4,537)
Stock options expense 60,699 60,699
Net loss (128,961) (128,961)
Balance at Dec. 31, 2022 $ 133,296,816 (135,738,356) (2,441,540)
Balance (in Shares) at Dec. 31, 2022 123,156,941    
Cummulative Dividend on Series L CV Preferred (4,438) (4,438)
Net loss (41,390) (41,390)
Balance at Mar. 31, 2023 $ 133,296,816 $ (135,784,184) $ (2,487,368)
Balance (in Shares) at Mar. 31, 2023 123,156,941    
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net loss $ (287,676) $ (469,667)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock option expense 60,699 181,178
Changes in assets and liabilities:    
Decrease in prepaid expenses and deposits 206 528
Increase in accounts payable and accrued expenses 147,272 212,718
Total adjustments 208,177 394,424
Net cash used in operating activities (79,499) (75,243)
Cash flows from financing activities:    
Proceeds from promissory notes, related party 79,009 80,000
(Repayment) of Paycheck Protection Program Loan (6,670)
Net cash provided by financing activities 79,009 73,330
Net (decrease) in cash (490) (1,913)
Cash at the beginning of year 613 2,473
Cash at end of the period 123 560
Supplemental Disclosure of cash flow information:    
Cash paid for interest 1,497
Cash paid for taxes
Non-cash investing and financing activities:    
Promissory notes issued in exchange for settlement of accounts payable $ 3,669
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Nature of Business
9 Months Ended
Mar. 31, 2023
Organization and Nature of Business [Abstract]  
ORGANIZATION AND NATURE OF BUSINESS

(1) ORGANIZATION AND NATURE OF BUSINESS

 

Imaging Diagnostic Systems, Inc. (the “Company” or “IDSI”) is a medical technology company that has developed a new, non-invasive CT scanner called CTLM® that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM® will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound.

 

Since inception in December 1993 as a Florida corporation and subsequently its reverse merger with Alkan Corp., a New Jersey Corporation on April 14, 1994, we continued operations and changed our state of incorporation from New Jersey to Florida, effective July 1, 1995.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Going Concern and Management's Plans
9 Months Ended
Mar. 31, 2023
Going Concern and Management's Plans Disclosure [Abstract]  
GOING CONCERN AND MANAGEMENT’S PLANS

(2) GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying financial statements are prepared assuming the Company will continue as a going concern. As of March 31, 2023, the Company had an accumulated deficit of $135,784,184, a stockholders’ deficit of $2,487,368 and a working capital deficiency of $2,039,917. For the nine months ended March 31, 2023, net loss totaled $287,676. The net cash used in operating activities for the nine months ended March 31, 2023 totaled $79,499. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. The ability of the Company to continue as a going concern is dependent upon generating sales and obtaining additional capital and financing. While the Company believes in the viability of its strategy to generate material sales volume and in its ability to raise additional funds, there can be no assurances to that effect. The Company received from the Chinese FDA (“CFDA”) marketing clearance for the CTLM® effective November 16, 2018 to November 15, 2023. However, there can be no assurance that we will obtain U.S. Food and Drug Administration (“FDA”) marketing or other new international marketing clearances, that the CTLM® will achieve market acceptance or that sufficient revenues will be generated from sales of the CTLM® in China or elsewhere to allow us to operate profitably. Since 2016, we have financed our operations through loans by Viable International Investments, LLC (“Viable”), our majority shareholder, and its affiliates and the private placement of common stock to Viable affiliates and independent Chinese investors. We do not have any formal financing arrangements with Viable and its affiliates; however, Viable has stated its intention to continue to provide financing of our operations consistent with past practice. While we believe that Viable and its affiliates will provide on commercially reasonable terms the funding we need until we achieve a positive cash flow from operations, there can be no assurance that we will receive such funding or that we will ever achieve profitability. If Viable fails to continue funding, the Company would be materially adversely affected and may have to cease operations due to a lack of funding. These matters affect the Company’s liquidity profile, and management’s plans in those regards are discussed in the paragraphs that follow.

 

During fiscal year 2023, we anticipate that losses from operations will continue until we begin to generate revenues through the sales of CTLM® systems in China. These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM®, expenses associated with FDA approval processes, and the costs associated with advanced product development activities.

 

The Company’s next focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM® Breast Imaging System through the FDA. The premarket approval (“PMA”) process for U.S. marketing clearance is expected to take longer than the Chinese process, and we intend to resume this effort after achieving successful marketing and sales of CTLM® systems in China. Our sales and marketing efforts in China have been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue from China in the foreseeable future. No sales in other countries are expected in the foreseeable future, as we do not intend to pursue sales in other countries until after obtaining FDA marketing clearance, as to which there can be no assurance.

 

In analyzing the regulatory path forward, timeline, and costs associated with the level of effort required to upgrade the Company’s Quality Management System (QMS), we have decided not to renew our CE mark (required for sales in the European Union) for this year and to consider reapplying in 2 to 3 years to avoid these regulatory fees. Similarly, we will maintain our Quality Management System to be compliant to ISO 13485:2016 but not certify to ISO 13485:2016 by Underwriters Laboratories (UL) which will allow us to avoid fees associated with certification, travel, and hosting audits. Maintaining our QMS to be ISO 13485:2016 compliant will allow us to quickly schedule an audit with UL and become ISO 13485 certified when necessary.

 

On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s Computed Tomography Laser Mammography (CTLM®) breast imaging device. Dr. Jiang has completed the first phase of image quality improvement and is currently collecting image data for evaluation and further technical improvement.

 

Xi’an IDI has been working with Yiling Hospital Management Group based in Beijing, China (“Yiling”) to evaluate CTLM®’s potential use and application. As of the date of this report, Xi’an IDI has loaned three CTLM® systems to Yiling and Yiling is at the stage of testing and data validation.

 

It is important that the effectiveness of the image quality improvements be established before Xi’an IDI can resume their sales and marketing efforts in China. Once the Company has substantial revenues and cash flow, it believes it will be able to raise the necessary funding to allow the Company to move forward with its various R&D and regulatory initiatives that have been put on hold due to the COVID-19 pandemic.

 

The Company’s ability to continue as a going concern and its future success are dependent upon its ability to raise additional capital in the near term to: (1) satisfy its current obligations, (2) continue its research and development efforts, and (3) successfully develop, market, and sell its products. Due to the difficulty of raising additional capital during the current COVID-19 crisis, the Company has been taking aggressive measures to reduce its operating costs in order to preserve cash. The Company’s ability to meet its cash flow requirements through fiscal 2023 and continue its development and commercialization efforts will be dependent on the length and severity of the COVID-19 crisis and the Company’s ability to secure additional funding. There can be no assurance that IDSI will generate sufficient revenue to provide positive cash flows from operations or that sufficient capital will be available, when required, to permit the Company to execute its plan of operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
9 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

(a) Basis of presentation and use of estimates

 

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The unaudited interim financial information furnished herein reflects all adjustments, consisting only of normal recurring items, which in the opinion of management are necessary to fairly state the Company’s financial position, results of operations and cash flows for the dates and periods presented and to make such information not misleading. The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

 

These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal year ended June 30, 2022, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “Commission”) on October 4, 2022. The results of operations for the nine months ended March 31, 2023, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2023.

 

(b) Revenue recognition

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue.

 

The Company also receives royalties pursuant to a licensing relationship with Trifoil Imaging. Revenue is recognized in the reporting periods in which royalties are due to the Company. During the nine months ended March 31, 2023 and 2022, there was no income from royalties.

 

(c) Allowance for doubtful accounts

 

In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.

 

Our allowance for doubtful accounts was $850 as of March 31, 2023 and June 30, 2022. These amounts consist of other receivables that have been fully reserved.

 

(d) Cash and cash equivalents

 

Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2023 and June 30, 2022.

 

(e) Concentration of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

 

The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. March 31, 2023 and June 30, 2022, the Company did not have cash balances in excess of the federally insured limit.

 

The Company did not have any revenue for the nine months ended March 31, 2023 and 2022.

 

(f) Inventory

 

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of obsolete inventory. The Company maintains an allowance for obsolete inventory and generally makes inventory value adjustments against the allowance.

 

(g) Property and equipment

 

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.

 

(h) Research and development

 

Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company’s CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.

 

(i) Net loss per share

 

The Company relies on the guidance provided by ASC 260, (“Earnings per Share”), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.

 

The Company had 5,110,000 and 9,610,012 options vested as of March 31, 2023 and June 30, 2022, respectively and 1,095,290 and 1,595,290 options not yet vested as of March 31, 2023 and June 30, 2022, respectively.

 

(j) Stock-based compensation

 

In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard.

 

The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. No stock options were granted during nine months ended March 31, 2023 and 2022. Stock options are being expensed pursuant to ASC 718.

 

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (16) Stock Options.

 

(k) Long-lived assets

 

The Company relies on the guidance provided by ASC 360 (“Property, Plant & Equipment”). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.

 

The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2023 and 2022.

 

(l) Income taxes

 

The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.

 

Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. 

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2020 to 2022 are still potentially subject to audit by the taxing authorities.

 

(m) Warranty reserve

 

The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company’s experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company’s estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2023 or June 30, 2022.

 

(n) Impact of recently issued accounting pronouncements

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

 

(o) Fair Value of Financial Instruments

 

The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company’s debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2023 and June 30, 2022, the aggregate fair value of the Company’s debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 (“Fair Value Measurements and Disclosures”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities

 

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

 

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue
9 Months Ended
Mar. 31, 2023
Revenue [Abstract]  
REVENUE

(4) REVENUE

 

The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Sales taxes and other similar taxes are excluded from revenue. 

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on its financial statements. The Company expects that the impact to net income of the new standard will be immaterial on an ongoing quarterly and annual basis. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.

 

The Company had no revenues during the nine months ended March 31, 2023 and 2022.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
9 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

(5) RELATED PARTY TRANSACTIONS

 

Related party revenues

 

On March 22, 2018, the Board of Directors approved the execution of two agreements with Xi’an of China, an affiliated Company of IDSI. The agreements are a Know How Transfer Contract and a CTLM® Know How Confidentiality Agreement. The contract, having a term of 20 years, stipulates that Xi’an will pay IDSI a know how transfer fee of 25% of revenue for CTLM® product sales in their territory. There were no such sales during the nine months ended March 31, 2023 and 2022.

 

Related party fees

 

Erhfort, LLC earned a consulting fee of $51,000 for the nine-month period ended March 31, 2023 and $76,500 for the nine-month period ending March 31, 2022. Erhfort, LLC regularly reviews the Company’s operations and reports to IDSI’s CEO who lives in China. Erhfort, LLC is a related party because it owns Company common stock directly and indirectly.

 

David Fong, who served as the Company’s CFO through August 10, 2022 and as a consultant on an as needed basis thereafter, earned consulting fees of $32,545 for the nine-month period ended March 31, 2023 and $76,500 for the nine-month period ended March 31, 2022. These fees were assigned to his affiliated business, Fong & Associates, LLC.

 

Related party payables and accrued expenses

 

As of March 31, 2023 and June 30, 2022, the amount of interest on related party notes due to Erhfort, LLC, which is included in accounts payable, is $219,814 and $161,260, respectively.

 

As of March 31, 2023 and June 30, 2022, the amount of consulting fees due to Ehrfort, LLC, which is included in accounts payable, is $204,000 and $153,000, respectively.

 

As March 31, 2023 and June 30, 2022, the amount of consulting fees due to Fong & Associates, LLC, which is included in accounts payable and accrued expenses, is $318,545 and $286,000, respectively.

 

As of March 31, 2023 and June 30, 2022, the amount of reimbursable expenses due to Fong & Associates, LLC, which is included in accounts payable, is $2,808 and $839, respectively.

 

As of March 31, 2023 and June 30, 2022, the amount of interest on related party notes due to JM One Holdings, LLC, which is included in accrued expenses, is $11,112 and $8,860, respectively. JM One Holdings, LLC is an entity affiliated with David Fong.

 

Related party debt

 

As of March 31, 2023 and June 30, 2022, the amount in promissory notes due to related parties are $753,954 and $671,276, respectively (See Note 12).

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Royalty Receivable
9 Months Ended
Mar. 31, 2023
Royalty Receivable [Abstract]  
ROYALTY RECEIVABLE

(6) ROYALTY RECEIVABLE

 

On June 16, 2006, the Company entered into a Royalty Agreement with Bioscan Inc. whereby the Company established a licensing relationship with Bioscan which granted Bioscan an exclusive sublicensable, royalty-bearing license to make, use, offer for sale, import and otherwise develop and commercialize products in its territory. Bioscan Inc. was subsequently purchased by TriFoil Imaging. During the nine months ended March 31, 2023 and 2022, there was no royalty income. As of March 31, 2023 and June 30, 2022, the Company had royalty receivable balances of $0.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories
9 Months Ended
Mar. 31, 2023
Inventories Disclosure [Abstract]  
INVENTORIES

(7) INVENTORIES

 

Inventories consisted of the following:

 

   March 31,
2023
   June 30,
2022
 
         
Raw materials consisting of purchased parts, components and supplies  $92,587   $92,587 
Finished goods   7,500    7,500 
Total Inventory  $100,087   $100,087 
Allowance for Obsolete Inventory   (100,087)   (100,087)
Net Inventory  $
-
   $
-
 

 

Due to the age of the inventory, lack of demand for parts and lack of sales the Company reserved for all inventory during the year ended June 30, 2017. The Company is not carrying any inventory purchased after June 30, 2017 and has booked an allowance for the entire value of its inventory.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Prepaid Expenses and Deposits
9 Months Ended
Mar. 31, 2023
Prepaid Expenses and Deposits Disclosure [Abstract]  
PREPAID EXPENSES AND DEPOSITS

(8) PREPAID EXPENSES AND DEPOSITS

 

The following is a summary of prepaid expenses:

 

   March 31,
2023
   June 30,
2022
 
         
Prepaid Software  $
-
   $206 
Rent Security Deposits   1,783    1,783 
Consulting Retainers   10,000    10,000 
Total Prepaid expenses and Deposits  $11,783   $11,989 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment
9 Months Ended
Mar. 31, 2023
Property and Equipment Disclosure [Abstract]  
PROPERTY AND EQUIPMENT

(9) PROPERTY AND EQUIPMENT

 

The following is a summary of property and equipment, less accumulated depreciation:

 

   March 31,
2023
   June 30,
2022
   Useful life
            
Computers and Equipment  $12,612   $12,612   5 years
Third Party Software   10,291    10,291   5 years
Clinical Equipment   15,000    15,000   5 years
Total Property & Equipment  $37,903   $37,903    
Less: accumulated depreciation   (37,903)   (37,903)   
Total Property & Equipment - Net  $
-
   $
-
    

 

Depreciation expense for the nine months ended March 31, 2023 and 2022 was $0.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Accounts Payable and Accrued Expenses
9 Months Ended
Mar. 31, 2023
Accounts Payable and Accrued Expenses [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES

(10) ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

As of March 31, 2023 and June 30, 2022, accounts payable and accrued expenses totaled $910,920 and $767,317 respectively, which consists of accounts payable of $898,468 and $758,171 and other accrued expenses of $12,452 and $9,146, respectively.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Payroll Taxes and Penalties
9 Months Ended
Mar. 31, 2023
Accrued Payroll Taxes and Penalties [Abstract]  
ACCRUED PAYROLL TAXES AND PENALTIES

(11) ACCRUED PAYROLL TAXES AND PENALTIES

 

As of March 31, 2023 and June 30, 2022, the Company owed the IRS $314,019. Accrued payroll taxes represent outstanding interest and penalties based on prior management’s failure to pay payroll taxes commencing with the quarter ending March 31, 2010. As part of new management’s restructuring plan, the Company received funds from an accredited investor to be able to make a payment to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting penalty and interest abatement. The amount due at March 31, 2023 of $314,019 represents the interest and penalties. The Company has formally asked the IRS to abate all remaining interest and penalties of $314,019. The Company had a telephone conference on April 18, 2019 with the office of appeals and is waiting for further communications from the appeals officer. As of March 31, 2023, the Company’s tax counsel is in the process of reviewing recent IRS correspondence to determine appeals status and will work towards final resolutions with the IRS on all outstanding liabilities. The Company has decided to wait until all resolutions are final before making any adjustments to the balance of $314,019 owed to the IRS.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Promissory Notes – Related Party
9 Months Ended
Mar. 31, 2023
Promissory Notes – Related Party [Abstract]  
PROMISSORY NOTES – RELATED PARTY

(12) PROMISSORY NOTES – RELATED PARTY

 

The following table is a summary of the outstanding note balances as of March 31, 2023 and June 30, 2022.

 

Noteholder  Interest
Rate
   Maturity
Date
  March 31,
2023
   June 30,
2022
 
Related Party Notes:               
Erhfort, LLC   15%  6/30/23  $100,000   $100,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
JM One Holdings, LLC   15%  6/30/23   20,000    20,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
Erhfort, LLC   15%  6/30/23   10,000    10,000 
Erhfort, LLC   15%  6/30/23   10,000    10,000 
Erhfort, LLC   0%  On Demand   2,260    
-
 
Erhfort, LLC   0%  On Demand   3,669    
-
 
Viable International Investments, LLC   0%  On Demand   7,865    7,865 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   3,000    3,000 
Viable International Investments, LLC   0%  On Demand   15,000    15,000 
Viable International Investments, LLC   0%  On Demand   30,000    30,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   8,847    
-
 
Viable International Investments, LLC   0%  On Demand   12,768    
-
 
Viable International Investments, LLC   0%  On Demand   9,988    
-
 
Viable International Investments, LLC   0%  On Demand   7,968    
-
 
Viable International Investments, LLC   0%  On Demand   6,968    
-
 
Viable International Investments, LLC   0%  On Demand   7,786    
-
 
Viable International Investments, LLC   0%  On Demand   5,368    
-
 
Viable International Investments, LLC   0%  On Demand   5,488    
-
 
Viable International Investments, LLC   0%  On Demand   11,568    
-
 
Xi’an IDI   0%  On Demand   10,411    10,411 
Total Related Party Notes          $753,954   $671,276 

 

Erhfort, LLC and Viable International Investments, LLC own Company common stock directly and indirectly. JM One Holdings, LLC is an entity affiliated with the Company’s former CFO. Hence, these debts are considered related party debt. Xi’an IDI is affiliated with IDSI due to a licensing agreement.

 

During the nine months ended March 31, 2023, the Company received loan proceeds of $76,749 from Viable International Investments, LLC and $2,260 from Erhfort, LLC with an annual interest rate of 0%. The Company also converted $3,669 of accounts payables into a loan from Erhfort, LLC with an annual interest rate of 0%. During the nine months ended March 31, 2022, the Company received loan proceeds of $80,000 from Viable International Investments, LLC with an annual interest rate of 0%.

 

On March 31, 2023, the maturity dates of the loans that were due to mature on March 31, 2023 were extended to June 30, 2023. The extension of the maturity dates is a modification of the loans, and not accounted for as gain or loss extinguishments.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt
9 Months Ended
Mar. 31, 2023
Long-Term Debt [Abstract]  
LONG-TERM DEBT

(13) LONG-TERM DEBT

 

The following table is a summary of the outstanding loan balances as of March 31, 2023 and June 30, 2022.

 

Noteholder  Interest
Rate
   Maturity
Date
  March 31,
2023
   June 30,
2022
 
Truist Bank   1%  In Default  $72,930   $72,930 
Total Debt           72,930    72,930 
Current Portion of Debt           (72,930)   (72,930)
Total Long-term Debt          $
-
   $
-
 

 

On May 9, 2020, the Company entered into a loan with Truist Bank, a lender pursuant to the Paycheck Protection Program of the CARES Act as administered by the SBA in the amount of $79,600. The loan, in the form of a promissory note, had an original maturity date of May 1, 2025. No additional collateral or guarantees were provided by the Company for the loan. The PPP loan provides for customary events of default. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, rent payments, mortgage interest and covered utilities during the 24-week period beginning on the date of loan disbursement.  The Company is required to repay the entire amount of outstanding principal, along with accrued interest, as the Company is not eligible for forgiveness. The Company began to make payments, beginning October 2021, including interest accruing at an annual interest rate of 1.0% beginning on the date of disbursement. On May 17, 2022, the Company received a default and demand letter from Truist Bank in regards to the PPP loan due to non-payment. As such the remaining balance of the PPP loan became due immediately. As of March 31, 2023 and June 30, 2022, the Company reported an accrued interest balance related to the PPP Loan of $740 and $186, respectively. The accrued interest is included in accounts payable and accrued expenses on our balance sheets.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Preferred Stock
9 Months Ended
Mar. 31, 2023
Convertible Preferred Stock [Abstract]  
CONVERTIBLE PREFERRED STOCK

(14) CONVERTIBLE PREFERRED STOCK

 

The following schedule reflects the number of shares of preferred stock that have been issued, converted and are outstanding as of March 31, 2023:

 

Security  Date Issued  No. of
Shares
   Amount   Date of
Conversion
  No. of
Shares
Converted
   Amount
Converted
   Balance
3/31/2023
 
Series L Cv Pfd  3/31/2010   35   $350,000   1/6/2011   15   $150,000   $200,000 
Dividends                             247,451 
Total redemption value                        $447,451 
                                
Total Series M Cv Pfd  Various   600   $6,000,000   1/6/2011   600   $6,000,000   $-0- 
Dividends                             -0- 
Total redemption value                        $-0- 

 

Series L Convertible Preferred Stock

 

On March 31, 2010, a private investor converted a $350,000 short-term promissory note into 35 shares of Series L Convertible Preferred Stock. The original purchase price/stated value is $10,000 per share and dividends accrue at an annual rate of 9%. The preferred stock is convertible into 474 shares of common stock for each share of preferred stock. On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time. At March 31, 2023 and June 30, 2022, the balance of cumulative dividends owed to the investor which is included in redemption value was $247,450 and $233,939, respectively. The total presented on the balance sheet as temporary equity is $447,451 as of March 31, 2023 and $433,939 as of June 30, 2022.

 

Series M Convertible Preferred Stock

 

The Company had previously sold 600 Series M Convertible Preferred Stock to Viable International Investments, LLC, a Florida limited liability company, (“Viable”). Each share of the Series M Preferred Stock was convertible into 147,283 shares of Common Stock. In the event of a liquidation, the holders of the Series M Preferred Stock would have been entitled to receive, prior to any distribution of assets to holders of Common Stock or other class of capital stock or other equity securities of the Corporation, $10,000 per share of Series M Preferred Stock held plus accrued but unpaid dividends. The holders of the Series M Preferred Stock would have had identical voting rights as any holder of Common Stock and would have voted together, not as separate classes. The original purchase price/stated value of each share of Series M Preferred Stock was $10,000 and Viable was be entitled to receive cumulative dividends at the fixed rate of 9% of the stated value per share per annum. On November 21, 2017, Viable converted 3 shares of its Series M Preferred Stock to 441,878 shares of restricted common stock. On April 18, 2017, Viable converted 6 shares of its Series M Preferred Stock to 883,696 shares of restricted common stock, and on August 7, 2018, Viable converted its remaining 591 shares of Series M Preferred Stock into 87,044,089 shares of restricted common stock. As of March 31, 2023 and June 30, 2022, the balance of Series M Preferred Stock was $0.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Common Stock
9 Months Ended
Mar. 31, 2023
Common Stock [Abstract]  
COMMON STOCK

(15) COMMON STOCK

 

The Company has 500,000,000 of common shares no par value authorized and 2,000,000 of no par preferred shares authorized.

 

The Company did not issue any shares of common or preferred stock during the nine months ended March 31, 2023 and 2022.

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Options
9 Months Ended
Mar. 31, 2023
Stock Options [Abstract]  
STOCK OPTIONS

(16) STOCK OPTIONS

 

On December 4, 2016, the Board of Directors adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”) which was subsequently approved and adopted by majority written consent in lieu of an annual meeting. The purpose of the 2016 Plan is to encourage and enable the officers, employees, directors and other key persons (including consultants) of the Company, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

 

In computing the impact of stock option grants, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility of a comparable company; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future.

 

In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company cannot assess its forfeiture rate at this time due to the lack of historical data.

 

   As of
March 31,
2023
   As of
June 30,
2022
 
Expected volatility   20% to 44%    20% to 44% 
Expected term   0.08 to 3.08 Years    0.5 to 4.83 Years 
Risk-Free interest rate   0.05% to 2.49%    0.05% to 2.49% 
Forfeiture rate   0.00%    0.00% 
Expected dividend rate   0.00%   0.00%

 

At March 31, 2023, the Company has unvested and vested options under the 2016 Plan with exercise prices that range from a low of $.20 per share to a high of $.51 per share. The following table summarizes information about all of the stock options granted, exercised, expired and cancelled under the 2016 Plan at March 31, 2023 and June 30, 2022:

 

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
   Wtd. Avg.
Remaining
Term
  Aggregate
Intrinsic
Value
 
Outstanding at June 30, 2021   16,752,935   $0.25   1.76 Years  $
         -
 
Granted   
-
   $
-
         
Expired   (5,547,645)  $0.20         
Exercised   
-
   $
-
       
 
 
Cancelled   
-
   $
-
       
 
 
Outstanding at June 30, 2022   11,205,290   $0.30   1.39 Years  $
-
 
Granted   
-
   $
-
         
Expired   (5,000,000)  $0.20         
Exercised   
-
   $
-
         
Cancelled   
-
   $
-
       
 
 
Outstanding at March 31, 2023   6,205,290   $0.39   1.34 Years  $
-
 

 

The following table summarizes information about vested and unvested options under the 2016 Plan at March 31, 2023 and June 30, 2022. The Company recognized an expense of $60,699 for options vested during the nine months ended March 31, 2023.

 

 

Employees/Consultants

  Unvested   Vested and Exercisable   Total 
Outstanding at June 30, 2021   2,830,290    13,922,645    16,752,935 
Granted   
-
    
-
    
-
 
Vested and Exercisable   (1,235,000)   1,235,000    
-
 
Cancelled   
-
    
-
    
-
 
Expired   
-
    (5,547,645)   
-
 
Outstanding at June 30, 2022   1,595,290    9,610,000    11,205,290 
Granted   
-
    
-
    
-
 
Vested and Exercisable   (500,000)   500,000    
-
 
Cancelled   
-
    
-
    
-
 
Expired   
-
    (5,000,000)   
-
 
Adjustment   
-
    
-
    
-
 
Outstanding at March 31, 2023   1,095,290    5,110,000    6,205,290 

 

Unvested options will be expensed under the Black-Scholes options-pricing model when they vest. As of March 31, 2023 remaining options to be expensed when vested over the next year are estimated to be $118,328.

 

At March 31, 2023, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan. All the options for the previous five plans through and including the 2012 Non-Statutory Plan have expired.

 

The tables below summarize information about these five plans:

 

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
   Wtd. Avg.
Remaining
Term
   Aggregate Intrinsic Value 
Outstanding at June 30, 2021   12   $350     1.11 Years   $
         -
 
Granted   
-
   $
-
           
Exercised   
-
   $
-
           
Cancelled   
-
   $
-
      
 
   
Outstanding at June 30, 2022   12   $350     0.11 Years   $
-
 
Granted   
-
   $
-
           
Exercised   
-
   $
-
           
Cancelled   (12)  $350           
Outstanding at March 31, 2023   
-
   $
-
    
-
   $
-
 

 

Vested & Exercisable Stock Options  March 31,
2023
   June 30,
2022
 
Employee 2016 Equity Plan   
-
    
-
 
Director 2016 Equity Plan   
-
    
-
 
Employee Other Plans   
-
    12 
Directors and Consultants Other Plans   
-
    
-
 
Total   
-
    12 

 

The table below summarizes information about all stock options outstanding as of March 31, 2023:

 

   Outstanding Options   Vested Options 
Range of Exercise price  Number
Outstanding at
March 31,
2023
   Weighted
Averaged
Exercise
Price
   Weighted
Averaged
Remaining
Life (Years)
   Number
Exercisable at
March 31,
2023
   Weighted
Averaged
Exercise
Price
   Weighted
Averaged
Remaining
Life (Years)
 
$0.20 - $0.51   6,205,290   $0.39    1.34    5,110,000   $0.36    1.05 
Total Outstanding options   6,205,290   $0.39    1.34    5,110,000   $0.36    1.05 

 

The Company’s common stock, symbol IMDS, was quoted on OTCmarkets.com Pink until September 25, 2014 at which time IDSI’s registration was revoked by the Securities and Exchange Commission (SEC) for failure to timely file its Quarterly and Annual Reports. The last quoted price was $0.1. Because the Company was de-registered and OTC markets did not provide a quote for IMDS, there is no public market for the Company’s shares. Given the exercise prices adjusted for the reverse split, it is highly unlikely that any employee holding pre-2016 Plan options will exercise them. The Company has sufficient authorized shares available for all outstanding option; however, if exercised, the shares will be issued with a restrictive legend because the Company was not an SEC reporting company until October 2018. Further, given its recent return to SEC reporting status, the Company is unable to file an S-8 Registration Statement to register shares issued because of option exercise pursuant to various stock option agreements.

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
9 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

(17) COMMITMENTS AND CONTINGENCIES

 

The Company previously carried $3,000,000 in product liability insurance to cover both clinical sites and sales. As part of its cost savings initiatives, the Company cancelled the policy as it had not had any adverse experiences after conducting more than 25,000 patient scans worldwide. The Company is now self-insuring the risk of product liability.

 

From May 2010 to June 2012, claims were made by the IRS for payment of the Company’s accrued payroll taxes, interest and penalties, which as of June 30, 2012 was $1,489,640. The Company engaged tax counsel to handle this matter and intends to fully satisfy its payroll tax obligations. On August 4, 2014, Viable purchased 250 shares of convertible preferred stock for $2,500,000, which gave them a 78.9% voting and economic interest in the Company’s capital stock representing a change in control of the Company. New management’s tax counsel negotiated a new Installment Agreement which stipulated a lump sum payment of $250,000, which was paid on September 4, 2014 and monthly installment payments of $20,000 beginning in September 2014 due on the 18th of each month until the balance of payroll taxes, interest and penalties are paid in full (Note 11).

 

During fiscal 2018, as part of new management’s restructuring plan, the Company received funds from an accredited investor to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting abatement of penalties and interest totaling $314,019. As of March 31, 2023, the Company’s tax counsel is in the process of reviewing recent IRS correspondence to determine appeals status and will work towards final resolutions with the IRS on all outstanding liabilities. The Company has decided to wait until all resolutions are final before making any adjustments to the balance of $314,019 owed to the IRS.

 

On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s CTLM® breast imaging device. Per the Agreement, the goal of the initial project was to complete image quality improvement by November 1, 2020. A payment of $500,000 will be due upon satisfactory completion of the project. As of March 31, 2023, Dr. Jiang has completed the first phase of image quality improvement and is currently collecting image data for evaluation and further technical improvement. We have yet to establish the effectiveness of the improvements, as completion of the project has been delayed due to the COVID-19 crisis.

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
9 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

(18) SUBSEQUENT EVENTS

 

On April 5, 2023, the Company received loan proceeds of $1,620 from Erhfort, LLC. Interest is 0% and the principal is payable upon demand.

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Accounting Policies, by Policy (Policies)
9 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of presentation and use of estimates

(a) Basis of presentation and use of estimates

 

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The unaudited interim financial information furnished herein reflects all adjustments, consisting only of normal recurring items, which in the opinion of management are necessary to fairly state the Company’s financial position, results of operations and cash flows for the dates and periods presented and to make such information not misleading. The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

 

These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal year ended June 30, 2022, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “Commission”) on October 4, 2022. The results of operations for the nine months ended March 31, 2023, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2023.

 

Revenue recognition

(b) Revenue recognition

 

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue.

 

The Company also receives royalties pursuant to a licensing relationship with Trifoil Imaging. Revenue is recognized in the reporting periods in which royalties are due to the Company. During the nine months ended March 31, 2023 and 2022, there was no income from royalties.

 

Allowance for doubtful accounts

(c) Allowance for doubtful accounts

 

In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.

 

Our allowance for doubtful accounts was $850 as of March 31, 2023 and June 30, 2022. These amounts consist of other receivables that have been fully reserved.

 

Cash and cash equivalents

(d) Cash and cash equivalents

 

Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2023 and June 30, 2022.

 

Concentration of Risk

(e) Concentration of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

 

The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. March 31, 2023 and June 30, 2022, the Company did not have cash balances in excess of the federally insured limit.

 

The Company did not have any revenue for the nine months ended March 31, 2023 and 2022.

 

Inventory

(f) Inventory

 

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of obsolete inventory. The Company maintains an allowance for obsolete inventory and generally makes inventory value adjustments against the allowance.

 

Property and equipment

(g) Property and equipment

 

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.

 

Research and development

(h) Research and development

 

Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company’s CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.

 

Net loss per share

(i) Net loss per share

 

The Company relies on the guidance provided by ASC 260, (“Earnings per Share”), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.

 

The Company had 5,110,000 and 9,610,012 options vested as of March 31, 2023 and June 30, 2022, respectively and 1,095,290 and 1,595,290 options not yet vested as of March 31, 2023 and June 30, 2022, respectively.

 

Stock-based compensation

(j) Stock-based compensation

 

In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard.

 

The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. No stock options were granted during nine months ended March 31, 2023 and 2022. Stock options are being expensed pursuant to ASC 718.

 

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (16) Stock Options.

 

Long-lived assets

(k) Long-lived assets

 

The Company relies on the guidance provided by ASC 360 (“Property, Plant & Equipment”). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.

 

The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2023 and 2022.

 

Income taxes

(l) Income taxes

 

The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.

 

Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. 

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2020 to 2022 are still potentially subject to audit by the taxing authorities.

 

Warranty reserve

(m) Warranty reserve

 

The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company’s experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company’s estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2023 or June 30, 2022.

 

Impact of recently issued accounting pronouncements

(n) Impact of recently issued accounting pronouncements

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

 

Fair Value of Financial Instruments

(o) Fair Value of Financial Instruments

 

The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company’s debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2023 and June 30, 2022, the aggregate fair value of the Company’s debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 (“Fair Value Measurements and Disclosures”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities

 

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

 

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Tables)
9 Months Ended
Mar. 31, 2023
Inventories [Abstract]  
Schedule of inventories
   March 31,
2023
   June 30,
2022
 
         
Raw materials consisting of purchased parts, components and supplies  $92,587   $92,587 
Finished goods   7,500    7,500 
Total Inventory  $100,087   $100,087 
Allowance for Obsolete Inventory   (100,087)   (100,087)
Net Inventory  $
-
   $
-
 

 

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Prepaid Expenses and Deposits (Tables)
9 Months Ended
Mar. 31, 2023
Prepaid Expenses and Deposits [Abstract]  
Schedule of prepaid expenses
   March 31,
2023
   June 30,
2022
 
         
Prepaid Software  $
-
   $206 
Rent Security Deposits   1,783    1,783 
Consulting Retainers   10,000    10,000 
Total Prepaid expenses and Deposits  $11,783   $11,989 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment (Tables)
9 Months Ended
Mar. 31, 2023
Property and Equipment [Abstract]  
Schedule of property and equipment, less accumulated depreciation
   March 31,
2023
   June 30,
2022
   Useful life
            
Computers and Equipment  $12,612   $12,612   5 years
Third Party Software   10,291    10,291   5 years
Clinical Equipment   15,000    15,000   5 years
Total Property & Equipment  $37,903   $37,903    
Less: accumulated depreciation   (37,903)   (37,903)   
Total Property & Equipment - Net  $
-
   $
-
    

 

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Promissory Notes – Related Party (Tables)
9 Months Ended
Mar. 31, 2023
Promissory Notes – Related Party [Abstract]  
Schedule of outstanding note balances
Noteholder  Interest
Rate
   Maturity
Date
  March 31,
2023
   June 30,
2022
 
Related Party Notes:               
Erhfort, LLC   15%  6/30/23  $100,000   $100,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
JM One Holdings, LLC   15%  6/30/23   20,000    20,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
Erhfort, LLC   15%  6/30/23   100,000    100,000 
Erhfort, LLC   15%  6/30/23   10,000    10,000 
Erhfort, LLC   15%  6/30/23   10,000    10,000 
Erhfort, LLC   0%  On Demand   2,260    
-
 
Erhfort, LLC   0%  On Demand   3,669    
-
 
Viable International Investments, LLC   0%  On Demand   7,865    7,865 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   3,000    3,000 
Viable International Investments, LLC   0%  On Demand   15,000    15,000 
Viable International Investments, LLC   0%  On Demand   30,000    30,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   5,000    5,000 
Viable International Investments, LLC   0%  On Demand   10,000    10,000 
Viable International Investments, LLC   0%  On Demand   8,847    
-
 
Viable International Investments, LLC   0%  On Demand   12,768    
-
 
Viable International Investments, LLC   0%  On Demand   9,988    
-
 
Viable International Investments, LLC   0%  On Demand   7,968    
-
 
Viable International Investments, LLC   0%  On Demand   6,968    
-
 
Viable International Investments, LLC   0%  On Demand   7,786    
-
 
Viable International Investments, LLC   0%  On Demand   5,368    
-
 
Viable International Investments, LLC   0%  On Demand   5,488    
-
 
Viable International Investments, LLC   0%  On Demand   11,568    
-
 
Xi’an IDI   0%  On Demand   10,411    10,411 
Total Related Party Notes          $753,954   $671,276 

 

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt (Tables)
9 Months Ended
Mar. 31, 2023
Long-Term Debt [Abstract]  
Schedule of a summary of the outstanding loan balances
Noteholder  Interest
Rate
   Maturity
Date
  March 31,
2023
   June 30,
2022
 
Truist Bank   1%  In Default  $72,930   $72,930 
Total Debt           72,930    72,930 
Current Portion of Debt           (72,930)   (72,930)
Total Long-term Debt          $
-
   $
-
 

 

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Preferred Stock (Tables)
9 Months Ended
Mar. 31, 2023
Convertible Preferred Stock [Abstract]  
Schedule of number of shares of preferred stock that have been issued, converted and are outstanding
Security  Date Issued  No. of
Shares
   Amount   Date of
Conversion
  No. of
Shares
Converted
   Amount
Converted
   Balance
3/31/2023
 
Series L Cv Pfd  3/31/2010   35   $350,000   1/6/2011   15   $150,000   $200,000 
Dividends                             247,451 
Total redemption value                        $447,451 
                                
Total Series M Cv Pfd  Various   600   $6,000,000   1/6/2011   600   $6,000,000   $-0- 
Dividends                             -0- 
Total redemption value                        $-0- 

 

XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Options (Tables)
9 Months Ended
Mar. 31, 2023
Stock Options [Abstract]  
Schedule of estimate the expected forfeiture rate and only recognize expense
   As of
March 31,
2023
   As of
June 30,
2022
 
Expected volatility   20% to 44%    20% to 44% 
Expected term   0.08 to 3.08 Years    0.5 to 4.83 Years 
Risk-Free interest rate   0.05% to 2.49%    0.05% to 2.49% 
Forfeiture rate   0.00%    0.00% 
Expected dividend rate   0.00%   0.00%

 

Schedule of stock options granted, exercised, expired and cancelled
Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
   Wtd. Avg.
Remaining
Term
  Aggregate
Intrinsic
Value
 
Outstanding at June 30, 2021   16,752,935   $0.25   1.76 Years  $
         -
 
Granted   
-
   $
-
         
Expired   (5,547,645)  $0.20         
Exercised   
-
   $
-
       
 
 
Cancelled   
-
   $
-
       
 
 
Outstanding at June 30, 2022   11,205,290   $0.30   1.39 Years  $
-
 
Granted   
-
   $
-
         
Expired   (5,000,000)  $0.20         
Exercised   
-
   $
-
         
Cancelled   
-
   $
-
       
 
 
Outstanding at March 31, 2023   6,205,290   $0.39   1.34 Years  $
-
 

 

Employees/Consultants  Options   Wtd. Avg.
Exercise
Price
   Wtd. Avg.
Remaining
Term
   Aggregate Intrinsic Value 
Outstanding at June 30, 2021   12   $350     1.11 Years   $
         -
 
Granted   
-
   $
-
           
Exercised   
-
   $
-
           
Cancelled   
-
   $
-
      
 
   
Outstanding at June 30, 2022   12   $350     0.11 Years   $
-
 
Granted   
-
   $
-
           
Exercised   
-
   $
-
           
Cancelled   (12)  $350           
Outstanding at March 31, 2023   
-
   $
-
    
-
   $
-
 

 

Schedule of vested and unvested options

 

Employees/Consultants

  Unvested   Vested and Exercisable   Total 
Outstanding at June 30, 2021   2,830,290    13,922,645    16,752,935 
Granted   
-
    
-
    
-
 
Vested and Exercisable   (1,235,000)   1,235,000    
-
 
Cancelled   
-
    
-
    
-
 
Expired   
-
    (5,547,645)   
-
 
Outstanding at June 30, 2022   1,595,290    9,610,000    11,205,290 
Granted   
-
    
-
    
-
 
Vested and Exercisable   (500,000)   500,000    
-
 
Cancelled   
-
    
-
    
-
 
Expired   
-
    (5,000,000)   
-
 
Adjustment   
-
    
-
    
-
 
Outstanding at March 31, 2023   1,095,290    5,110,000    6,205,290 

 

Schedule of information about vested & exercisable stock options
Vested & Exercisable Stock Options  March 31,
2023
   June 30,
2022
 
Employee 2016 Equity Plan   
-
    
-
 
Director 2016 Equity Plan   
-
    
-
 
Employee Other Plans   
-
    12 
Directors and Consultants Other Plans   
-
    
-
 
Total   
-
    12 

 

Schedule of stock options outstanding
   Outstanding Options   Vested Options 
Range of Exercise price  Number
Outstanding at
March 31,
2023
   Weighted
Averaged
Exercise
Price
   Weighted
Averaged
Remaining
Life (Years)
   Number
Exercisable at
March 31,
2023
   Weighted
Averaged
Exercise
Price
   Weighted
Averaged
Remaining
Life (Years)
 
$0.20 - $0.51   6,205,290   $0.39    1.34    5,110,000   $0.36    1.05 
Total Outstanding options   6,205,290   $0.39    1.34    5,110,000   $0.36    1.05 

 

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Going Concern and Management's Plans (Details)
9 Months Ended
Mar. 31, 2023
USD ($)
Going Concern and Management's Plans [Abstract]  
Accumulated deficit $ 135,784,184
Stockholders’ deficit 2,487,368
Working capital deficit 2,039,917
Net loss 287,676
Net cash used in operating activities $ 79,499
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details) - USD ($)
9 Months Ended 12 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Accounting Policies [Abstract]    
Allowance for doubtful accounts (in Dollars) $ 850 $ 850
Federal deposit insurance corporation limit (in Dollars) $ 250,000  
Options vested 5,110,000 9,610,012
Options non vested 1,095,290 1,595,290
Tax position, description Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority.  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Details) - USD ($)
1 Months Ended 9 Months Ended
Mar. 22, 2018
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
Related Party Transactions (Details) [Line Items]        
Contract term 20 years      
Percentage of transfer fee 25.00%      
Accounts payable   $ 2,808   $ 839
Short-Term Debt   753,954   671,276
Ehrfort, LLC [Member]        
Related Party Transactions (Details) [Line Items]        
Consulting fee   51,000 $ 76,500  
Accounts payable   219,814   161,260
David Fong [Member]        
Related Party Transactions (Details) [Line Items]        
Consulting fee   32,545 $ 76,500  
Erhfort, LLC One [Member]        
Related Party Transactions (Details) [Line Items]        
Accounts payable   204,000   153,000
Fong & Associates, LLC [Member]        
Related Party Transactions (Details) [Line Items]        
Accounts payable and accrued expense   318,545   286,000
JM One Holdings, LLC [Member]        
Related Party Transactions (Details) [Line Items]        
Accrued expenses   $ 11,112   $ 8,860
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Royalty Receivable (Details) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Royalty Receivable [Abstract]    
Royalty receivable balances $ 0 $ 0
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Details) - Schedule of inventories - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Schedule of inventories [Abstract]    
Raw materials consisting of purchased parts, components and supplies $ 92,587 $ 92,587
Finished goods 7,500 7,500
Total Inventory 100,087 100,087
Allowance for Obsolete Inventory (100,087) (100,087)
Net Inventory
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Prepaid Expenses and Deposits (Details) - Schedule of prepaid expenses - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Prepaid Expenses and Deposits [Abstract]    
Prepaid Software $ 206
Rent Security Deposits 1,783 1,783
Consulting Retainers 10,000 10,000
Total Prepaid expenses and Deposits $ 11,783 $ 11,989
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment (Details) - USD ($)
9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 0 $ 0
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment (Details) - Schedule of property and equipment, less accumulated depreciation - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Property, Plant and Equipment [Line Items]    
Total Property & Equipment $ 37,903 $ 37,903
Less: accumulated depreciation (37,903) (37,903)
Total Property & Equipment - Net
Computers and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total Property & Equipment $ 12,612 12,612
Useful life 5 years  
Third Party Software [Member]    
Property, Plant and Equipment [Line Items]    
Total Property & Equipment $ 10,291 10,291
Useful life 5 years  
Clinical Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total Property & Equipment $ 15,000 $ 15,000
Useful life 5 years  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Accounts Payable and Accrued Expenses (Details) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Accounts Payable and Accrued Expenses [Abstract]    
Accounts payable and accrued expenses $ 910,920 $ 767,317
Accounts payable 898,468 758,171
Other accrued expenses $ 12,452 $ 9,146
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Payroll Taxes and Penalties (Details) - USD ($)
Mar. 31, 2023
Jun. 30, 2022
Jun. 27, 2018
Accrued Payroll Taxes and Penalties [Abstract]      
Accrued payroll taxes $ 314,019 $ 314,019  
Balance of taxes due     $ 381,224
Interest and penalties 314,019    
Remaining interest and penalties 314,019    
Adjustments balance $ 314,019    
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Promissory Notes – Related Party (Details) - USD ($)
9 Months Ended
Mar. 31, 2023
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
Promissory Notes – Related Party (Details) [Line Items]        
Annual interest rate, percentage   0.00%    
Accounts payables $ 898,468 $ 898,468   $ 758,171
Promissory notes related party, description the maturity dates of the loans that were due to mature on March 31, 2023 were extended to June 30, 2023.      
Viable International Investments, LLC [Member]        
Promissory Notes – Related Party (Details) [Line Items]        
Loan proceeds     $ 80,000  
Annual interest rate, percentage     0.00%  
Viable International Investments, LLC [Member]        
Promissory Notes – Related Party (Details) [Line Items]        
Loan proceeds   76,749    
Related parties amount   $ 2,260    
Annual interest rate, percentage   0.00%    
Accounts payables $ 3,669 $ 3,669    
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Promissory Notes – Related Party (Details) - Schedule of outstanding note balances - USD ($)
9 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Promissory Notes – Related Party [Abstract]    
Total Related Party Notes $ 753,954 $ 671,276
Erhfort, LLC [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 15.00%  
Maturity Date 6/30/23  
Total Related Party Notes $ 100,000 100,000
Erhfort, LLC One [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 15.00%  
Maturity Date 6/30/23  
Total Related Party Notes $ 100,000 100,000
JM One Holdings, LLC [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 15.00%  
Maturity Date 6/30/23  
Total Related Party Notes $ 20,000 20,000
Erhfort, LLC Two [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 15.00%  
Maturity Date 6/30/23  
Total Related Party Notes $ 100,000 100,000
Erhfort, LLC Three [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 15.00%  
Maturity Date 6/30/23  
Total Related Party Notes $ 100,000 100,000
Erhfort, LLC Four [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 15.00%  
Maturity Date 6/30/23  
Total Related Party Notes $ 100,000 100,000
Erhfort, LLC Five [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 15.00%  
Maturity Date 6/30/23  
Total Related Party Notes $ 10,000 10,000
Erhfort, LLC Six [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 15.00%  
Maturity Date 6/30/23  
Total Related Party Notes $ 10,000 10,000
Erhfort, LLC Seven [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 2,260
Erhfort, LLC Eight [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 3,669
Viable International Investments, LLC [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 7,865 7,865
Viable International Investments, LLC One [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 5,000 5,000
Viable International Investments, LLC Two [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 5,000 5,000
Viable International Investments, LLC Three [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 5,000 5,000
Viable International Investments, LLC Four [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 5,000 5,000
Viable International Investments, LLC Five [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 3,000 3,000
Viable International Investments, LLC Six [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 15,000 15,000
Viable International Investments, LLC Seven [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 30,000 30,000
Viable International Investments, LLC Eight [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 10,000 10,000
Viable International Investments, LLC Nine [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 10,000 10,000
Viable International Investments, LLC Ten [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 10,000 10,000
Viable International Investments, LLC Eleven [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 5,000 5,000
Viable International Investments, LLC Twelve [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 10,000 10,000
Viable International Investments, LLC Thirteen [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 8,847
Viable International Investments, LLC Fourteen [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 12,768
Viable International Investments, LLC Fifteen [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 9,988
Viable International Investments, LLC Sixteen [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 7,968
Viable International Investments, LLC Seventeen [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 6,968
Viable International Investments, LLC Eighteen [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 7,786
Viable International Investments, LLC Nineteen [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 5,368
Viable International Investments, LLC Twenty [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 5,488
Viable International Investments, LLC Twenty One [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 11,568
Xi’an IDI [Member]    
Promissory Notes – Related Party [Abstract]    
Interest Rate 0.00%  
Maturity Date On Demand  
Total Related Party Notes $ 10,411 $ 10,411
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt (Details) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
May 09, 2020
Oct. 31, 2021
Mar. 31, 2023
Jun. 30, 2022
Long-Term Debt (Details) [Line Items]        
Loan amount $ 79,600      
Maturity date May 01, 2025      
Interest rate   1.00%    
PPP Loan [Member]        
Long-Term Debt (Details) [Line Items]        
Accrued interest     $ 740 $ 186
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt (Details) - Schedule of a summary of the outstanding loan balances - USD ($)
9 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Debt Instrument [Line Items]    
Total Debt $ 72,930 $ 72,930
Current Portion of Debt (72,930) (72,930)
Total Long-term Debt
Truist Bank [Member]    
Debt Instrument [Line Items]    
Interest Rate 1.00%  
Maturity Date In Default  
Total Debt $ 72,930 $ 72,930
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Preferred Stock (Details) - USD ($)
1 Months Ended 9 Months Ended
Aug. 07, 2018
Jan. 06, 2011
Nov. 21, 2017
Apr. 18, 2017
Mar. 31, 2010
Mar. 31, 2023
Jun. 30, 2022
Convertible Preferred Stock (Details) [Line Items]              
Redemption value (in Dollars)           $ 247,450 $ 233,939
Total temporary equity (in Dollars)           $ 447,451 $ 433,939
Series L Convertible Preferred Stock [Member]              
Convertible Preferred Stock (Details) [Line Items]              
Converted short term promissory note (in Dollars)         $ 350,000    
Convertible preferred stock         35    
Original purchase price (in Dollars)         $ 10,000    
Annual rate         9.00%    
Conversion of preferred stock to common stock         474    
Convertible preferred stock description   On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time.          
Series M Preferred Stock [Member]              
Convertible Preferred Stock (Details) [Line Items]              
Convertible preferred stock           147,283  
Original purchase price (in Dollars)           $ 10,000  
Conversion of preferred stock to common stock 591   3 6      
Convertible preferred stock           600  
Other equity securities (in Dollars per share)           $ 10,000  
Cumulative dividend fixed rate           9.00%  
Shares of restricted common stock 87,044,089   441,878 883,696      
Preferred stock, shares issued           0 0
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Preferred Stock (Details) - Schedule of number of shares of preferred stock that have been issued, converted and are outstanding
9 Months Ended
Mar. 31, 2023
USD ($)
shares
Series L Cv Pfd [Member]  
Convertible Preferred Stock [Abstract]  
Dividends $ 247,451
Total redemption value $ 447,451
Series L Cv Pfd [Member] | Issued on 3/31/2010 [Member]  
Convertible Preferred Stock [Abstract]  
No. of Shares (in Shares) | shares 35
Amount $ 350,000
Date of Conversion Jan. 06, 2011
No. of Shares Converted (in Shares) | shares 15
Amount Converted $ 150,000
Balance 12/31/2022 $ 200,000
Series M Cv Pfd [Member]  
Convertible Preferred Stock [Abstract]  
No. of Shares (in Shares) | shares 600
Amount $ 6,000,000
Date of Conversion Jan. 06, 2011
No. of Shares Converted (in Shares) | shares 600
Amount Converted $ 6,000,000
Balance 12/31/2022 0
Dividends 0
Total redemption value $ 0
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Common Stock (Details) - $ / shares
Mar. 31, 2023
Jun. 30, 2022
Common Stock [Abstract]    
Common stock, shares authorized 500,000,000 500,000,000
Preferred stock, shares authorized 2,000,000 2,000,000
Common stock, no par value  
Preferred stock, no par value
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Options (Details)
9 Months Ended
Mar. 31, 2023
USD ($)
$ / shares
Stock Options [Abstract]  
Lower range of exercise price $ 0.20
Purchase exercise price $ 0.51
Expense of options vested (in Dollars) | $ $ 60,699
Estimated vesting expense (in Dollars) | $ $ 118,328
Stock options, description At March 31, 2023, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan.
Shares issued, price per share $ 0.1
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense
9 Months Ended 12 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense [Line Items]    
Forfeiture rate 0.00% 0.00%
Expected dividend rate 0.00% 0.00%
Minimum [Member]    
Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense [Line Items]    
Expected volatility 20.00% 20.00%
Expected term 29 days 6 months
Risk-Free interest rate 0.05% 0.05%
Maximum [Member]    
Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense [Line Items]    
Expected volatility 44.00% 44.00%
Expected term 3 years 29 days 4 years 9 months 29 days
Risk-Free interest rate 2.49% 2.49%
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled - USD ($)
9 Months Ended 12 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Vested and Unvested Options [Member]    
Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled [Line Items]    
Options, Outstanding 11,205,290 16,752,935
Wtd. Avg. Exercise Price, Outstanding $ 0.3 $ 0.25
Wtd. Avg. Remaining Term, Outstanding   1 year 9 months 3 days
Aggregate Intrinsic Value, Outstanding
Options, Granted
GrantedWtd. Avg. Exercise Price, Granted
Options, Expired (5,000,000) (5,547,645)
Wtd. Avg. Exercise Price, Expired $ 0.2 $ 0.2
Options, Exercised
Wtd. Avg. Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised  
Options, Cancelled
Wtd. Avg. Exercise Price, Cancelled
Aggregate Intrinsic Value, Cancelled
Options, Outstanding 6,205,290 11,205,290
Wtd. Avg. Exercise Price, Outstanding $ 0.39 $ 0.3
Wtd. Avg. Remaining Term, Outstanding 1 year 4 months 2 days 1 year 4 months 20 days
Aggregate Intrinsic Value, Outstanding
Previous Five Plan Including Non-Statutory Plan [Member]    
Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled [Line Items]    
Options, Outstanding 12 12
Wtd. Avg. Exercise Price, Outstanding $ 350 $ 350
Wtd. Avg. Remaining Term, Outstanding   1 year 1 month 9 days
Aggregate Intrinsic Value, Outstanding
Options, Granted
GrantedWtd. Avg. Exercise Price, Granted
Options, Exercised
Wtd. Avg. Exercise Price, Exercised
Options, Cancelled (12)
Wtd. Avg. Exercise Price, Cancelled $ 350
Aggregate Intrinsic Value, Cancelled  
Options, Outstanding 12
Wtd. Avg. Exercise Price, Outstanding $ 350
Wtd. Avg. Remaining Term, Outstanding 1 month 9 days
Aggregate Intrinsic Value, Outstanding
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Options (Details) - Schedule of vested and unvested options - shares
9 Months Ended 12 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Stock Options (Details) - Schedule of vested and unvested options [Line Items]    
Outstanding, beginning balance 11,205,290 16,752,935
Granted
Vested and Exercisable
Cancelled
Expired
Adjustment  
Outstanding, ending balance 6,205,290 11,205,290
Unvested [Member]    
Stock Options (Details) - Schedule of vested and unvested options [Line Items]    
Outstanding, beginning balance 1,595,290 2,830,290
Granted
Vested and Exercisable (500,000) (1,235,000)
Cancelled
Expired
Adjustment  
Outstanding, ending balance 1,095,290 1,595,290
Vested and Exercisable [Member]    
Stock Options (Details) - Schedule of vested and unvested options [Line Items]    
Outstanding, beginning balance 9,610,000 13,922,645
Granted
Vested and Exercisable 500,000 1,235,000
Cancelled
Expired (5,000,000) (5,547,645)
Adjustment  
Outstanding, ending balance 5,110,000 9,610,000
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Options (Details) - Schedule of information about vested & exercisable stock options - shares
Mar. 31, 2023
Jun. 30, 2022
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]    
Vested & Exercisable Stock Options, Total 12
Employee 2016 Equity Plan [Member]    
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]    
Vested & Exercisable Stock Options, Total
Director 2016 Equity Plan [Member]    
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]    
Vested & Exercisable Stock Options, Total
Employee Other Plans [Member]    
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]    
Vested & Exercisable Stock Options, Total 12
Directors and Consultants Other Plans [Member]    
Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]    
Vested & Exercisable Stock Options, Total
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Options (Details) - Schedule of stock options outstanding
9 Months Ended
Mar. 31, 2023
$ / shares
shares
Outstanding Options [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number of outstanding | shares 6,205,290
Weighted Averaged Exercise Price | $ / shares $ 0.39
Weighted Averaged Remaining Life (Years) 1 year 4 months 2 days
Vested Options [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Weighted Averaged Exercise Price | $ / shares $ 0.36
Weighted Averaged Remaining Life (Years) 1 year 18 days
Number of Exercisable | shares 5,110,000
$0.20 - $0.51 [Member] | Outstanding Options [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number of outstanding | shares 6,205,290
Weighted Averaged Exercise Price | $ / shares $ 0.39
Weighted Averaged Remaining Life (Years) 1 year 4 months 2 days
$0.20 - $0.51 [Member] | Vested Options [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Weighted Averaged Exercise Price | $ / shares $ 0.36
Weighted Averaged Remaining Life (Years) 1 year 18 days
Number of Exercisable | shares 5,110,000
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details)
9 Months Ended
Aug. 04, 2014
USD ($)
shares
Mar. 31, 2023
USD ($)
Jun. 29, 2018
USD ($)
Jun. 27, 2018
USD ($)
Sep. 04, 2014
USD ($)
Apr. 04, 2014
USD ($)
Jun. 30, 2012
USD ($)
Commitments and Contingencies Disclosure [Abstract]              
Product liability insurance   $ 3,000,000          
Number of patients   25,000          
Accrued payroll taxes, interest and penalties             $ 1,489,640
Purchase of convertible preferred stock (in Shares) | shares 250            
Convertible preferred stock value $ 2,500,000            
Voting and economic interest percentage 78.90%            
Lump sum payment         $ 250,000    
Monthly installment payments           $ 20,000  
Balance of taxes due       $ 381,224      
Penalties and interest totaling     $ 314,019        
Balance owed adjustments   $ 314,019          
Payment of satisfactory completion   $ 500,000          
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details) - Subsequent Event [Member]
Apr. 05, 2023
USD ($)
Subsequent Events (Details) [Line Items]  
Interest percentage 0.00%
Erhfort, LLC [Member]  
Subsequent Events (Details) [Line Items]  
Loan proceeds $ 1,620
XML 70 f10q0323_imagingdia_htm.xml IDEA: XBRL DOCUMENT 0000790652 2022-07-01 2023-03-31 0000790652 2023-05-15 0000790652 2023-03-31 0000790652 2022-06-30 0000790652 imds:SeriesMPreferredStockMember 2023-03-31 0000790652 imds:SeriesMPreferredStockMember 2022-06-30 0000790652 2023-01-01 2023-03-31 0000790652 2022-01-01 2022-03-31 0000790652 2021-07-01 2022-03-31 0000790652 us-gaap:CommonStockMember 2022-06-30 0000790652 us-gaap:RetainedEarningsMember 2022-06-30 0000790652 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000790652 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000790652 2022-07-01 2022-09-30 0000790652 us-gaap:CommonStockMember 2022-09-30 0000790652 us-gaap:RetainedEarningsMember 2022-09-30 0000790652 2022-09-30 0000790652 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0000790652 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0000790652 2022-10-01 2022-12-31 0000790652 us-gaap:CommonStockMember 2022-12-31 0000790652 us-gaap:RetainedEarningsMember 2022-12-31 0000790652 2022-12-31 0000790652 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000790652 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000790652 us-gaap:CommonStockMember 2023-03-31 0000790652 us-gaap:RetainedEarningsMember 2023-03-31 0000790652 us-gaap:CommonStockMember 2021-06-30 0000790652 us-gaap:RetainedEarningsMember 2021-06-30 0000790652 2021-06-30 0000790652 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000790652 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000790652 2021-07-01 2021-09-30 0000790652 us-gaap:CommonStockMember 2021-09-30 0000790652 us-gaap:RetainedEarningsMember 2021-09-30 0000790652 2021-09-30 0000790652 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0000790652 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0000790652 2021-10-01 2021-12-31 0000790652 us-gaap:CommonStockMember 2021-12-31 0000790652 us-gaap:RetainedEarningsMember 2021-12-31 0000790652 2021-12-31 0000790652 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000790652 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000790652 us-gaap:CommonStockMember 2022-03-31 0000790652 us-gaap:RetainedEarningsMember 2022-03-31 0000790652 2022-03-31 0000790652 2021-07-01 2022-06-30 0000790652 2018-03-01 2018-03-22 0000790652 imds:EhrfortLLCMember 2022-07-01 2023-03-31 0000790652 imds:EhrfortLLCMember 2021-07-01 2022-03-31 0000790652 imds:DavidFongMember 2022-07-01 2023-03-31 0000790652 imds:DavidFongMember 2021-07-01 2022-03-31 0000790652 imds:EhrfortLLCMember 2023-03-31 0000790652 imds:EhrfortLLCMember 2022-06-30 0000790652 imds:ErhfortLLCOneMember 2023-03-31 0000790652 imds:ErhfortLLCOneMember 2022-06-30 0000790652 imds:FongAssociatesLLCMember 2023-03-31 0000790652 imds:FongAssociatesLLCMember 2022-06-30 0000790652 imds:JMOneHoldingsLLCMember 2023-03-31 0000790652 imds:JMOneHoldingsLLCMember 2022-06-30 0000790652 us-gaap:ComputerEquipmentMember 2023-03-31 0000790652 us-gaap:ComputerEquipmentMember 2022-06-30 0000790652 imds:ThirdPartySoftwareMember 2023-03-31 0000790652 imds:ThirdPartySoftwareMember 2022-06-30 0000790652 imds:ClinicalEquipmentMember 2023-03-31 0000790652 imds:ClinicalEquipmentMember 2022-06-30 0000790652 2018-06-27 0000790652 imds:ViableInternationalInvestmentsMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsMember 2021-07-01 2022-03-31 0000790652 2023-03-31 2023-03-31 0000790652 imds:ErhfortLLCsMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsMember 2023-03-31 0000790652 imds:ErhfortLLCsMember 2022-06-30 0000790652 imds:ErhfortLLCOneMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCOneMember 2023-03-31 0000790652 imds:ErhfortLLCOneMember 2022-06-30 0000790652 imds:JMOneHoldingsLLCMember 2022-07-01 2023-03-31 0000790652 imds:JMOneHoldingsLLCMember 2023-03-31 0000790652 imds:JMOneHoldingsLLCMember 2022-06-30 0000790652 imds:ErhfortLLCTwoMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCTwoMember 2023-03-31 0000790652 imds:ErhfortLLCTwoMember 2022-06-30 0000790652 imds:ErhfortLLCsThreeMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsThreeMember 2023-03-31 0000790652 imds:ErhfortLLCsThreeMember 2022-06-30 0000790652 imds:ErhfortLLCsFourMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsFourMember 2023-03-31 0000790652 imds:ErhfortLLCsFourMember 2022-06-30 0000790652 imds:ErhfortLLCsFiveMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsFiveMember 2023-03-31 0000790652 imds:ErhfortLLCsFiveMember 2022-06-30 0000790652 imds:ErhfortLLCsSixMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCsSixMember 2023-03-31 0000790652 imds:ErhfortLLCsSixMember 2022-06-30 0000790652 imds:ErhfortLLCSevenMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCSevenMember 2023-03-31 0000790652 imds:ErhfortLLCSevenMember 2022-06-30 0000790652 imds:ErhfortLLCEightMember 2022-07-01 2023-03-31 0000790652 imds:ErhfortLLCEightMember 2023-03-31 0000790652 imds:ErhfortLLCEightMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCOneMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCOneMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCOneMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTwoMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwoMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwoMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCThreeMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCThreeMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCThreeMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCFourMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFourMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFourMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCFiveMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFiveMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFiveMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCSixMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSixMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSixMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCSevenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSevenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSevenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCEightMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCEightMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCEightMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCNineMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCNineMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCNineMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCElevenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCElevenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCElevenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTwelveMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwelveMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwelveMember 2022-06-30 0000790652 imds:ViablesInternationalInvestmentsLLCThirteenMember 2022-07-01 2023-03-31 0000790652 imds:ViablesInternationalInvestmentsLLCThirteenMember 2023-03-31 0000790652 imds:ViablesInternationalInvestmentsLLCThirteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCFourteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFourteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFourteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCFifteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFifteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCFifteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCSixteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSixteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSixteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCSeventeenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSeventeenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCSeventeenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCEighteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCEighteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCEighteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCNineteenMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCNineteenMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCNineteenMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTwentyMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwentyMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwentyMember 2022-06-30 0000790652 imds:ViableInternationalInvestmentsLLCTwentyOneMember 2022-07-01 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwentyOneMember 2023-03-31 0000790652 imds:ViableInternationalInvestmentsLLCTwentyOneMember 2022-06-30 0000790652 imds:XianIDIMember 2022-07-01 2023-03-31 0000790652 imds:XianIDIMember 2023-03-31 0000790652 imds:XianIDIMember 2022-06-30 0000790652 2020-05-01 2020-05-09 0000790652 2020-05-09 0000790652 2021-10-01 2021-10-31 0000790652 imds:PPPLoanMember 2022-07-01 2023-03-31 0000790652 imds:PPPLoanMember 2021-07-01 2022-06-30 0000790652 imds:TruistBankMember 2023-03-31 0000790652 imds:TruistBankMember 2022-07-01 2023-03-31 0000790652 imds:TruistBankMember 2022-06-30 0000790652 imds:SeriesLPreferredStockMember 2010-03-31 0000790652 imds:SeriesLPreferredStockMember 2010-03-01 2010-03-31 0000790652 imds:SeriesLPreferredStockMember 2011-01-01 2011-01-06 0000790652 imds:SeriesMPreferredStockMember 2022-07-01 2023-03-31 0000790652 imds:SeriesMPreferredStockMember 2017-11-21 0000790652 imds:SeriesMPreferredStockMember 2017-11-01 2017-11-21 0000790652 imds:SeriesMPreferredStockMember 2017-04-18 0000790652 imds:SeriesMPreferredStockMember 2017-04-01 2017-04-18 0000790652 imds:SeriesMPreferredStockMember 2018-08-07 0000790652 imds:SeriesMPreferredStockMember 2018-08-01 2018-08-07 0000790652 imds:IssuanceDate6Member imds:SeriesLPreferredStockMember 2022-07-01 2023-03-31 0000790652 imds:IssuanceDate6Member imds:SeriesLPreferredStockMember 2023-03-31 0000790652 imds:SeriesLPreferredStockMember 2022-07-01 2023-03-31 0000790652 srt:MinimumMember 2022-07-01 2023-03-31 0000790652 srt:MaximumMember 2022-07-01 2023-03-31 0000790652 srt:MinimumMember 2021-07-01 2022-06-30 0000790652 srt:MaximumMember 2021-07-01 2022-06-30 0000790652 imds:VestedAndUnvestedOptionsMember 2021-06-30 0000790652 imds:VestedAndUnvestedOptionsMember 2021-07-01 2022-06-30 0000790652 imds:VestedAndUnvestedOptionsMember 2022-06-30 0000790652 imds:VestedAndUnvestedOptionsMember 2022-07-01 2023-03-31 0000790652 imds:VestedAndUnvestedOptionsMember 2023-03-31 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2021-06-30 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2021-07-01 2022-06-30 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2022-06-30 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2022-07-01 2023-03-31 0000790652 imds:PreviousFivePlanIncludingNonStatutoryPlanMember 2023-03-31 0000790652 imds:UnvestedMember 2021-06-30 0000790652 imds:VestedAndExercisableMember 2021-06-30 0000790652 imds:UnvestedMember 2021-07-01 2022-06-30 0000790652 imds:VestedAndExercisableMember 2021-07-01 2022-06-30 0000790652 imds:UnvestedMember 2022-06-30 0000790652 imds:VestedAndExercisableMember 2022-06-30 0000790652 imds:UnvestedMember 2022-07-01 2023-03-31 0000790652 imds:VestedAndExercisableMember 2022-07-01 2023-03-31 0000790652 imds:UnvestedMember 2023-03-31 0000790652 imds:VestedAndExercisableMember 2023-03-31 0000790652 imds:EmployeeTwoThousandSixteenPlanMember 2023-03-31 0000790652 imds:EmployeeTwoThousandSixteenPlanMember 2022-06-30 0000790652 imds:DirectorTwoThousandSixteenEquityPlanMember 2023-03-31 0000790652 imds:DirectorTwoThousandSixteenEquityPlanMember 2022-06-30 0000790652 imds:EmployeeOtherPlansMember 2023-03-31 0000790652 imds:EmployeeOtherPlansMember 2022-06-30 0000790652 imds:DirectorsAndConsultantsOtherPlansMember 2023-03-31 0000790652 imds:DirectorsAndConsultantsOtherPlansMember 2022-06-30 0000790652 imds:OutstandingOptionsMember imds:ExercisePriceRangeMember 2023-03-31 0000790652 imds:OutstandingOptionsMember imds:ExercisePriceRangeMember 2022-07-01 2023-03-31 0000790652 imds:VestedOptionsMember imds:ExercisePriceRangeMember 2023-03-31 0000790652 imds:VestedOptionsMember imds:ExercisePriceRangeMember 2022-07-01 2023-03-31 0000790652 imds:OutstandingOptionsMember 2023-03-31 0000790652 imds:OutstandingOptionsMember 2022-07-01 2023-03-31 0000790652 imds:VestedOptionsMember 2023-03-31 0000790652 imds:VestedOptionsMember 2022-07-01 2023-03-31 0000790652 2012-06-30 0000790652 2014-08-01 2014-08-04 0000790652 2014-09-04 0000790652 2014-04-04 0000790652 2018-06-29 0000790652 imds:ErhfortLLCMember us-gaap:SubsequentEventMember 2023-04-01 2023-04-05 0000790652 us-gaap:SubsequentEventMember 2023-04-05 shares iso4217:USD iso4217:USD shares pure 10-Q true 2023-03-31 2023 false 000-26028 FL 22-2671269 618 E South St Suite 500 Orlando FL 32801 (954) 581-9800 Yes Yes true Non-accelerated Filer false false 123156941 123 613 11783 11989 11906 12602 11906 12602 910920 767317 314019 314019 753954 671276 72930 72930 2051823 1825542 2051823 1825542 447451 433939 447451 433939 2000000 2000000 600 600 0 0 0 0 500000000 500000000 123156941 123156941 123156941 123156941 133296816 133236117 -135784184 -135482996 -2487368 -2246879 11906 12602 15223 13873 76983 73547 124 314 630 551 5888 171479 148704 334178 21235 185666 226317 408276 -21235 -185666 -226317 -408276 20155 20215 61359 61391 -20155 -20215 -61359 -61391 -41390 -205881 -287676 -469667 4438 4438 13512 13512 -45828 -210319 -301188 -483179 123156941 123156941 123156941 123156941 123156941 133236117 -135482996 -2246879 4537 4537 -117325 -117325 123156941 133236117 -135604858 -2368741 4537 4537 60699 60699 -128961 -128961 123156941 133296816 -135738356 -2441540 4438 4438 -41390 -41390 123156941 133296816 -135784184 -2487368 123156941 132974686 -134817667 -1842981 4537 4537 -111984 -111984 123156941 132974686 -134934188 -1959502 4537 4537 60699 60699 -151802 -151802 123156941 133035385 -135090527 -2055142 4438 4438 120479 120479 -205881 -205881 123156941 133155864 -135300846 -2144982 -287676 -469667 60699 181178 -206 -528 147272 212718 208177 394424 -79499 -75243 79009 80000 -6670 79009 73330 -490 -1913 613 2473 123 560 1497 3669 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(1) ORGANIZATION AND NATURE OF BUSINESS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Imaging Diagnostic Systems, Inc. (the “Company” or “IDSI”) is a medical technology company that has developed a new, non-invasive CT scanner called CTLM® that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM® will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since inception in December 1993 as a Florida corporation and subsequently its reverse merger with Alkan Corp., a New Jersey Corporation on April 14, 1994, we continued operations and changed our state of incorporation from New Jersey to Florida, effective July 1, 1995.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(2) GOING CONCERN AND MANAGEMENT’S PLANS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statements are prepared assuming the Company will continue as a going concern. As of March 31, 2023, the Company had an accumulated deficit of $135,784,184, a stockholders’ deficit of $2,487,368 and a working capital deficiency of $2,039,917. For the nine months ended March 31, 2023, net loss totaled $287,676. The net cash used in operating activities for the nine months ended March 31, 2023 totaled $79,499. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. The ability of the Company to continue as a going concern is dependent upon generating sales and obtaining additional capital and financing. While the Company believes in the viability of its strategy to generate material sales volume and in its ability to raise additional funds, there can be no assurances to that effect. The Company received from the Chinese FDA (“CFDA”) marketing clearance for the CTLM® effective November 16, 2018 to November 15, 2023. However, there can be no assurance that we will obtain U.S. Food and Drug Administration (“FDA”) marketing or other new international marketing clearances, that the CTLM® will achieve market acceptance or that sufficient revenues will be generated from sales of the CTLM® in China or elsewhere to allow us to operate profitably. Since 2016, we have financed our operations through loans by Viable International Investments, LLC (“Viable”), our majority shareholder, and its affiliates and the private placement of common stock to Viable affiliates and independent Chinese investors. We do not have any formal financing arrangements with Viable and its affiliates; however, Viable has stated its intention to continue to provide financing of our operations consistent with past practice. While we believe that Viable and its affiliates will provide on commercially reasonable terms the funding we need until we achieve a positive cash flow from operations, there can be no assurance that we will receive such funding or that we will ever achieve profitability. If Viable fails to continue funding, the Company would be materially adversely affected and may have to cease operations due to a lack of funding. These matters affect the Company’s liquidity profile, and management’s plans in those regards are discussed in the paragraphs that follow.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal year 2023, we anticipate that losses from operations will continue until we begin to generate revenues through the sales of CTLM® systems in China. These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM®, expenses associated with FDA approval processes, and the costs associated with advanced product development activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s next focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM® Breast Imaging System through the FDA. The premarket approval (“PMA”) process for U.S. marketing clearance is expected to take longer than the Chinese process, and we intend to resume this effort after achieving successful marketing and sales of CTLM® systems in China. Our sales and marketing efforts in China have been significantly hindered by the ongoing COVID-19 pandemic, and therefore we do not expect revenue from China in the foreseeable future. No sales in other countries are expected in the foreseeable future, as we do not intend to pursue sales in other countries until after obtaining FDA marketing clearance, as to which there can be no assurance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In analyzing the regulatory path forward, timeline, and costs associated with the level of effort required to upgrade the Company’s Quality Management System (QMS), we have decided not to renew our CE mark (required for sales in the European Union) for this year and to consider reapplying in 2 to 3 years to avoid these regulatory fees. Similarly, we will maintain our Quality Management System to be compliant to ISO 13485:2016 but not certify to ISO 13485:2016 by Underwriters Laboratories (UL) which will allow us to avoid fees associated with certification, travel, and hosting audits. Maintaining our QMS to be ISO 13485:2016 compliant will allow us to quickly schedule an audit with UL and become ISO 13485 certified when necessary.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s Computed Tomography Laser Mammography (CTLM<sup>®</sup>) breast imaging device. Dr. Jiang has completed the first phase of image quality improvement and is currently collecting image data for evaluation and further technical improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xi’an IDI has been working with Yiling Hospital Management Group based in Beijing, China (“Yiling”) to evaluate CTLM®’s potential use and application. As of the date of this report, Xi’an IDI has loaned three CTLM® systems to Yiling and Yiling is at the stage of testing and data validation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is important that the effectiveness of the image quality improvements be established before Xi’an IDI can resume their sales and marketing efforts in China. Once the Company has substantial revenues and cash flow, it believes it will be able to raise the necessary funding to allow the Company to move forward with its various R&amp;D and regulatory initiatives that have been put on hold due to the COVID-19 pandemic.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s ability to continue as a going concern and its future success are dependent upon its ability to raise additional capital in the near term to: (1) satisfy its current obligations, (2) continue its research and development efforts, and (3) successfully develop, market, and sell its products. Due to the difficulty of raising additional capital during the current COVID-19 crisis, the Company has been taking aggressive measures to reduce its operating costs in order to preserve cash. The Company’s ability to meet its cash flow requirements through fiscal 2023 and continue its development and commercialization efforts will be dependent on the length and severity of the COVID-19 crisis and the Company’s ability to secure additional funding. There can be no assurance that IDSI will generate sufficient revenue to provide positive cash flows from operations or that sufficient capital will be available, when required, to permit the Company to execute its plan of operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> 135784184 2487368 2039917 287676 79499 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(a) Basis of presentation and use of estimates</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The unaudited interim financial information furnished herein reflects all adjustments, consisting only of normal recurring items, which in the opinion of management are necessary to fairly state the Company’s financial position, results of operations and cash flows for the dates and periods presented and to make such information not misleading. The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal year ended June 30, 2022, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “Commission”) on October 4, 2022. The results of operations for the nine months ended March 31, 2023, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(b) Revenue recognition</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also receives royalties pursuant to a licensing relationship with Trifoil Imaging. Revenue is recognized in the reporting periods in which royalties are due to the Company. During the nine months ended March 31, 2023 and 2022, there was no income from royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(c) Allowance for doubtful accounts</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our allowance for doubtful accounts was $850 as of March 31, 2023 and June 30, 2022. These amounts consist of other receivables that have been fully reserved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(d) Cash and cash equivalents</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2023 and June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(e) Concentration of Risk</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. March 31, 2023 and June 30, 2022, the Company did not have cash balances in excess of the federally insured limit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not have any revenue for the nine months ended March 31, 2023 and 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) Inventory</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of obsolete inventory. The Company maintains an allowance for obsolete inventory and generally makes inventory value adjustments against the allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(g) Property and equipment</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(h) Research and development</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company’s CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(i) Net loss per share</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company relies on the guidance provided by ASC 260, (“Earnings per Share”), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company had 5,110,000 and 9,610,012 options vested as of March 31, 2023 and June 30, 2022, respectively and 1,095,290 and 1,595,290 options not yet vested as of March 31, 2023 and June 30, 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(j) Stock-based compensation</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. No stock options were granted during nine months ended March 31, 2023 and 2022. Stock options are being expensed pursuant to ASC 718.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (16) Stock Options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(k) Long-lived assets</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company relies on the guidance provided by ASC 360 (“Property, Plant &amp; Equipment”). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2023 and 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(l) Income taxes</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2020 to 2022 are still potentially subject to audit by the taxing authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(m) Warranty reserve</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company’s experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company’s estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2023 or June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(n) Impact of recently issued accounting pronouncements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(o) Fair Value of Financial Instruments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company’s debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2023 and June 30, 2022, the aggregate fair value of the Company’s debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 (“Fair Value Measurements and Disclosures”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(a) Basis of presentation and use of estimates</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“U.S. GAAP”). The unaudited interim financial information furnished herein reflects all adjustments, consisting only of normal recurring items, which in the opinion of management are necessary to fairly state the Company’s financial position, results of operations and cash flows for the dates and periods presented and to make such information not misleading. The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These unaudited financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal year ended June 30, 2022, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “Commission”) on October 4, 2022. The results of operations for the nine months ended March 31, 2023, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(b) Revenue recognition</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also receives royalties pursuant to a licensing relationship with Trifoil Imaging. Revenue is recognized in the reporting periods in which royalties are due to the Company. During the nine months ended March 31, 2023 and 2022, there was no income from royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(c) Allowance for doubtful accounts</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our allowance for doubtful accounts was $850 as of March 31, 2023 and June 30, 2022. These amounts consist of other receivables that have been fully reserved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> 850 850 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(d) Cash and cash equivalents</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at March 31, 2023 and June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(e) Concentration of Risk</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. March 31, 2023 and June 30, 2022, the Company did not have cash balances in excess of the federally insured limit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not have any revenue for the nine months ended March 31, 2023 and 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 250000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) Inventory</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of obsolete inventory. The Company maintains an allowance for obsolete inventory and generally makes inventory value adjustments against the allowance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(g) Property and equipment</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(h) Research and development</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company’s CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(i) Net loss per share</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company relies on the guidance provided by ASC 260, (“Earnings per Share”), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company had 5,110,000 and 9,610,012 options vested as of March 31, 2023 and June 30, 2022, respectively and 1,095,290 and 1,595,290 options not yet vested as of March 31, 2023 and June 30, 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> 5110000 9610012 1095290 1595290 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(j) Stock-based compensation</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, an accounting standard update to improve non-employee share-based payment accounting. The accounting standard update more closely aligns the accounting for employee and non-employee share-based payments. The accounting standards update is effective as of the beginning of 2019 with early adoption permitted. We have elected to adopt this standard.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has elected to use the Black-Scholes-Merton, or BSM, option-pricing model to estimate the fair value of its options and similar awards, which incorporates various subjective assumptions including volatility, risk-free interest rate, expected life, and dividend yield to calculate the fair value of outstanding and vested stock option awards. Compensation expense recognized in the statements of operations is based on awards ultimately expected to vest and reflects estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. No stock options were granted during nine months ended March 31, 2023 and 2022. Stock options are being expensed pursuant to ASC 718.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite vesting period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See Note (16) Stock Options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(k) Long-lived assets</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company relies on the guidance provided by ASC 360 (“Property, Plant &amp; Equipment”). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has determined that no impairment losses need to be recognized through the nine months ended March 31, 2023 and 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(l) Income taxes</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2020 to 2022 are still potentially subject to audit by the taxing authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(m) Warranty reserve</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products were shipped from IDSI, whichever occurs first. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company’s experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company’s estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The Company had no warranty reserve balance as of March 31, 2023 or June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(n) Impact of recently issued accounting pronouncements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">(o) Fair Value of Financial Instruments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company’s debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At March 31, 2023 and June 30, 2022, the aggregate fair value of the Company’s debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 (“Fair Value Measurements and Disclosures”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(4) REVENUE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Sales taxes and other similar taxes are excluded from revenue. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on its financial statements. The Company expects that the impact to net income of the new standard will be immaterial on an ongoing quarterly and annual basis. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company had no revenues during the nine months ended March 31, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(5) RELATED PARTY TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Related party revenues</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On March 22, 2018, the Board of Directors approved the execution of two agreements with Xi’an of China, an affiliated Company of IDSI. The agreements are a Know How Transfer Contract and a CTLM</span>® <span style="font-family: Times New Roman, Times, Serif">Know How Confidentiality Agreement. The contract, having a term of 20 years, stipulates that Xi’an will pay IDSI a know how transfer fee of 25% of revenue for CTLM</span>® <span style="font-family: Times New Roman, Times, Serif">product sales in their territory. There were no such sales during the nine months ended March 31, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Related party fees</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Erhfort, LLC earned a consulting fee of $51,000 for the nine-month period ended March 31, 2023 and $76,500 for the nine-month period ending March 31, 2022. Erhfort, LLC regularly reviews the Company’s operations and reports to IDSI’s CEO who lives in China. Erhfort, LLC is a related party because it owns Company common stock directly and indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">David Fong, who served as the Company’s CFO through August 10, 2022 and as a consultant on an as needed basis thereafter, earned consulting fees of $32,545 for the nine-month period ended March 31, 2023 and $76,500 for the nine-month period ended March 31, 2022. These fees were assigned to his affiliated business, Fong &amp; Associates, LLC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Related party payables and accrued expenses</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023 and June 30, 2022, the amount of interest on related party notes due to Erhfort, LLC, which is included in accounts payable, is $219,814 and $161,260, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023 and June 30, 2022, the amount of consulting fees due to Ehrfort, LLC, which is included in accounts payable, is $204,000 and $153,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As March 31, 2023 and June 30, 2022, the amount of consulting fees due to Fong &amp; Associates, LLC, which is included in accounts payable and accrued expenses, is $318,545 and $286,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023 and June 30, 2022, the amount of reimbursable expenses due to Fong &amp; Associates, LLC, which is included in accounts payable, is $2,808 and $839, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023 and June 30, 2022, the amount of interest on related party notes due to JM One Holdings, LLC, which is included in accrued expenses, is $11,112 and $8,860, respectively. JM One Holdings, LLC is an entity affiliated with David Fong.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Related party debt</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023 and June 30, 2022, the amount in promissory notes due to related parties are $753,954 and $671,276, respectively (See Note 12).</p> P20Y 0.25 51000 76500 32545 76500 219814 161260 204000 153000 318545 286000 2808 839 11112 8860 753954 671276 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(6) ROYALTY RECEIVABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 16, 2006, the Company entered into a Royalty Agreement with Bioscan Inc. whereby the Company established a licensing relationship with Bioscan which granted Bioscan an exclusive sublicensable, royalty-bearing license to make, use, offer for sale, import and otherwise develop and commercialize products in its territory. Bioscan Inc. was subsequently purchased by TriFoil Imaging. During the nine months ended March 31, 2023 and 2022, there was no royalty income. As of March 31, 2023 and June 30, 2022, the Company had royalty receivable balances of $0.</p> 0 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(7) INVENTORIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials consisting of purchased parts, components and supplies</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,587</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,587</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Inventory</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,087</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Allowance for Obsolete Inventory</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,087</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,087</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net Inventory</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to the age of the inventory, lack of demand for parts and lack of sales the Company reserved for all inventory during the year ended June 30, 2017. The Company is not carrying any inventory purchased after June 30, 2017 and has booked an allowance for the entire value of its inventory.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials consisting of purchased parts, components and supplies</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,587</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,587</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Inventory</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,087</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Allowance for Obsolete Inventory</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,087</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,087</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net Inventory</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 92587 92587 7500 7500 100087 100087 100087 100087 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(8) PREPAID EXPENSES AND DEPOSITS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of prepaid expenses:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Prepaid Software</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">206</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Rent Security Deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Consulting Retainers</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Prepaid expenses and Deposits</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,783</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,989</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Prepaid Software</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">206</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Rent Security Deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Consulting Retainers</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Prepaid expenses and Deposits</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,783</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,989</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 206 1783 1783 10000 10000 11783 11989 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(9) PROPERTY AND EQUIPMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of property and equipment, less accumulated depreciation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful life</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Computers and Equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,612</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,612</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Third Party Software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Clinical Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">5 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total Property &amp; Equipment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">37,903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">37,903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,903</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,903</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Property &amp; Equipment - Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense for the nine months ended March 31, 2023 and 2022 was $0.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Useful life</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Computers and Equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,612</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,612</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Third Party Software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">5 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Clinical Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">5 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total Property &amp; Equipment</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">37,903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">37,903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,903</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,903</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Property &amp; Equipment - Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 12612 12612 P5Y 10291 10291 P5Y 15000 15000 P5Y 37903 37903 37903 37903 0 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(10) ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2023 and June 30, 2022, accounts payable and accrued expenses totaled $910,920 and $767,317 respectively, which consists of accounts payable of $898,468 and $758,171 and other accrued expenses of $12,452 and $9,146, respectively.</p> 910920 767317 898468 758171 12452 9146 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(11) ACCRUED PAYROLL TAXES AND PENALTIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2023 and June 30, 2022, the Company owed the IRS $314,019. Accrued payroll taxes represent outstanding interest and penalties based on prior management’s failure to pay payroll taxes commencing with the quarter ending March 31, 2010. As part of new management’s restructuring plan, the Company received funds from an accredited investor to be able to make a payment to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting penalty and interest abatement. The amount due at March 31, 2023 of $314,019 represents the interest and penalties. The Company has formally asked the IRS to abate all remaining interest and penalties of $314,019. The Company had a telephone conference on April 18, 2019 with the office of appeals and is waiting for further communications from the appeals officer. As of March 31, 2023, the Company’s tax counsel is in the process of reviewing recent IRS correspondence to determine appeals status and will work towards final resolutions with the IRS on all outstanding liabilities. The Company has decided to wait until all resolutions are final before making any adjustments to the balance of $314,019 owed to the IRS.</p> 314019 314019 381224 314019 314019 314019 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(12) PROMISSORY NOTES – RELATED PARTY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table is a summary of the outstanding note balances as of March 31, 2023 and June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Noteholder</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Interest <br/> Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maturity<br/> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Related Party Notes:</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Erhfort, LLC</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">6/30/23</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">JM One Holdings, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,669</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,865</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,865</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,847</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,786</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,568</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Xi’an IDI</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">On Demand</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,411</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,411</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Related Party Notes</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">753,954</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">671,276</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Erhfort, LLC and Viable International Investments, LLC own Company common stock directly and indirectly. JM One Holdings, LLC is an entity affiliated with the Company’s former CFO. Hence, these debts are considered related party debt. Xi’an IDI is affiliated with IDSI due to a licensing agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">During the nine months ended March 31, 2023, the Company received loan proceeds of $76,749 from Viable International Investments, LLC and $2,260 from Erhfort, LLC with an annual interest rate of 0%. The Company also converted $3,669 of accounts payables into a loan from Erhfort, LLC with an annual interest rate of 0%. During the nine months ended March 31, 2022, the Company received loan proceeds of $80,000 from Viable International Investments, LLC with an annual interest rate of 0%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On March 31, 2023, the maturity dates of the loans that were due to mature on March 31, 2023 were extended to June 30, 2023. The extension of the maturity dates is a modification of the loans, and not accounted for as gain or loss extinguishments.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Noteholder</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Interest <br/> Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maturity<br/> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Related Party Notes:</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Erhfort, LLC</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">6/30/23</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">JM One Holdings, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">6/30/23</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Erhfort, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,669</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,865</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,865</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,847</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,786</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,488</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Viable International Investments, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">On Demand</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,568</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Xi’an IDI</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">On Demand</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,411</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,411</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Related Party Notes</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">753,954</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">671,276</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 0.15 6/30/23 100000 100000 0.15 6/30/23 100000 100000 0.15 6/30/23 20000 20000 0.15 6/30/23 100000 100000 0.15 6/30/23 100000 100000 0.15 6/30/23 100000 100000 0.15 6/30/23 10000 10000 0.15 6/30/23 10000 10000 0 On Demand 2260 0 On Demand 3669 0 On Demand 7865 7865 0 On Demand 5000 5000 0 On Demand 5000 5000 0 On Demand 5000 5000 0 On Demand 5000 5000 0 On Demand 3000 3000 0 On Demand 15000 15000 0 On Demand 30000 30000 0 On Demand 10000 10000 0 On Demand 10000 10000 0 On Demand 10000 10000 0 On Demand 5000 5000 0 On Demand 10000 10000 0 On Demand 8847 0 On Demand 12768 0 On Demand 9988 0 On Demand 7968 0 On Demand 6968 0 On Demand 7786 0 On Demand 5368 0 On Demand 5488 0 On Demand 11568 0 On Demand 10411 10411 753954 671276 76749 2260 0 3669 0 80000 0 the maturity dates of the loans that were due to mature on March 31, 2023 were extended to June 30, 2023. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(13) LONG-TERM DEBT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table is a summary of the outstanding loan balances as of March 31, 2023 and June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Noteholder</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Interest <br/> Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maturity<br/> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Truist Bank</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right">1</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 11%; text-align: center; padding-bottom: 1.5pt">In Default</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">72,930</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">72,930</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,930</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,930</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current Portion of Debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(72,930</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(72,930</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Long-term Debt</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On May 9, 2020, the Company entered into a loan with Truist Bank, a lender pursuant to the Paycheck Protection Program of the CARES Act as administered by the SBA in the amount of $79,600. The loan, in the form of a promissory note, had an original maturity date of May 1, 2025. No additional collateral or guarantees were provided by the Company for the loan. The PPP loan provides for customary events of default. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, rent payments, mortgage interest and covered utilities during the 24-week period beginning on the date of loan disbursement.  The Company is required to repay the entire amount of outstanding principal, along with accrued interest, as the Company is not eligible for forgiveness. The Company began to make payments, beginning October 2021, including interest accruing at an annual interest rate of 1.0% beginning on the date of disbursement. On May 17, 2022, the Company received a default and demand letter from Truist Bank in regards to the PPP loan due to non-payment. As such the remaining balance of the PPP loan became due immediately. As of March 31, 2023 and June 30, 2022, the Company reported an accrued interest balance related to the PPP Loan of $740 and $186, respectively. The accrued interest is included in accounts payable and accrued expenses on our balance sheets.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Noteholder</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Interest <br/> Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maturity<br/> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Truist Bank</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right">1</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">%</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 11%; text-align: center; padding-bottom: 1.5pt">In Default</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">72,930</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">72,930</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,930</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,930</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current Portion of Debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(72,930</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(72,930</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Long-term Debt</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 0.01 In Default 72930 72930 72930 72930 72930 72930 79600 2025-05-01 0.01 740 186 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(14) CONVERTIBLE PREFERRED STOCK</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following schedule reflects the number of shares of preferred stock that have been issued, converted and are outstanding as of March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Security</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date Issued</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">No. of <br/> Shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date of<br/> Conversion</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">No. of <br/> Shares<br/> Converted</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount<br/> Converted</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance<br/> 3/31/2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 16%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Series L Cv Pfd</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">3/31/2010</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">35</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">350,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="text-align: center; width: 11%">1/6/2011</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Dividends</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">247,451</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total redemption value</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td colspan="4" style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">447,451</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total Series M Cv Pfd</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt">Various</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">600</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt">1/6/2011</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">600</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">-0-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Dividends</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-0-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total redemption value</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td colspan="4" style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-0-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Series L Convertible Preferred Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 31, 2010, a private investor converted a $350,000 short-term promissory note into 35 shares of Series L Convertible Preferred Stock. The original purchase price/stated value is $10,000 per share and dividends accrue at an annual rate of 9%. The preferred stock is convertible into 474 shares of common stock for each share of preferred stock. On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time. At March 31, 2023 and June 30, 2022, the balance of cumulative dividends owed to the investor which is included in redemption value was $247,450 and $233,939, respectively. The total presented on the balance sheet as temporary equity is $447,451 as of March 31, 2023 and $433,939 as of June 30, 2022.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Series M Convertible Preferred Stock</span></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company had previously sold 600 Series M Convertible Preferred Stock to Viable International Investments, LLC, a Florida limited liability company, (“Viable”). Each share of the Series M Preferred Stock was convertible into 147,283 shares of Common Stock. In the event of a liquidation, the holders of the Series M Preferred Stock would have been entitled to receive, prior to any distribution of assets to holders of Common Stock or other class of capital stock or other equity securities of the Corporation, $10,000 per share of Series M Preferred Stock held plus accrued but unpaid dividends. The holders of the Series M Preferred Stock would have had identical voting rights as any holder of Common Stock and would have voted together, not as separate classes. The original purchase price/stated value of each share of Series M Preferred Stock was $10,000 and Viable was be entitled to receive cumulative dividends at the fixed rate of 9% of the stated value per share per annum. On November 21, 2017, Viable converted 3 shares of its Series M Preferred Stock to 441,878 shares of restricted common stock. On April 18, 2017, Viable converted 6 shares of its Series M Preferred Stock to 883,696 shares of restricted common stock, and on August 7, 2018, Viable converted its remaining 591 shares of Series M Preferred Stock into 87,044,089 shares of restricted common stock. As of March 31, 2023 and June 30, 2022, the balance of Series M Preferred Stock was $0.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Security</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date Issued</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">No. of <br/> Shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date of<br/> Conversion</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">No. of <br/> Shares<br/> Converted</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount<br/> Converted</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance<br/> 3/31/2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 16%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Series L Cv Pfd</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">3/31/2010</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">35</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">350,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="text-align: center; width: 11%">1/6/2011</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Dividends</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">247,451</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total redemption value</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td colspan="4" style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">447,451</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total Series M Cv Pfd</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt">Various</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">600</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt">1/6/2011</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">600</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">-0-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Dividends</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-0-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total redemption value</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td colspan="4" style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-0-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> 35 350000 2011-01-06 15 150000 200000 247451 447451 600 6000000 2011-01-06 600 6000000 0 0 0 350000 35 10000 0.09 474 On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as temporary equity, as the holder has the option to redeem for cash at any time. 247450 233939 447451 433939 600 147283 10000 10000 0.09 3 441878 6 883696 591 87044089 0 0 <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(15) COMMON STOCK</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has 500,000,000 of common shares no par value authorized and 2,000,000 of <span style="-sec-ix-hidden: hidden-fact-72"><span style="-sec-ix-hidden: hidden-fact-73">no</span></span> par preferred shares authorized.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not issue any shares of common or preferred stock during the nine months ended March 31, 2023 and 2022.</p> 500000000 2000000 <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(16) STOCK OPTIONS</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 4, 2016, the Board of Directors adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”) which was subsequently approved and adopted by majority written consent in lieu of an annual meeting. The purpose of the 2016 Plan is to encourage and enable the officers, employees, directors and other key persons (including consultants) of the Company, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In computing the impact of stock option grants, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility of a comparable company; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company cannot assess its forfeiture rate at this time due to the lack of historical data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/> March 31,<br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/> June 30,<br/> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20% to 44%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20% to 44%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: center"> </td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.08 to 3.08 Years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5 to 4.83 Years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-Free interest rate</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05% to 2.49%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05% to 2.49%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 76%; text-align: left">Forfeiture rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">0.00%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">0.00%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend rate</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">0.00%</td><td style="text-align: left"/><td> </td> <td style="text-align: center"> </td><td style="text-align: center">0.00%</td><td style="text-align: left"/></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At March 31, 2023, the Company has unvested and vested options under the 2016 Plan with exercise prices that range from a low of $.20 per share to a high of $.51 per share. The following table summarizes information about all of the stock options granted, exercised, expired and cancelled under the 2016 Plan at March 31, 2023 and June 30, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Employees/Consultants</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Wtd. Avg.<br/> Remaining<br/> Term</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt; width: 54%">Outstanding at June 30, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">16,752,935</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 9%; text-align: center">1.76 Years</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">         -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,547,645</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"> </div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"> </div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.30</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt">1.39 Years</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,000,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90"> </div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.39</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt">1.34 Years</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes information about vested and unvested options under the 2016 Plan at March 31, 2023 and June 30, 2022. The Company recognized an expense of $60,699 for options vested during the nine months ended March 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees/Consultants</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unvested</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vested and Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at June 30, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,830,290</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,922,645</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">16,752,935</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and Exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,235,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,235,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,547,645</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,595,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,610,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Vested and Exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(500,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,000,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Adjustment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,095,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,110,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unvested options will be expensed under the Black-Scholes options-pricing model when they vest. As of March 31, 2023 remaining options to be expensed when vested over the next year are estimated to be $118,328.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At March 31, 2023, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan. All the options for the previous five plans through and including the 2012 Non-Statutory Plan have expired.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The tables below summarize information about these five plans:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Employees/Consultants</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Wtd. Avg.<br/> Exercise<br/> Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Wtd. Avg.<br/> Remaining<br/> Term</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at June 30, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">350</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 1.11 Years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">         -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-99"> </div></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">12</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">350</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: right"> </td><td style="border-bottom: Black 4pt double; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 0.11 Years</span></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: right"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 332.25pt"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Vested &amp; Exercisable Stock Options</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">March 31,<br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">June 30,<br/> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee 2016 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Director 2016 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Employee Other Plans</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Directors and Consultants Other Plans</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">12</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below summarizes information about all stock options outstanding as of March 31, 2023:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Outstanding Options</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Vested Options</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><b>Range of Exercise price</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number<br/> Outstanding at<br/> March 31,<br/> 2023</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted<br/> Averaged<br/> Exercise<br/> Price</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted<br/> Averaged<br/> Remaining<br/> Life (Years)</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number<br/> Exercisable at<br/> March 31,<br/> 2023</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted<br/> Averaged<br/> Exercise<br/> Price</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted<br/> Averaged<br/> Remaining<br/> Life (Years)</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; padding-bottom: 1.5pt">$0.20 - $0.51</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">6,205,290</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.39</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1.34</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,110,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.36</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1.05</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Outstanding options</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.39</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.34</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,110,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.36</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.05</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s common stock, symbol IMDS, was quoted on OTCmarkets.com Pink until September 25, 2014 at which time IDSI’s registration was revoked by the Securities and Exchange Commission (SEC) for failure to timely file its Quarterly and Annual Reports. The last quoted price was $0.1. Because the Company was de-registered and OTC markets did not provide a quote for IMDS, there is no public market for the Company’s shares. Given the exercise prices adjusted for the reverse split, it is highly unlikely that any employee holding pre-2016 Plan options will exercise them. The Company has sufficient authorized shares available for all outstanding option; however, if exercised, the shares will be issued with a restrictive legend because the Company was not an SEC reporting company until October 2018. Further, given its recent return to SEC reporting status, the Company is unable to file an S-8 Registration Statement to register shares issued because of option exercise pursuant to various stock option agreements.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/> March 31,<br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/> June 30,<br/> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20% to 44%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20% to 44%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: center"> </td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.08 to 3.08 Years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5 to 4.83 Years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-Free interest rate</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05% to 2.49%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05% to 2.49%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 76%; text-align: left">Forfeiture rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">0.00%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">0.00%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend rate</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">0.00%</td><td style="text-align: left"/><td> </td> <td style="text-align: center"> </td><td style="text-align: center">0.00%</td><td style="text-align: left"/></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 0.20 0.44 0.20 0.44 P0Y29D P3Y29D P0Y6M P4Y9M29D 0.0005 0.0249 0.0005 0.0249 0 0 0 0 0.20 0.51 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Employees/Consultants</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Wtd. Avg.<br/> Remaining<br/> Term</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt; width: 54%">Outstanding at June 30, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">16,752,935</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 9%; text-align: center">1.76 Years</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">         -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,547,645</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"> </div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"> </div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.30</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt">1.39 Years</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,000,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90"> </div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.39</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt">1.34 Years</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Employees/Consultants</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Wtd. Avg.<br/> Exercise<br/> Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Wtd. Avg.<br/> Remaining<br/> Term</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at June 30, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">350</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 1.11 Years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">         -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-99"> </div></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">12</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">350</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: right"> </td><td style="border-bottom: Black 4pt double; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 0.11 Years</span></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: right"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 332.25pt"> </p> 16752935 0.25 P1Y9M3D 5547645 0.2 11205290 0.3 P1Y4M20D 5000000 0.2 6205290 0.39 P1Y4M2D 60699 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees/Consultants</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unvested</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vested and Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at June 30, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,830,290</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,922,645</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">16,752,935</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and Exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,235,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,235,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,547,645</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,595,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,610,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Vested and Exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(500,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,000,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Adjustment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,095,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,110,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 2830290 13922645 16752935 -1235000 1235000 5547645 1595290 9610000 11205290 -500000 500000 5000000 1095290 5110000 6205290 118328 At March 31, 2023, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan. 12 350 P1Y1M9D 12 350 P0Y1M9D 12 350 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Vested &amp; Exercisable Stock Options</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">March 31,<br/> 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">June 30,<br/> 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee 2016 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Director 2016 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Employee Other Plans</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Directors and Consultants Other Plans</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">12</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 12 12 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Outstanding Options</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Vested Options</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><b>Range of Exercise price</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number<br/> Outstanding at<br/> March 31,<br/> 2023</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted<br/> Averaged<br/> Exercise<br/> Price</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted<br/> Averaged<br/> Remaining<br/> Life (Years)</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number<br/> Exercisable at<br/> March 31,<br/> 2023</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted<br/> Averaged<br/> Exercise<br/> Price</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted<br/> Averaged<br/> Remaining<br/> Life (Years)</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; padding-bottom: 1.5pt">$0.20 - $0.51</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">6,205,290</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.39</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1.34</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,110,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.36</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1.05</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total Outstanding options</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,205,290</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.39</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.34</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,110,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.36</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.05</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 6205290 0.39 P1Y4M2D 5110000 0.36 P1Y18D 6205290 0.39 P1Y4M2D 5110000 0.36 P1Y18D 0.1 <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(17) COMMITMENTS AND CONTINGENCIES</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company previously carried $3,000,000 in product liability insurance to cover both clinical sites and sales. As part of its cost savings initiatives, the Company cancelled the policy as it had not had any adverse experiences after conducting more than 25,000 patient scans worldwide. The Company is now self-insuring the risk of product liability.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From May 2010 to June 2012, claims were made by the IRS for payment of the Company’s accrued payroll taxes, interest and penalties, which as of June 30, 2012 was $1,489,640. The Company engaged tax counsel to handle this matter and intends to fully satisfy its payroll tax obligations. On August 4, 2014, Viable purchased 250 shares of convertible preferred stock for $2,500,000, which gave them a 78.9% voting and economic interest in the Company’s capital stock representing a change in control of the Company. New management’s tax counsel negotiated a new Installment Agreement which stipulated a lump sum payment of $250,000, which was paid on September 4, 2014 and monthly installment payments of $20,000 beginning in September 2014 due on the 18<sup>th</sup> of each month until the balance of payroll taxes, interest and penalties are paid in full (Note 11).</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2018, as part of new management’s restructuring plan, the Company received funds from an accredited investor to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting abatement of penalties and interest totaling $314,019. As of March 31, 2023, the Company’s tax counsel is in the process of reviewing recent IRS correspondence to determine appeals status and will work towards final resolutions with the IRS on all outstanding liabilities. The Company has decided to wait until all resolutions are final before making any adjustments to the balance of $314,019 owed to the IRS.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 23, 2019, the Company entered into a consulting agreement (“the Agreement”) effective as of November 1, 2019, with Dr. Huabei Jiang to serve as IDSI’s Chief Scientific Consultant. Pursuant to the Agreement, Dr. Jiang is focused on improving the technical performance and image quality of IDSI’s CTLM® breast imaging device. Per the Agreement, the goal of the initial project was to complete image quality improvement by November 1, 2020. A payment of $500,000 will be due upon satisfactory completion of the project. As of March 31, 2023, Dr. Jiang has completed the first phase of image quality improvement and is currently collecting image data for evaluation and further technical improvement. We have yet to establish the effectiveness of the improvements, as completion of the project has been delayed due to the COVID-19 crisis.</p> 3000000 25000 1489640 250 2500000 0.789 250000 20000 381224 314019 314019 500000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>(18) SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 5, 2023, the Company received loan proceeds of $1,620 from Erhfort, LLC. Interest is 0% and the principal is payable upon demand.</p> 1620 0 IMAGING DIAGNOSTIC SYSTEMS INC /FL/ 123156941 123156941 123156941 123156941 false --06-30 Q3 0000790652 EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end
XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 239 255 1 false 65 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Balance Sheets Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet Balance Sheets Statements 2 false false R3.htm 002 - Statement - Balance Sheets (Parentheticals) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Statements of Operations (Unaudited) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Statements of Operations (Unaudited) (Parentheticals) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement_Parentheticals Statements of Operations (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Statements of Changes in Stockholders??? Deficit (Unaudited) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3 Statements of Changes in Stockholders??? Deficit (Unaudited) Statements 6 false false R7.htm 006 - Statement - Statements of Cash Flows (Unaudited) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Organization and Nature of Business Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/OrganizationandNatureofBusiness Organization and Nature of Business Notes 8 false false R9.htm 008 - Disclosure - Going Concern and Management's Plans Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlans Going Concern and Management's Plans Notes 9 false false R10.htm 009 - Disclosure - Summary of Significant Accounting Policies Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - Revenue Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Revenue Revenue Notes 11 false false R12.htm 011 - Disclosure - Related Party Transactions Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 012 - Disclosure - Royalty Receivable Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivable Royalty Receivable Notes 13 false false R14.htm 013 - Disclosure - Inventories Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Inventories Inventories Notes 14 false false R15.htm 014 - Disclosure - Prepaid Expenses and Deposits Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDeposits Prepaid Expenses and Deposits Notes 15 false false R16.htm 015 - Disclosure - Property and Equipment Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipment Property and Equipment Notes 16 false false R17.htm 016 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableandAccruedExpenses Accounts Payable and Accrued Expenses Notes 17 false false R18.htm 017 - Disclosure - Accrued Payroll Taxes and Penalties Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenalties Accrued Payroll Taxes and Penalties Notes 18 false false R19.htm 018 - Disclosure - Promissory Notes ??? Related Party Notes http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedParty Promissory Notes ??? Related Party Notes 19 false false R20.htm 019 - Disclosure - Long-Term Debt Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebt Long-Term Debt Notes 20 false false R21.htm 020 - Disclosure - Convertible Preferred Stock Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStock Convertible Preferred Stock Notes 21 false false R22.htm 021 - Disclosure - Common Stock Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStock Common Stock Notes 22 false false R23.htm 022 - Disclosure - Stock Options Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptions Stock Options Notes 23 false false R24.htm 023 - Disclosure - Commitments and Contingencies Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 24 false false R25.htm 024 - Disclosure - Subsequent Events Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 025 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 026 - Disclosure - Inventories (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/InventoriesTables Inventories (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Inventories 27 false false R28.htm 027 - Disclosure - Prepaid Expenses and Deposits (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDepositsTables Prepaid Expenses and Deposits (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDeposits 28 false false R29.htm 028 - Disclosure - Property and Equipment (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipment 29 false false R30.htm 029 - Disclosure - Promissory Notes ??? Related Party (Tables) Notes http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyTables Promissory Notes ??? Related Party (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedParty 30 false false R31.htm 030 - Disclosure - Long-Term Debt (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebt 31 false false R32.htm 031 - Disclosure - Convertible Preferred Stock (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables Convertible Preferred Stock (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStock 32 false false R33.htm 032 - Disclosure - Stock Options (Tables) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables Stock Options (Tables) Tables http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptions 33 false false R34.htm 033 - Disclosure - Going Concern and Management's Plans (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlansDetails Going Concern and Management's Plans (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlans 34 false false R35.htm 034 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 35 false false R36.htm 035 - Disclosure - Related Party Transactions (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactions 36 false false R37.htm 036 - Disclosure - Royalty Receivable (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivableDetails Royalty Receivable (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivable 37 false false R38.htm 037 - Disclosure - Inventories (Details) - Schedule of inventories Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable Inventories (Details) - Schedule of inventories Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/InventoriesTables 38 false false R39.htm 038 - Disclosure - Prepaid Expenses and Deposits (Details) - Schedule of prepaid expenses Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable Prepaid Expenses and Deposits (Details) - Schedule of prepaid expenses Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDepositsTables 39 false false R40.htm 039 - Disclosure - Property and Equipment (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentTables 40 false false R41.htm 040 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment, less accumulated depreciation Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable Property and Equipment (Details) - Schedule of property and equipment, less accumulated depreciation Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentTables 41 false false R42.htm 041 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableandAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableandAccruedExpenses 42 false false R43.htm 042 - Disclosure - Accrued Payroll Taxes and Penalties (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenaltiesDetails Accrued Payroll Taxes and Penalties (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenalties 43 false false R44.htm 043 - Disclosure - Promissory Notes ??? Related Party (Details) Notes http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails Promissory Notes ??? Related Party (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyTables 44 false false R45.htm 044 - Disclosure - Promissory Notes ??? Related Party (Details) - Schedule of outstanding note balances Notes http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable Promissory Notes ??? Related Party (Details) - Schedule of outstanding note balances Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyTables 45 false false R46.htm 045 - Disclosure - Long-Term Debt (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails Long-Term Debt (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtTables 46 false false R47.htm 046 - Disclosure - Long-Term Debt (Details) - Schedule of a summary of the outstanding loan balances Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable Long-Term Debt (Details) - Schedule of a summary of the outstanding loan balances Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtTables 47 false false R48.htm 047 - Disclosure - Convertible Preferred Stock (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails Convertible Preferred Stock (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables 48 false false R49.htm 048 - Disclosure - Convertible Preferred Stock (Details) - Schedule of number of shares of preferred stock that have been issued, converted and are outstanding Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable Convertible Preferred Stock (Details) - Schedule of number of shares of preferred stock that have been issued, converted and are outstanding Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables 49 false false R50.htm 049 - Disclosure - Common Stock (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStockDetails Common Stock (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStock 50 false false R51.htm 050 - Disclosure - Stock Options (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails Stock Options (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 51 false false R52.htm 051 - Disclosure - Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 52 false false R53.htm 052 - Disclosure - Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 53 false false R54.htm 053 - Disclosure - Stock Options (Details) - Schedule of vested and unvested options Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable Stock Options (Details) - Schedule of vested and unvested options Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 54 false false R55.htm 054 - Disclosure - Stock Options (Details) - Schedule of information about vested & exercisable stock options Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable Stock Options (Details) - Schedule of information about vested & exercisable stock options Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 55 false false R56.htm 055 - Disclosure - Stock Options (Details) - Schedule of stock options outstanding Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable Stock Options (Details) - Schedule of stock options outstanding Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables 56 false false R57.htm 056 - Disclosure - Commitments and Contingencies (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingencies 57 false false R58.htm 057 - Disclosure - Subsequent Events (Details) Sheet http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEvents 58 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10q0323_imagingdia.htm 4031, 4061, 4062, 4063, 4064 f10q0323_imagingdia.htm f10q0323ex31-1_imagingdiag.htm f10q0323ex31-2_imagingdiag.htm f10q0323ex32-1_imagingdiag.htm f10q0323ex32-2_imagingdiag.htm imds-20230331.xsd imds-20230331_cal.xml imds-20230331_def.xml imds-20230331_lab.xml imds-20230331_pre.xml image_001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0323_imagingdia.htm": { "axisCustom": 0, "axisStandard": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 593, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 239, "dts": { "calculationLink": { "local": [ "imds-20230331_cal.xml" ] }, "definitionLink": { "local": [ "imds-20230331_def.xml" ] }, "inline": { "local": [ "f10q0323_imagingdia.htm" ] }, "labelLink": { "local": [ "imds-20230331_lab.xml" ] }, "presentationLink": { "local": [ "imds-20230331_pre.xml" ] }, "schema": { "local": [ "imds-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] } }, "elementCount": 456, "entityCount": 1, "hidden": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331": 9, "http://fasb.org/us-gaap/2023": 128, "http://xbrl.sec.gov/dei/2023": 5, "total": 142 }, "keyCustom": 48, "keyStandard": 207, "memberCustom": 56, "memberStandard": 6, "nsprefix": "imds", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Revenue", "menuCat": "Notes", "order": "11", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "12", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "imds:RoyaltyReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Royalty Receivable", "menuCat": "Notes", "order": "13", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivable", "shortName": "Royalty Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "imds:RoyaltyReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Inventories", "menuCat": "Notes", "order": "14", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "imds:PrepaidExpensesAndDepositsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Prepaid Expenses and Deposits", "menuCat": "Notes", "order": "15", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDeposits", "shortName": "Prepaid Expenses and Deposits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "imds:PrepaidExpensesAndDepositsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Property and Equipment", "menuCat": "Notes", "order": "16", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Accounts Payable and Accrued Expenses", "menuCat": "Notes", "order": "17", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableandAccruedExpenses", "shortName": "Accounts Payable and Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "imds:AccruedPayrollTaxesAndPenaltiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Accrued Payroll Taxes and Penalties", "menuCat": "Notes", "order": "18", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenalties", "shortName": "Accrued Payroll Taxes and Penalties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "imds:AccruedPayrollTaxesAndPenaltiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Promissory Notes \u2013 Related Party", "menuCat": "Notes", "order": "19", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedParty", "shortName": "Promissory Notes \u2013 Related Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Long-Term Debt", "menuCat": "Notes", "order": "20", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Convertible Preferred Stock", "menuCat": "Notes", "order": "21", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStock", "shortName": "Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Common Stock", "menuCat": "Notes", "order": "22", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Stock Options", "menuCat": "Notes", "order": "23", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptions", "shortName": "Stock Options", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "24", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "25", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "26", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Inventories (Tables)", "menuCat": "Tables", "order": "27", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "imds:ScheduleOfOfPrepaidExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Prepaid Expenses and Deposits (Tables)", "menuCat": "Tables", "order": "28", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDepositsTables", "shortName": "Prepaid Expenses and Deposits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "imds:ScheduleOfOfPrepaidExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Property and Equipment (Tables)", "menuCat": "Tables", "order": "29", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Promissory Notes \u2013 Related Party (Tables)", "menuCat": "Tables", "order": "30", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyTables", "shortName": "Promissory Notes \u2013 Related Party (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Long-Term Debt (Tables)", "menuCat": "Tables", "order": "31", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Convertible Preferred Stock (Tables)", "menuCat": "Tables", "order": "32", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables", "shortName": "Convertible Preferred Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Stock Options (Tables)", "menuCat": "Tables", "order": "33", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables", "shortName": "Stock Options (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CumulativeEarningsDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Going Concern and Management's Plans (Details)", "menuCat": "Details", "order": "34", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlansDetails", "shortName": "Going Concern and Management's Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CumulativeEarningsDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "35", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c48", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Related Party Transactions (Details)", "menuCat": "Details", "order": "36", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c48", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Royalty Receivable (Details)", "menuCat": "Details", "order": "37", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivableDetails", "shortName": "Royalty Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Inventories (Details) - Schedule of inventories", "menuCat": "Details", "order": "38", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable", "shortName": "Inventories (Details) - Schedule of inventories", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "imds:ScheduleOfOfPrepaidExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Prepaid Expenses and Deposits (Details) - Schedule of prepaid expenses", "menuCat": "Details", "order": "39", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable", "shortName": "Prepaid Expenses and Deposits (Details) - Schedule of prepaid expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "imds:ScheduleOfOfPrepaidExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement", "shortName": "Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Property and Equipment (Details)", "menuCat": "Details", "order": "40", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment, less accumulated depreciation", "menuCat": "Details", "order": "41", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable", "shortName": "Property and Equipment (Details) - Schedule of property and equipment, less accumulated depreciation", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Accounts Payable and Accrued Expenses (Details)", "menuCat": "Details", "order": "42", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableandAccruedExpensesDetails", "shortName": "Accounts Payable and Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "imds:AccruedPayrollTaxeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Accrued Payroll Taxes and Penalties (Details)", "menuCat": "Details", "order": "43", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenaltiesDetails", "shortName": "Accrued Payroll Taxes and Penalties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "imds:AccruedPayrollTaxeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "imds:AnnualIntrestRatesPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Promissory Notes \u2013 Related Party (Details)", "menuCat": "Details", "order": "44", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails", "shortName": "Promissory Notes \u2013 Related Party (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "imds:AnnualIntrestRatesPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Promissory Notes \u2013 Related Party (Details) - Schedule of outstanding note balances", "menuCat": "Details", "order": "45", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable", "shortName": "Promissory Notes \u2013 Related Party (Details) - Schedule of outstanding note balances", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c72", "decimals": "2", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c171", "decimals": "0", "first": true, "lang": null, "name": "imds:SmallBusinessAdministrationLoanAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Long-Term Debt (Details)", "menuCat": "Details", "order": "46", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails", "shortName": "Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c171", "decimals": "0", "first": true, "lang": null, "name": "imds:SmallBusinessAdministrationLoanAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Long-Term Debt (Details) - Schedule of a summary of the outstanding loan balances", "menuCat": "Details", "order": "47", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable", "shortName": "Long-Term Debt (Details) - Schedule of a summary of the outstanding loan balances", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockRedemptionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Convertible Preferred Stock (Details)", "menuCat": "Details", "order": "48", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails", "shortName": "Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockRedemptionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c191", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Dividends", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Convertible Preferred Stock (Details) - Schedule of number of shares of preferred stock that have been issued, converted and are outstanding", "menuCat": "Details", "order": "49", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable", "shortName": "Convertible Preferred Stock (Details) - Schedule of number of shares of preferred stock that have been issued, converted and are outstanding", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c191", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Dividends", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Statements of Operations (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Statements of Operations (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Common Stock (Details)", "menuCat": "Details", "order": "50", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStockDetails", "shortName": "Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Stock Options (Details)", "menuCat": "Details", "order": "51", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails", "shortName": "Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "imds:imds_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense", "menuCat": "Details", "order": "52", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable", "shortName": "Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "imds:imds_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c198", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled", "menuCat": "Details", "order": "53", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable", "shortName": "Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c196", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "imds:ScheduleOfVestedAndUnvestedOptions", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Stock Options (Details) - Schedule of vested and unvested options", "menuCat": "Details", "order": "54", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable", "shortName": "Stock Options (Details) - Schedule of vested and unvested options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "imds:ScheduleOfVestedAndUnvestedOptions", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c29", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Stock Options (Details) - Schedule of information about vested & exercisable stock options", "menuCat": "Details", "order": "55", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable", "shortName": "Stock Options (Details) - Schedule of information about vested & exercisable stock options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c228", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Stock Options (Details) - Schedule of stock options outstanding", "menuCat": "Details", "order": "56", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable", "shortName": "Stock Options (Details) - Schedule of stock options outstanding", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c228", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "imds:ProductLiabilityInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "57", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "imds:ProductLiabilityInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c238", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "58", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c238", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c27", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Statements of Changes in Stockholders\u2019 Deficit (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3", "shortName": "Statements of Changes in Stockholders\u2019 Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c31", "decimals": "0", "lang": null, "name": "us-gaap:DividendsPreferredStock", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow", "shortName": "Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:StockOptionPlanExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Organization and Nature of Business", "menuCat": "Notes", "order": "8", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/OrganizationandNatureofBusiness", "shortName": "Organization and Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Going Concern and Management's Plans", "menuCat": "Notes", "order": "9", "role": "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlans", "shortName": "Going Concern and Management's Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_imagingdia.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "imds_AccruedInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued interest.", "label": "Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "AccruedInterest", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "imds_AccruedPayrollTaxeCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxe Current", "terseLabel": "Accrued payroll taxes" } } }, "localname": "AccruedPayrollTaxeCurrent", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenaltiesDetails" ], "xbrltype": "monetaryItemType" }, "imds_AccruedPayrollTaxesAndPenaltiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Payroll Taxes and Penalties [Abstract]" } } }, "localname": "AccruedPayrollTaxesAndPenaltiesDisclosureAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_AccruedPayrollTaxesAndPenaltiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accrued payroll taxes and penalties.", "label": "Accrued Payroll Taxes And Penalties Disclosure Text Block", "terseLabel": "ACCRUED PAYROLL TAXES AND PENALTIES" } } }, "localname": "AccruedPayrollTaxesAndPenaltiesDisclosureTextBlock", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenalties" ], "xbrltype": "textBlockItemType" }, "imds_AdjustmentShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustment shares.", "label": "Adjustment Share", "terseLabel": "Adjustment" } } }, "localname": "AdjustmentShare", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "sharesItemType" }, "imds_AmountOfDesignatedPreferredShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of designated preferred shares.", "label": "Amount Of Designated Preferred Shares", "terseLabel": "Amount" } } }, "localname": "AmountOfDesignatedPreferredShares", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "monetaryItemType" }, "imds_AnnualIntrestRatesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The value of annual intrest rates, percentage.", "label": "Annual Intrest Rates Percentage", "terseLabel": "Annual interest rate, percentage" } } }, "localname": "AnnualIntrestRatesPercentage", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails" ], "xbrltype": "percentItemType" }, "imds_AnnualRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The dividends accrue at an annual rate.", "label": "Annual Rate", "terseLabel": "Annual rate" } } }, "localname": "AnnualRate", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "imds_BalanceOwedAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Balance owed adjustments.", "label": "Balance Owed Adjustments", "terseLabel": "Balance owed adjustments" } } }, "localname": "BalanceOwedAdjustments", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "imds_ClinicalEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Clinical Equipment Member", "terseLabel": "Clinical Equipment [Member]" } } }, "localname": "ClinicalEquipmentMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "domainItemType" }, "imds_ConsultingRetainers": { "auth_ref": [], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consulting Retainers.", "label": "Consulting Retainers", "terseLabel": "Consulting Retainers" } } }, "localname": "ConsultingRetainers", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "imds_ConversionOfPreferredStockToCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of preferred shares converted into common shares.", "label": "Conversion Of Preferred Stock To Common Stock", "terseLabel": "Conversion of preferred stock to common stock" } } }, "localname": "ConversionOfPreferredStockToCommonStock", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "imds_ConvertiblePreferredSeries": { "auth_ref": [], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_TemporaryEquityCarryingAmountAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of convertible preferred series.", "label": "Convertible Preferred Series", "terseLabel": "Convertible Preferred Stock -Series L" } } }, "localname": "ConvertiblePreferredSeries", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "imds_ConvertiblePreferredStockDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock description.", "label": "Convertible Preferred Stock Description", "terseLabel": "Convertible preferred stock description" } } }, "localname": "ConvertiblePreferredStockDescription", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "imds_ConvertiblePreferredStockDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Details) [Line Items]" } } }, "localname": "ConvertiblePreferredStockDetailsLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "imds_ConvertiblePreferredStockDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Details) [Table]" } } }, "localname": "ConvertiblePreferredStockDetailsTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "imds_ConvertiblePreferredStockTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock Tables Line Items", "terseLabel": "Convertible Preferred Stock [Abstract]" } } }, "localname": "ConvertiblePreferredStockTablesLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables" ], "xbrltype": "stringItemType" }, "imds_ConvertiblePreferredStockTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock (Tables) [Table]" } } }, "localname": "ConvertiblePreferredStockTablesTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables" ], "xbrltype": "stringItemType" }, "imds_CumulativeDividendFixedRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative dividend fixed rate.", "label": "Cumulative Dividend Fixed Rate", "terseLabel": "Cumulative dividend fixed rate" } } }, "localname": "CumulativeDividendFixedRate", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "imds_DateOfConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date of stock conversion.", "label": "Date Of Conversion", "terseLabel": "Date of Conversion" } } }, "localname": "DateOfConversion", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "dateItemType" }, "imds_DavidFongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "David Fong Member", "terseLabel": "David Fong [Member]" } } }, "localname": "DavidFongMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "imds_DebtInstrumentInterestRateStatedPercentage1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage1", "terseLabel": "Interest Rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage1", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "percentItemType" }, "imds_DebtInstrumentInterestRateStatedPercentage2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual interest rate.", "label": "Debt Instrument Interest Rate Stated Percentage2", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage2", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "imds_DebtInstrumentsMaturityDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt Instruments Maturity Date Description", "terseLabel": "Maturity Date" } } }, "localname": "DebtInstrumentsMaturityDateDescription", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "stringItemType" }, "imds_DirectorTwoThousandSixteenEquityPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Director Two Thousand Sixteen Equity Plan Member", "terseLabel": "Director 2016 Equity Plan [Member]" } } }, "localname": "DirectorTwoThousandSixteenEquityPlanMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "imds_DirectorsAndConsultantsOtherPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Directors And Consultants Other Plans Member", "terseLabel": "Directors and Consultants Other Plans [Member]" } } }, "localname": "DirectorsAndConsultantsOtherPlansMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "imds_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_DueFromRelatedPartie": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due From Related Partie", "terseLabel": "Adjustments balance" } } }, "localname": "DueFromRelatedPartie", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenaltiesDetails" ], "xbrltype": "monetaryItemType" }, "imds_EhrfortLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ehrfort LLCMember", "terseLabel": "Ehrfort, LLC [Member]" } } }, "localname": "EhrfortLLCMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "imds_EmployeeOtherPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Other Plans Member", "terseLabel": "Employee Other Plans [Member]" } } }, "localname": "EmployeeOtherPlansMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "imds_EmployeeTwoThousandSixteenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Two Thousand Sixteen Plan Member", "terseLabel": "Employee 2016 Equity Plan [Member]" } } }, "localname": "EmployeeTwoThousandSixteenPlanMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Erhfort LLCEight Member", "terseLabel": "Erhfort, LLC Eight [Member]" } } }, "localname": "ErhfortLLCEightMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Erhfort, LLC [Member]", "label": "Erhfort LLCMember", "terseLabel": "Erhfort, LLC [Member]" } } }, "localname": "ErhfortLLCMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ErhfortLLCOneMember", "label": "Erhfort LLCOne Member", "terseLabel": "Erhfort, LLC One [Member]" } } }, "localname": "ErhfortLLCOneMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Erhfort LLCSeven Member", "terseLabel": "Erhfort, LLC Seven [Member]" } } }, "localname": "ErhfortLLCSevenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Erhfort LLCTwo Member", "terseLabel": "Erhfort, LLC Two [Member]" } } }, "localname": "ErhfortLLCTwoMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCsFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Erhfort LLCs Five Member", "terseLabel": "Erhfort, LLC Five [Member]" } } }, "localname": "ErhfortLLCsFiveMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCsFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Erhfort LLCs Four Member", "terseLabel": "Erhfort, LLC Four [Member]" } } }, "localname": "ErhfortLLCsFourMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Erhfort LLCs Member", "terseLabel": "Erhfort, LLC [Member]" } } }, "localname": "ErhfortLLCsMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCsSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Erhfort LLCs Six Member", "terseLabel": "Erhfort, LLC Six [Member]" } } }, "localname": "ErhfortLLCsSixMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ErhfortLLCsThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Erhfort LLCs Three Member", "terseLabel": "Erhfort, LLC Three [Member]" } } }, "localname": "ErhfortLLCsThreeMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_EstimatedVestingExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Options to be expensed when vested are estimated.", "label": "Estimated Vesting Expense", "terseLabel": "Estimated vesting expense (in Dollars)" } } }, "localname": "EstimatedVestingExpense", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "imds_ExercisePriceRangeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price Range Member", "terseLabel": "$0.20 - $0.51 [Member]" } } }, "localname": "ExercisePriceRangeMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "domainItemType" }, "imds_FongAssociatesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fong Associates LLCMember", "terseLabel": "Fong & Associates, LLC [Member]" } } }, "localname": "FongAssociatesLLCMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "imds_GoingConcernandManagementsPlansDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern and Management's Plans [Abstract]" } } }, "localname": "GoingConcernandManagementsPlansDetailsLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "stringItemType" }, "imds_GoingConcernandManagementsPlansDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern and Management's Plans (Details) [Table]" } } }, "localname": "GoingConcernandManagementsPlansDetailsTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "stringItemType" }, "imds_GoingConcernandManagementsPlansLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern and Management's Plans Disclosure [Abstract]" } } }, "localname": "GoingConcernandManagementsPlansLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlans" ], "xbrltype": "stringItemType" }, "imds_GoingConcernandManagementsPlansTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern and Management's Plans [Table]" } } }, "localname": "GoingConcernandManagementsPlansTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlans" ], "xbrltype": "stringItemType" }, "imds_InventoriesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories Disclosure [Abstract]" } } }, "localname": "InventoriesLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Inventories" ], "xbrltype": "stringItemType" }, "imds_InventoriesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories [Table]" } } }, "localname": "InventoriesTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Inventories" ], "xbrltype": "stringItemType" }, "imds_InventoriesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories [Abstract]" } } }, "localname": "InventoriesTablesLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/InventoriesTables" ], "xbrltype": "stringItemType" }, "imds_InventoriesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories (Tables) [Table]" } } }, "localname": "InventoriesTablesTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/InventoriesTables" ], "xbrltype": "stringItemType" }, "imds_IssuanceDate6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance Date6 Member", "terseLabel": "Issued on 3/31/2010 [Member]" } } }, "localname": "IssuanceDate6Member", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "domainItemType" }, "imds_JMOneHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JMOne Holdings LLCMember", "terseLabel": "JM One Holdings, LLC [Member]" } } }, "localname": "JMOneHoldingsLLCMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_LongTermDebtDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt (Details) [Line Items]" } } }, "localname": "LongTermDebtDetailsLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "imds_LongTermDebtDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt (Details) [Table]" } } }, "localname": "LongTermDebtDetailsTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "imds_LongTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Abstract]" } } }, "localname": "LongTermDebtLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebt" ], "xbrltype": "stringItemType" }, "imds_LongTermDebtTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Table]" } } }, "localname": "LongTermDebtTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebt" ], "xbrltype": "stringItemType" }, "imds_LongTermDebtTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt Tables Line Items", "terseLabel": "Long-Term Debt [Abstract]" } } }, "localname": "LongTermDebtTablesLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtTables" ], "xbrltype": "stringItemType" }, "imds_LongTermDebtTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt (Tables) [Table]" } } }, "localname": "LongTermDebtTablesTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtTables" ], "xbrltype": "stringItemType" }, "imds_LumpSumPaymentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lump sum payment.", "label": "Lump Sum Payment Amount", "terseLabel": "Lump sum payment" } } }, "localname": "LumpSumPaymentAmount", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "imds_MonthlyInstallmentPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Monthly installment payments.", "label": "Monthly Installment Payments", "terseLabel": "Monthly installment payments" } } }, "localname": "MonthlyInstallmentPayments", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "imds_NetIncomeLossAttributableToParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Income (Loss) Attributable to Parent.", "label": "Net Income Loss Attributable To Parent", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLossAttributableToParent", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "monetaryItemType" }, "imds_NoOfSharesConvertedinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of converted shares.", "label": "No Of Shares Convertedin Shares", "terseLabel": "No. of Shares Converted (in Shares)" } } }, "localname": "NoOfSharesConvertedinShares", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "sharesItemType" }, "imds_NoOfSharesinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued.", "label": "No Of Sharesin Shares", "terseLabel": "No. of Shares (in Shares)" } } }, "localname": "NoOfSharesinShares", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "sharesItemType" }, "imds_NumberOfPatients": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of patients.", "label": "Number Of Patients", "terseLabel": "Number of patients" } } }, "localname": "NumberOfPatients", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "imds_OrganizationandNatureofBusinessLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Nature of Business [Abstract]" } } }, "localname": "OrganizationandNatureofBusinessLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/OrganizationandNatureofBusiness" ], "xbrltype": "stringItemType" }, "imds_OrganizationandNatureofBusinessTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Nature of Business [Table]" } } }, "localname": "OrganizationandNatureofBusinessTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/OrganizationandNatureofBusiness" ], "xbrltype": "stringItemType" }, "imds_OtherEquitySecuritiesConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other equity securities.", "label": "Other Equity Securities Convertible Preferred Stock", "terseLabel": "Other equity securities (in Dollars per share)" } } }, "localname": "OtherEquitySecuritiesConvertiblePreferredStock", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "imds_OutstandingOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Options Member", "terseLabel": "Outstanding Options [Member]" } } }, "localname": "OutstandingOptionsMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "domainItemType" }, "imds_PPPLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PPPLoan Member", "terseLabel": "PPP Loan [Member]" } } }, "localname": "PPPLoanMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "imds_PaymentOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock value.", "label": "Payment Of Convertible Preferred Stock", "terseLabel": "Convertible preferred stock value" } } }, "localname": "PaymentOfConvertiblePreferredStock", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "imds_PaymentOfSatisfactoryCompletion": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of satisfactory completion.", "label": "Payment Of Satisfactory Completion", "terseLabel": "Payment of satisfactory completion" } } }, "localname": "PaymentOfSatisfactoryCompletion", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "imds_PenaltiesAndInterestTotaling": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Penalties and interest totaling.", "label": "Penalties And Interest Totaling", "terseLabel": "Penalties and interest totaling" } } }, "localname": "PenaltiesAndInterestTotaling", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "imds_PreferredStockSharesDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock shares designated.", "label": "Preferred Stock Shares Designated", "terseLabel": "Preferred stock, designated" } } }, "localname": "PreferredStockSharesDesignated", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "imds_PrepaidExpensesAndDepositsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Deposits Abstract" } } }, "localname": "PrepaidExpensesAndDepositsAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_PrepaidExpensesAndDepositsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Deposits Text Block", "terseLabel": "PREPAID EXPENSES AND DEPOSITS" } } }, "localname": "PrepaidExpensesAndDepositsTextBlock", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDeposits" ], "xbrltype": "textBlockItemType" }, "imds_PrepaidExpensesandDepositsDetailsScheduleofprepaidexpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expensesand Deposits Details Scheduleofprepaidexpenses Line Items", "terseLabel": "Prepaid Expenses and Deposits [Abstract]" } } }, "localname": "PrepaidExpensesandDepositsDetailsScheduleofprepaidexpensesLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "stringItemType" }, "imds_PrepaidExpensesandDepositsDetailsScheduleofprepaidexpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Deposits (Details) - Schedule of prepaid expenses [Table]" } } }, "localname": "PrepaidExpensesandDepositsDetailsScheduleofprepaidexpensesTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "stringItemType" }, "imds_PrepaidExpensesandDepositsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Deposits Disclosure [Abstract]" } } }, "localname": "PrepaidExpensesandDepositsLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDeposits" ], "xbrltype": "stringItemType" }, "imds_PrepaidExpensesandDepositsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Deposits [Table]" } } }, "localname": "PrepaidExpensesandDepositsTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDeposits" ], "xbrltype": "stringItemType" }, "imds_PrepaidExpensesandDepositsTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Deposits [Abstract]" } } }, "localname": "PrepaidExpensesandDepositsTablesLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDepositsTables" ], "xbrltype": "stringItemType" }, "imds_PrepaidExpensesandDepositsTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Deposits (Tables) [Table]" } } }, "localname": "PrepaidExpensesandDepositsTablesTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDepositsTables" ], "xbrltype": "stringItemType" }, "imds_PreviousFivePlanIncludingNonStatutoryPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Previous Five Plan Including Non Statutory Plan Member", "terseLabel": "Previous Five Plan Including Non-Statutory Plan [Member]" } } }, "localname": "PreviousFivePlanIncludingNonStatutoryPlanMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "domainItemType" }, "imds_ProductLiabilityInsurance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Product Liability Insurance", "terseLabel": "Product liability insurance" } } }, "localname": "ProductLiabilityInsurance", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "imds_PromissoryNotesRelatedPartyDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory notes related party description", "label": "Promissory Notes Related Party Description", "terseLabel": "Promissory notes related party, description" } } }, "localname": "PromissoryNotesRelatedPartyDescription", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails" ], "xbrltype": "stringItemType" }, "imds_PromissoryNotesRelatedPartyDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes \u2013 Related Party (Details) [Line Items]" } } }, "localname": "PromissoryNotesRelatedPartyDetailsLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails" ], "xbrltype": "stringItemType" }, "imds_PromissoryNotesRelatedPartyDetailsScheduleofoutstandingnotebalancesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes Related Party Details Scheduleofoutstandingnotebalances Line Items", "terseLabel": "Promissory Notes \u2013 Related Party [Abstract]" } } }, "localname": "PromissoryNotesRelatedPartyDetailsScheduleofoutstandingnotebalancesLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "stringItemType" }, "imds_PromissoryNotesRelatedPartyDetailsScheduleofoutstandingnotebalancesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes \u2013 Related Party (Details) - Schedule of outstanding note balances [Table]" } } }, "localname": "PromissoryNotesRelatedPartyDetailsScheduleofoutstandingnotebalancesTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "stringItemType" }, "imds_PromissoryNotesRelatedPartyDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes \u2013 Related Party (Details) [Table]" } } }, "localname": "PromissoryNotesRelatedPartyDetailsTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails" ], "xbrltype": "stringItemType" }, "imds_PromissoryNotesRelatedPartyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes \u2013 Related Party [Abstract]" } } }, "localname": "PromissoryNotesRelatedPartyLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedParty" ], "xbrltype": "stringItemType" }, "imds_PromissoryNotesRelatedPartyTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes \u2013 Related Party [Table]" } } }, "localname": "PromissoryNotesRelatedPartyTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedParty" ], "xbrltype": "stringItemType" }, "imds_PromissoryNotesRelatedPartyTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes Related Party Tables Line Items", "terseLabel": "Promissory Notes \u2013 Related Party [Abstract]" } } }, "localname": "PromissoryNotesRelatedPartyTablesLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyTables" ], "xbrltype": "stringItemType" }, "imds_PromissoryNotesRelatedPartyTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Notes \u2013 Related Party (Tables) [Table]" } } }, "localname": "PromissoryNotesRelatedPartyTablesTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyTables" ], "xbrltype": "stringItemType" }, "imds_PropertyandEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment Disclosure [Abstract]" } } }, "localname": "PropertyandEquipmentLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipment" ], "xbrltype": "stringItemType" }, "imds_PropertyandEquipmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment [Table]" } } }, "localname": "PropertyandEquipmentTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipment" ], "xbrltype": "stringItemType" }, "imds_PropertyandEquipmentTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]" } } }, "localname": "PropertyandEquipmentTablesLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentTables" ], "xbrltype": "stringItemType" }, "imds_PropertyandEquipmentTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment (Tables) [Table]" } } }, "localname": "PropertyandEquipmentTablesTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentTables" ], "xbrltype": "stringItemType" }, "imds_PurchaseOfConvertiblePreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase of convertible preferred stock.", "label": "Purchase Of Convertible Preferred Stock Shares", "terseLabel": "Purchase of convertible preferred stock (in Shares)" } } }, "localname": "PurchaseOfConvertiblePreferredStockShares", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "imds_RelatedPartyConsultingFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party consulting fee.", "label": "Related Party Consulting Fee", "terseLabel": "Consulting fee" } } }, "localname": "RelatedPartyConsultingFee", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "imds_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "imds_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "imds_RemainingInterestAndPenalties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of remaining interest and penalties.", "label": "Remaining Interest And Penalties", "terseLabel": "Remaining interest and penalties" } } }, "localname": "RemainingInterestAndPenalties", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenaltiesDetails" ], "xbrltype": "monetaryItemType" }, "imds_RentDeposits": { "auth_ref": [], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rent deposits.", "label": "Rent Deposits", "terseLabel": "Rent Security Deposits" } } }, "localname": "RentDeposits", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "imds_RoyaltyReceivableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty Receivable [Abstract]" } } }, "localname": "RoyaltyReceivableAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_RoyaltyReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of royalty receivable.", "label": "Royalty Receivable Text Block", "terseLabel": "ROYALTY RECEIVABLE" } } }, "localname": "RoyaltyReceivableTextBlock", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivable" ], "xbrltype": "textBlockItemType" }, "imds_ScheduleOfASummaryOfTheOutstandingLoanBalancesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of ASummary Of The Outstanding Loan Balances Abstract" } } }, "localname": "ScheduleOfASummaryOfTheOutstandingLoanBalancesAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfEstimateTheExpectedForfeitureRateAndOnlyRecognizeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Estimate The Expected Forfeiture Rate And Only Recognize Expense Abstract" } } }, "localname": "ScheduleOfEstimateTheExpectedForfeitureRateAndOnlyRecognizeExpenseAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfInformationAboutVestedExercisableStockOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Information About Vested Exercisable Stock Options Abstract" } } }, "localname": "ScheduleOfInformationAboutVestedExercisableStockOptionsAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfInventoriesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of inventories [Abstract]" } } }, "localname": "ScheduleOfInventoriesAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfNumberOfSharesOfPreferredStockThatHaveBeenIssuedConvertedAndAreOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Number Of Shares Of Preferred Stock That Have Been Issued Converted And Are Outstanding Abstract" } } }, "localname": "ScheduleOfNumberOfSharesOfPreferredStockThatHaveBeenIssuedConvertedAndAreOutstandingAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfOfPrepaidExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Of Prepaid Expenses Table Text Block", "terseLabel": "Schedule of prepaid expenses" } } }, "localname": "ScheduleOfOfPrepaidExpensesTableTextBlock", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PrepaidExpensesandDepositsTables" ], "xbrltype": "textBlockItemType" }, "imds_ScheduleOfOutstandingNoteBalancesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding Note Balances Abstract" } } }, "localname": "ScheduleOfOutstandingNoteBalancesAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfPrepaidExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Prepaid Expenses Abstract" } } }, "localname": "ScheduleOfPrepaidExpensesAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfPropertyAndEquipmentLessAccumulatedDepreciationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Less Accumulated Depreciation Abstract" } } }, "localname": "ScheduleOfPropertyAndEquipmentLessAccumulatedDepreciationAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfStockOptionsGrantedExercisedExpiredAndCancelledAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Stock Options Granted Exercised Expired And Cancelled Abstract" } } }, "localname": "ScheduleOfStockOptionsGrantedExercisedExpiredAndCancelledAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfStockOptionsOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Stock Options Outstanding Abstract" } } }, "localname": "ScheduleOfStockOptionsOutstandingAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_ScheduleOfVestedAndUnvestedOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of vested and unvested options.", "label": "Schedule Of Vested And Unvested Options", "terseLabel": "Schedule of vested and unvested options" } } }, "localname": "ScheduleOfVestedAndUnvestedOptions", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "imds_ScheduleOfVestedAndUnvestedOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Vested And Unvested Options Abstract" } } }, "localname": "ScheduleOfVestedAndUnvestedOptionsAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "xbrltype": "stringItemType" }, "imds_SeriesLPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series LPreferred Stock Member", "terseLabel": "Series L Cv Pfd [Member]", "verboseLabel": "Series L Convertible Preferred Stock [Member]" } } }, "localname": "SeriesLPreferredStockMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "domainItemType" }, "imds_SeriesMPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series MPreferred Stock Member", "netLabel": "Series M Preferred Stock [Member]", "terseLabel": "Series M", "verboseLabel": "Series M Cv Pfd [Member]" } } }, "localname": "SeriesMPreferredStockMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "domainItemType" }, "imds_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "monetaryItemType" }, "imds_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term2", "terseLabel": "Wtd. Avg. Remaining Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "durationItemType" }, "imds_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndUnvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested and unvested.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Unvested Number Of Shares", "terseLabel": "Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndUnvestedNumberOfShares", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "sharesItemType" }, "imds_SmallBusinessAdministrationLoanAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Small business administration loan amount.", "label": "Small Business Administration Loan Amount", "terseLabel": "Loan amount" } } }, "localname": "SmallBusinessAdministrationLoanAmount", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "imds_StockOptionsDetailsScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense [Line Items]" } } }, "localname": "StockOptionsDetailsScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "stringItemType" }, "imds_StockOptionsDetailsScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options (Details) - Schedule of estimate the expected forfeiture rate and only recognize expense [Table]" } } }, "localname": "StockOptionsDetailsScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "stringItemType" }, "imds_StockOptionsDetailsScheduleofinformationaboutvestedexercisablestockoptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options (Details) - Schedule of information about vested & exercisable stock options [Line Items]" } } }, "localname": "StockOptionsDetailsScheduleofinformationaboutvestedexercisablestockoptionsLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable" ], "xbrltype": "stringItemType" }, "imds_StockOptionsDetailsScheduleofinformationaboutvestedexercisablestockoptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options (Details) - Schedule of information about vested & exercisable stock options [Table]" } } }, "localname": "StockOptionsDetailsScheduleofinformationaboutvestedexercisablestockoptionsTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable" ], "xbrltype": "stringItemType" }, "imds_StockOptionsDetailsScheduleofstockoptionsgrantedexercisedexpiredandcancelledLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled [Line Items]" } } }, "localname": "StockOptionsDetailsScheduleofstockoptionsgrantedexercisedexpiredandcancelledLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "stringItemType" }, "imds_StockOptionsDetailsScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options (Details) - Schedule of stock options granted, exercised, expired and cancelled [Table]" } } }, "localname": "StockOptionsDetailsScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "stringItemType" }, "imds_StockOptionsDetailsScheduleofvestedandunvestedoptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options (Details) - Schedule of vested and unvested options [Line Items]" } } }, "localname": "StockOptionsDetailsScheduleofvestedandunvestedoptionsLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "stringItemType" }, "imds_StockOptionsDetailsScheduleofvestedandunvestedoptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options (Details) - Schedule of vested and unvested options [Table]" } } }, "localname": "StockOptionsDetailsScheduleofvestedandunvestedoptionsTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "stringItemType" }, "imds_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "imds_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "imds_ThirdPartySoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Third Party Software Member", "terseLabel": "Third Party Software [Member]" } } }, "localname": "ThirdPartySoftwareMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "domainItemType" }, "imds_TruistBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Truist Bank Member", "terseLabel": "Truist Bank [Member]" } } }, "localname": "TruistBankMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "domainItemType" }, "imds_UnvestedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unvested Member", "terseLabel": "Unvested [Member]" } } }, "localname": "UnvestedMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "domainItemType" }, "imds_VestedAndExercisableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested And Exercisable Member", "terseLabel": "Vested and Exercisable [Member]" } } }, "localname": "VestedAndExercisableMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "domainItemType" }, "imds_VestedAndUnvestedOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested And Unvested Options Member", "terseLabel": "Vested and Unvested Options [Member]" } } }, "localname": "VestedAndUnvestedOptionsMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "domainItemType" }, "imds_VestedOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested Options Member", "terseLabel": "Vested Options [Member]" } } }, "localname": "VestedOptionsMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCEight Member", "terseLabel": "Viable International Investments, LLC Eight [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCEightMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCEighteen Member", "terseLabel": "Viable International Investments, LLC Eighteen [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCEighteenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCEleven Member", "terseLabel": "Viable International Investments, LLC Eleven [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCElevenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCFifteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCFifteen Member", "terseLabel": "Viable International Investments, LLC Fifteen [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCFifteenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCFive Member", "terseLabel": "Viable International Investments, LLC Five [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCFiveMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCFour Member", "terseLabel": "Viable International Investments, LLC Four [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCFourMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCFourteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCFourteen Member", "terseLabel": "Viable International Investments, LLC Fourteen [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCFourteenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCMember", "terseLabel": "Viable International Investments, LLC [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCNine Member", "terseLabel": "Viable International Investments, LLC Nine [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCNineMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCNineteen Member", "terseLabel": "Viable International Investments, LLC Nineteen [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCNineteenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCOne Member", "terseLabel": "Viable International Investments, LLC One [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCOneMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCSeven Member", "terseLabel": "Viable International Investments, LLC Seven [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCSevenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCSeventeen Member", "terseLabel": "Viable International Investments, LLC Seventeen [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCSeventeenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCSix Member", "terseLabel": "Viable International Investments, LLC Six [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCSixMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCSixteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCSixteen Member", "terseLabel": "Viable International Investments, LLC Sixteen [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCSixteenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCTen Member", "terseLabel": "Viable International Investments, LLC Ten [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCTenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCThree Member", "terseLabel": "Viable International Investments, LLC Three [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCThreeMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCTwelveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCTwelve Member", "terseLabel": "Viable International Investments, LLC Twelve [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCTwelveMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCTwenty Member", "terseLabel": "Viable International Investments, LLC Twenty [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCTwentyMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCTwenty One Member", "terseLabel": "Viable International Investments, LLC Twenty One [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCTwentyOneMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsLLCTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments LLCTwo Member", "terseLabel": "Viable International Investments, LLC Two [Member]" } } }, "localname": "ViableInternationalInvestmentsLLCTwoMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_ViableInternationalInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viable International Investments Member", "terseLabel": "Viable International Investments, LLC [Member]", "verboseLabel": "Viable International Investments [Member]" } } }, "localname": "ViableInternationalInvestmentsMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails" ], "xbrltype": "domainItemType" }, "imds_ViablesInternationalInvestmentsLLCThirteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Viables International Investments LLCThirteen Member", "terseLabel": "Viable International Investments, LLC Thirteen [Member]" } } }, "localname": "ViablesInternationalInvestmentsLLCThirteenMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_VotingAndEconomicInterestPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voting and economic interest percentage.", "label": "Voting And Economic Interest Percentage", "terseLabel": "Voting and economic interest percentage" } } }, "localname": "VotingAndEconomicInterestPercentage", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "imds_WarrantyReservesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for class of warranty reserves.", "label": "Warranty Reserves Policy Text Block", "terseLabel": "Warranty reserve" } } }, "localname": "WarrantyReservesPolicyTextBlock", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "imds_WorkingCapitalDeficiency": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "WorkingCapitalDeficiency", "label": "Working Capital Deficiency", "terseLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficiency", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "monetaryItemType" }, "imds_XianIDIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Xian IDIMember", "terseLabel": "Xi\u2019an IDI [Member]" } } }, "localname": "XianIDIMember", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "imds_arningsPerShareBasicAndDilutedOtherDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "arnings Per Share Basic And Diluted Other Disclosure Abstract", "terseLabel": "Weighted average number of common shares outstanding:" } } }, "localname": "arningsPerShareBasicAndDilutedOtherDisclosureAbstract", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "imds_imds_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a forfeiture rate.", "label": "imds_ Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate", "terseLabel": "Forfeiture rate" } } }, "localname": "imds_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "nsuri": "http://IMAGINGDIAGNOSTICSYSTEMS.com/20230331", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "percentItemType" }, "srt_MaximumMember": { "auth_ref": [ "r222", "r223", "r224", "r225", "r290", "r378", "r409", "r438", "r439", "r501", "r502", "r503", "r504", "r505", "r513", "r514", "r523", "r529", "r530", "r533", "r576", "r610", "r611", "r612", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r222", "r223", "r224", "r225", "r290", "r378", "r409", "r438", "r439", "r501", "r502", "r503", "r504", "r505", "r513", "r514", "r523", "r529", "r530", "r533", "r576", "r610", "r611", "r612", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r222", "r223", "r224", "r225", "r288", "r290", "r319", "r320", "r321", "r377", "r378", "r409", "r438", "r439", "r501", "r502", "r503", "r504", "r505", "r513", "r514", "r523", "r529", "r530", "r533", "r536", "r572", "r576", "r611", "r612", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r222", "r223", "r224", "r225", "r288", "r290", "r319", "r320", "r321", "r377", "r378", "r409", "r438", "r439", "r501", "r502", "r503", "r504", "r505", "r513", "r514", "r523", "r529", "r530", "r533", "r536", "r572", "r576", "r611", "r612", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r178", "r291", "r550", "r567" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r178", "r291", "r550", "r551", "r567" ], "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.", "label": "Legal Entity of Counterparty, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableandAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities, Noncurrent", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableandAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "verboseLabel": "Accounts payables" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableandAccruedExpensesDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r68", "r616" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r75", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Balance of taxes due" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenaltiesDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxes, Current", "terseLabel": "Accrued payroll taxes and penalties" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs.", "label": "Accrued Payroll Taxes", "terseLabel": "Accrued payroll taxes, interest and penalties" } } }, "localname": "AccruedPayrollTaxesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r44", "r134", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "totalLabel": "Total adjustments" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r140", "r208", "r212", "r213", "r214", "r619" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts (in Dollars)" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r111", "r135", "r163", "r193", "r199", "r203", "r209", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r343", "r345", "r357", "r396", "r463", "r532", "r543", "r574", "r575", "r608" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r130", "r144", "r163", "r209", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r343", "r345", "r357", "r532", "r574", "r575", "r608" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Auction Market Preferred Securities, Stock Series [Line Items]", "terseLabel": "Convertible Preferred Stock [Abstract]" } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable": { "auth_ref": [ "r47", "r48", "r49", "r50", "r76" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to auction market preferred securities, including liquidation preference, liquidation value, par value, rate setting interval, redemption requirements, dividend distributions, roll forward of shares outstanding, shares authorized, aggregate value of auction market preferred securities, variable interest rate earned, and other information necessary to a fair presentation. If redeemable, the auction market preferred securities are redeemable solely at the option of the issuer.", "label": "Auction Market Preferred Securities, Stock Series [Table]" } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation and use of estimates" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r118", "r398", "r436", "r457", "r532", "r543", "r552" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r31", "r92", "r159" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of the period", "periodStartLabel": "Cash at the beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r1", "r92" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Federal deposit insurance corporation limit (in Dollars)" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r127", "r136", "r137", "r138", "r163", "r182", "r183", "r186", "r188", "r191", "r192", "r209", "r226", "r228", "r229", "r230", "r233", "r234", "r263", "r264", "r267", "r270", "r277", "r357", "r417", "r418", "r419", "r420", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r437", "r449", "r472", "r493", "r506", "r507", "r508", "r509", "r510", "r549", "r561", "r568" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r26", "r69", "r397", "r448" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitment and Contingencies (Note 17)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r100", "r220", "r221", "r512", "r573" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r565", "r566", "r604", "r620", "r622" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "terseLabel": "Common stock, no par value" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, shares par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r77", "r449" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStockDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r77", "r449", "r469", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r77", "r400", "r532" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, no par value, 500,000,000 authorized , 123,156,941 shares issued and outstanding March 31, 2023 and June 30, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computers and Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r71", "r121" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r35", "r36", "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "terseLabel": "Amount Converted" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Total temporary equity (in Dollars)" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r13", "r48", "r76", "r104", "r273" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleSubordinatedDebtCurrent": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment upon liquidation of the entity's assets.", "label": "Convertible Subordinated Debt, Current", "terseLabel": "Balance 12/31/2022" } } }, "localname": "ConvertibleSubordinatedDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r88", "r380" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeEarningsDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative earnings (deficits) for relevant time periods.", "label": "Cumulative Earnings (Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "CumulativeEarningsDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDefaultShorttermDebtAmount": { "auth_ref": [ "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding short-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt Default, Short-Term Debt, Amount", "terseLabel": "Original purchase price (in Dollars)" } } }, "localname": "DebtDefaultShorttermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r101", "r161", "r235", "r241", "r242", "r243", "r244", "r245", "r246", "r251", "r258", "r259", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "PROMISSORY NOTES \u2013 RELATED PARTY" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedParty" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r74", "r75", "r112", "r114", "r164", "r236", "r237", "r238", "r239", "r240", "r242", "r247", "r248", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r366", "r524", "r525", "r526", "r527", "r528", "r562" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "terseLabel": "Interest Rate" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r22", "r237" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r164", "r236", "r237", "r238", "r239", "r240", "r242", "r247", "r248", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r260", "r366", "r524", "r525", "r526", "r527", "r528", "r562" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description", "terseLabel": "Maturity Date" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r24", "r164", "r236", "r237", "r238", "r239", "r240", "r242", "r247", "r248", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r366", "r524", "r525", "r526", "r527", "r528", "r562" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r24", "r48", "r51", "r64", "r65", "r67", "r70", "r103", "r105", "r164", "r236", "r237", "r238", "r239", "r240", "r242", "r247", "r248", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r260", "r366", "r524", "r525", "r526", "r527", "r528", "r562" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Contract term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r5", "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r5", "r43" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Sales and marketing" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r292", "r293", "r323", "r324", "r325", "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK OPTIONS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptions" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r3", "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "terseLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r3", "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedLabel": "Cummulative Dividend on Series L CV Preferred" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net Loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r153", "r170", "r171", "r172", "r173", "r174", "r179", "r182", "r186", "r187", "r188", "r189", "r355", "r356", "r393", "r408", "r520" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic and diluted (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r153", "r170", "r171", "r172", "r173", "r174", "r182", "r186", "r187", "r188", "r189", "r355", "r356", "r393", "r408", "r520" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net Loss per common share diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r39", "r40" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r128", "r148", "r149", "r150", "r165", "r166", "r167", "r169", "r175", "r177", "r190", "r210", "r211", "r278", "r326", "r327", "r328", "r341", "r342", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r358", "r359", "r360", "r361", "r362", "r363", "r367", "r410", "r411", "r412", "r425", "r493" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r89", "r474" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r87", "r163", "r193", "r198", "r202", "r204", "r209", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r357", "r522", "r574" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationDescription": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.", "label": "Income Tax Examination, Description", "terseLabel": "Tax position, description" } } }, "localname": "IncomeTaxExaminationDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r147", "r335", "r336", "r337", "r338", "r339", "r340", "r416" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Increase in accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r4" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Decrease in prepaid expenses and deposits" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r66", "r117", "r151", "r196", "r365", "r478", "r542", "r621" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r155", "r157", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r554" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable, Current", "terseLabel": "Interest and penalties" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccruedPayrollTaxesandPenaltiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryAdjustments": { "auth_ref": [ "r42", "r556" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.", "label": "Inventory Adjustments", "negatedLabel": "Allowance for Obsolete Inventory" } } }, "localname": "InventoryAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r555" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r556" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total Inventory" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r142", "r516", "r532" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Net Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r119", "r132", "r141", "r215", "r216", "r217", "r379", "r518" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r556" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials consisting of purchased parts, components and supplies" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of the other party participating in a financial transaction.", "label": "Legal Entity Type of Counterparty [Domain]" } } }, "localname": "LegalEntityTypeOfCounterpartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r163", "r209", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r344", "r345", "r346", "r357", "r447", "r521", "r543", "r574", "r608", "r609" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r81", "r115", "r403", "r532", "r563", "r570", "r606" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r131", "r163", "r209", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r344", "r345", "r346", "r357", "r532", "r574", "r608", "r609" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "PPP loan payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturityDate": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format.", "label": "Long-Term Debt, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "LongTermDebtMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r24", "r45" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r120", "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "ORGANIZATION AND NATURE OF BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/OrganizationandNatureofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r156" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r92", "r93", "r94" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r86", "r94", "r116", "r129", "r145", "r146", "r150", "r163", "r168", "r170", "r171", "r172", "r173", "r176", "r177", "r184", "r193", "r198", "r202", "r204", "r209", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r356", "r357", "r407", "r471", "r491", "r492", "r522", "r542", "r574" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r154", "r170", "r171", "r172", "r173", "r179", "r180", "r185", "r188", "r193", "r198", "r202", "r204", "r522" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Loss Available to Common Stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Impact of recently issued accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total Other Expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r193", "r198", "r202", "r204", "r522" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating Loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r46", "r62", "r63", "r110" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expense" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountsPayableandAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r90" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "terseLabel": "Consulting expenses (including share-based compensation)" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLoansPayableCurrent": { "auth_ref": [ "r20", "r444", "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer.", "label": "Other Loans Payable, Current", "negatedLabel": "Current Portion of Debt" } } }, "localname": "OtherLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebt": { "auth_ref": [ "r12", "r114", "r618" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other.", "label": "Other Long-Term Debt", "terseLabel": "Total Debt" } } }, "localname": "OtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r24", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Long-Term Debt, Noncurrent", "terseLabel": "Total Long-term Debt" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofasummaryoftheoutstandingloanbalancesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Net cash used in operating activities" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r557", "r571" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid Software" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r139", "r458" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Royalty receivable balances" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RoyaltyReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermBorrowings": { "auth_ref": [ "r15", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.", "label": "Other Short-Term Borrowings", "terseLabel": "Converted short term promissory note (in Dollars)" } } }, "localname": "OtherShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Expenses [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromDepositOnLoan": { "auth_ref": [ "r6", "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow from resulting from payment, receipt or drawdown of cash deposit to guarantee a loan during the period.", "label": "Payments for (Proceeds from) Deposit on Loan", "terseLabel": "Loan proceeds" } } }, "localname": "PaymentsForProceedsFromDepositOnLoan", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Preferred Stock, Convertible, Shares Issuable", "terseLabel": "Convertible preferred stock" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r38", "r548", "r569" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends and Other Adjustments", "negatedLabel": "Preferred Stock Dividends" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockNoParValue": { "auth_ref": [ "r76", "r577" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, No Par Value", "terseLabel": "Preferred stock, shares par value (in Dollars per share)", "verboseLabel": "Preferred stock, no par value" } } }, "localname": "PreferredStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStockDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r27", "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Preferred Stock, Redemption Amount", "terseLabel": "Redemption value (in Dollars)" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r76", "r449" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStockDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r76", "r263" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r76", "r449", "r469", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "Preferred Stock [Text Block]", "terseLabel": "CONVERTIBLE PREFERRED STOCK" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r76", "r399", "r532" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, no par , 2,000,000 authorized Convertible preferred stock, Series M, 600 designated 0 shares issued and outstanding at March 31, 2023 and June 30, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r143", "r218", "r219", "r517" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and deposits" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r553" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense, Noncurrent", "totalLabel": "Total Prepaid expenses and Deposits" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r2" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from promissory notes, related party" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans", "terseLabel": "Loan proceeds" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts": { "auth_ref": [ "r558", "r559", "r560" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer.", "label": "Proceeds from (Repayments of) Bank Overdrafts", "terseLabel": "(Repayment) of Paycheck Protection Program Loan" } } }, "localname": "ProceedsFromRepaymentsOfBankOverdrafts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r97", "r122", "r123", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r98", "r133", "r406" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total Property & Equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r395", "r406", "r532" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "verboseLabel": "Total Property & Equipment - Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r7", "r122", "r123", "r404" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, less accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartiesAmountInCostOfSales": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.", "label": "Related Parties Amount in Cost of Sales", "terseLabel": "Related parties amount" } } }, "localname": "RelatedPartiesAmountInCostOfSales", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r289", "r371", "r372", "r441", "r442", "r443", "r444", "r445", "r468", "r470", "r500" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r371", "r372", "r607" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate", "terseLabel": "Percentage of transfer fee" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r289", "r371", "r372", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r441", "r442", "r443", "r444", "r445", "r468", "r470", "r500", "r607" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r368", "r369", "r370", "r372", "r373", "r422", "r423", "r424", "r475", "r476", "r477", "r497", "r499" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Shares of restricted common stock" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r78", "r106", "r402", "r413", "r414", "r421", "r450", "r532" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r128", "r165", "r166", "r167", "r169", "r175", "r177", "r210", "r211", "r326", "r327", "r328", "r341", "r342", "r347", "r349", "r350", "r352", "r354", "r410", "r412", "r425", "r622" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r126", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r473", "r515", "r519" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r152", "r163", "r194", "r195", "r197", "r200", "r201", "r205", "r206", "r207", "r209", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r357", "r394", "r574" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock": { "auth_ref": [ "r47", "r48", "r49", "r50", "r76" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to auction market preferred securities, including liquidation preference, liquidation value, par value, rate setting interval, redemption requirements, dividend distributions, roll forward of shares outstanding, shares authorized, aggregate value of auction market preferred securities, variable interest rate earned, and other information necessary to a fair presentation. If redeemable, the auction market preferred securities are redeemable solely at the option of the issuer.", "label": "Schedule of Auction Market Preferred Securities by Stock Series [Table Text Block]", "terseLabel": "Schedule of number of shares of preferred stock that have been issued, converted and are outstanding" } } }, "localname": "ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r24", "r48", "r51", "r64", "r65", "r67", "r70", "r103", "r105", "r525", "r527", "r564" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of a summary of the outstanding loan balances" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of outstanding note balances" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/PromissoryNotesRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r82", "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofpropertyandequipmentlessaccumulateddepreciationTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Schedule of stock options outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r10", "r11", "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock options granted, exercised, expired and cancelled" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of estimate the expected forfeiture rate and only recognize expense" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r52", "r54" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "terseLabel": "Stock options, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Wtd. Avg. Exercise Price, Outstanding", "periodStartLabel": "Wtd. Avg. Exercise Price, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-Free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Options, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Options, Cancelled", "terseLabel": "Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Wtd. Avg. Exercise Price, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options, Granted", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding", "periodStartLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, Outstanding", "periodStartLabel": "Options, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Vested & Exercisable Stock Options, Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofinformationaboutvestedexercisablestockoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]", "terseLabel": "Schedule of information about vested & exercisable stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance", "periodStartLabel": "Outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofvestedandunvestedoptionsTable" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Wtd. Avg. Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Wtd. Avg. Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "GrantedWtd. Avg. Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r292", "r297", "r316", "r317", "r318", "r319", "r322", "r329", "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Lower range of exercise price" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Number of Exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Number of outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "sharesItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Purchase exercise price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofestimatetheexpectedforfeiturerateandonlyrecognizeexpenseTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Wtd. Avg. Remaining Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Options non vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Expense of options vested (in Dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted Averaged Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Averaged Remaining Life (Years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsoutstandingTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r73", "r112", "r532", "r617" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-Term Debt", "netLabel": "Short-Term Debt", "terseLabel": "Promissory notes, related party", "verboseLabel": "Total Related Party Notes" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/RelatedPartyTransactionsDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofoutstandingnotebalancesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r95", "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r127", "r136", "r137", "r138", "r163", "r182", "r183", "r186", "r188", "r191", "r192", "r209", "r226", "r228", "r229", "r230", "r233", "r234", "r263", "r264", "r267", "r270", "r277", "r357", "r417", "r418", "r419", "r420", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r437", "r449", "r472", "r493", "r506", "r507", "r508", "r509", "r510", "r549", "r561", "r568" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConvertiblePreferredStockDetails", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r28", "r128", "r148", "r149", "r150", "r165", "r166", "r167", "r169", "r175", "r177", "r190", "r210", "r211", "r278", "r326", "r327", "r328", "r341", "r342", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r358", "r359", "r360", "r361", "r362", "r363", "r367", "r410", "r411", "r412", "r425", "r493" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r165", "r166", "r167", "r190", "r380", "r415", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r449", "r452", "r453", "r454", "r455", "r456", "r459", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r470", "r473", "r474", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r537" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r165", "r166", "r167", "r190", "r380", "r415", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r449", "r452", "r453", "r454", "r455", "r456", "r459", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r470", "r473", "r474", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r537" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r35", "r36", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Promissory notes issued in exchange for settlement of accounts payable" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r76", "r77", "r106", "r303" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Options, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofstockoptionsgrantedexercisedexpiredandcancelledTable" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r58", "r76", "r77", "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock options expense" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r5" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "Stock option expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r77", "r79", "r80", "r96", "r451", "r469", "r494", "r495", "r532", "r543", "r563", "r570", "r606", "r622" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet", "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r102", "r162", "r262", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r278", "r353", "r496", "r498", "r511" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "COMMON STOCK" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "terseLabel": "Stockholders\u2019 deficit" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r364", "r375" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r364", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r374", "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "GOING CONCERN AND MANAGEMENT\u2019S PLANS" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/GoingConcernandManagementsPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity [Abstract]", "terseLabel": "Temporary equity" } } }, "localname": "TemporaryEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "terseLabel": "Total redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ScheduleofnumberofsharesofpreferredstockthathavebeenissuedconvertedandareoutstandingTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r226", "r228", "r229", "r230", "r233", "r234", "r333", "r401" ], "calculation": { "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "totalLabel": "Total temporary equity" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r181", "r188" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r179", "r188" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic and diluted (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://IMAGINGDIAGNOSTICSYSTEMS.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.E.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r544": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r545": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r546": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r547": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 78 0001213900-23-039823-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-039823-xbrl.zip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end